Development of tools for embryonic ECG for heart dysfunction in zebrafish by Hurst, Rhiannon Mary
  
 
 
Development and optimization of tools for 
embryonic electrocardiograph recording for 
heart dysfunction in zebrafish. 
by 
 
Rhiannon Mary Hurst 
 
 
A thesis submitted to  
The University of Birmingham  
for the degree of  
DOCTOR OF PHILOSOPHY 
College of Medical and Dental Sciences 
The University of Birmingham 
April 2018 
 
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
  
Table of Contents 
 
Acknowledgements ......................................................................................................... 9 
Abstract. .......................................................................................................................... 1 
1.1. The human cardiac cycle and drug induced cardiotoxicity................................. 2 
1.1.1 Human cardiac action potential, ion channels and ECG. ........................ 2 
1.1.2 Human cardiac arrhythmia and problems surrounding therapies. ............. 6 
1.1.3 Cardiac toxicity and QT prolongation. ........................................................... 6 
1.1.3.1 The drug development pathway and pre-clinical testing. ....................... 6 
1.1.3.2 Cardiac toxicity ........................................................................................... 7 
1.1.3.2 QT prolongation and hERG channel. ....................................................... 9 
1.2. Zebrafish as a model organism for human disease and drug development 
screens. ........................................................................................................................... 11 
1.2.1 The Zebrafish, Danio rerio: Background. ..................................................... 12 
1.2.2 Zebrafish embryo development ...................................................................... 12 
1.2.2.1 Zebrafish cardiac development. .............................................................. 14 
1.2.3 Zebrafish model compared to existing in vivo models ................................. 16 
1.2.3.1 Advantages of the zebrafish embryo model for drug screening 
compared to mammalian model systems. ........................................................... 17 
1.2.3.2 Advantages and disadvantages of zebrafish compared to other fish 
models .................................................................................................................... 19 
1.2.3.3 Advantages and disadvantages of zebrafish compared to other in vitro 
models for drug screening.................................................................................... 20 
1.2.3.4 Zebrafish as a complimentary model to existing in vitro models ......... 21 
1.3 Zebrafish as a model of human cardiac conditions and arrhythmia. ................ 23 
1.3.1 Zebrafish as a tool to evaluate cardiotoxicity ............................................... 23 
1.3.2 Zebrafish electrophysiology ............................................................................ 24 
1.3.2.1 Comparison of human, mouse and zebrafish action potentials and 
electrophysiology. ................................................................................................. 24 
1.3.2.2 The Human ECG compared to the zebrafish ECG. .............................. 26 
1.3.3 Zebrafish as a model for Long QT syndrome ............................................... 27 
1.3.4 Current cardiac models .................................................................................. 30 
1.3.4.1 In vitro and in silico cardiac models ........................................................ 30 
1.3.4.2 In vivo models: mammalian ..................................................................... 32 
1.3.5 Current Cardiac zebrafish cardiac models ................................................... 33 
1.3.5.1 Adult zebrafish cardiac models ............................................................... 33 
  
1.3.5.1.1 Adult zebrafish cardiac disease modelling. ......................................... 33 
1.3.5.1.2 Adult zebrafish cardiac arrhythmia models ....................................... 35 
1.3.5.2 The Zebrafish embryo as a cardiac model. ............................................ 38 
1.3.5.2.1 Zebrafish embryo genetic approachs .................................................. 38 
1.3.5.2.2 Zebrafish embryo cardiac drug screens and arrhythmia models. .... 39 
1.3.5.2.3 Zebrafish embryo ECG development and other technologies for 
cardiac assessment. ............................................................................................... 40 
1.3.6 Comparison of mammalian and zebrafish drug screens. ............................ 42 
1.3.7. Project Aims .................................................................................................... 45 
2.1. Introduction ........................................................................................................... 48 
2.1.1 Parameter development and optimisation of the single electrode zebrafish 
ECG recording system. ............................................................................................ 48 
2.1.1.1 The effect of temperature on the ECG parameters recorded. ............. 48 
2.1.1.2 Optimal larval zebrafish development stage for ECG recording. ....... 49 
2.1.1.3 Electrode position on the larval zebrafish heart. ................................... 50 
2.1.1.4 Immobilising agents to facilitate ECG recording. ................................. 50 
2.1.1.5 Parameter development summary .......................................................... 51 
2.1.2 Optimisation of parameters with the later goal of high throughput 
recording ................................................................................................................... 52 
2.1.2.1 High throughput parameter testing: non-contact recording................ 53 
2.1.2.2 High throughput parameter testing: development of new reusable, 
metal electrodes. ................................................................................................... 54 
2.1.3 Aims .................................................................................................................. 55 
2.2 Methods ................................................................................................................... 56 
2.2.1 Zebrafish Husbandry and embryo collection ............................................... 56 
2.2.2 Single electrode glass capillary recording procedure................................... 56 
2.2.2.1 Making glass capillary electrodes ........................................................... 56 
2.2.2.2 ECG Recording procedure ...................................................................... 57 
2.2.2.3 NPI Amplifier............................................................................................ 58 
2.2.3 Non -contact recording system development: Glass block recording set up 
and bent electrodes. .................................................................................................. 59 
2.2.3.1 Glass block set up ..................................................................................... 59 
2.2.3.2 Bending glass capillary electrodes. ......................................................... 59 
2.2.4 Method for ECG recording from non-anaesthetized embryos. .................. 59 
2.2.5 Microfabricated electrode manufacture and micropipette tip recording set 
up to aid zebrafish orientation. ............................................................................... 60 
  
2.2.5.1 Microfabricated Probes ........................................................................... 60 
2.2.5.2 Micropipette Tip set up. ........................................................................... 61 
2.2.6 Multichannel System ....................................................................................... 61 
2.2.7 Production of twisted pair electrodes. ........................................................... 62 
2.2.8 Labchart analysis............................................................................................. 62 
2.2.9 Statistical analysis ............................................................................................ 63 
2.2.10 Drug stocks ..................................................................................................... 63 
2.2.11 E3 Medium protocol ...................................................................................... 64 
2.2.12 PTU Phenylthiourea ...................................................................................... 64 
Table 2.2 NPI amplifier and labchart settings ....................................................... 64 
2.3. Results ..................................................................................................................... 65 
2.3.1 Investigations to determine if anaesthetic affects heart rate and QTc. ...... 65 
2.3.2 Zebrafish larvae ECG recording from a non-contact position. .................. 69 
2.3.2.1 Development of alternative electrode set up for non-contact recording.
 ................................................................................................................................ 69 
2.3.2.1.1: Preliminary experiments highlighting the issues with standard 
setup. ...................................................................................................................... 69 
2.3.2.1.2: Optimisation of visualisation of electrode set up for distance 
recording. .............................................................................................................. 71 
 ................................................................................................................................ 72 
2.3.2.2 Non-contact recording achieved and visualised using alternative 
electrode shape and positioning. ......................................................................... 72 
2.3.2.2.1 Non-contract recording achieved and confirmed with high resolution 
imaging. ................................................................................................................. 72 
2.3.1.2.2 Signal: noise ratio calculated for non-contact positions. ................... 74 
2.3.3 Investigations into alternative materials for microelectrode ECG recording 
of larval zebrafish ECG. .......................................................................................... 77 
2.3.3.1 Metal electrode development: twisted pair electrodes. ......................... 78 
2.3.3.2 Metal electrode development: microfabricated electrodes ................... 81 
2.4 Discussion ................................................................................................................ 92 
2.4.1 0.3mg/ml MS-222 does not significantly affect the heart rate and QTc 
interval of 3dpf zebrafish larvae. ............................................................................ 92 
2.4.2 Non-contact recording from zebrafish larvae is possible and a maximum 
distance of 16µM can be reached. ........................................................................... 93 
2.4.3 Recording ECG from 3 dpf Zebrafish larvae using twisted pair and 
microfabricated metal electrodes: a move towards a high throughput system. . 96 
  
2.4.3.1 Measurable QTc differences can be recorded using metal twisted pair 
electrodes. .............................................................................................................. 97 
2.4.4 ECG signal can be recorded from microfabricated electrodes; a potential 
electrode type for high throughput recording. ...................................................... 99 
3.1 Introduction .......................................................................................................... 104 
3.1.1 The Human 12 lead ECG procedure ........................................................... 104 
3.1.2 Atrium and ventricle specific signals ........................................................... 104 
3.1.3 Analysis of ECG using wavelet transformations. ....................................... 106 
3.1.4 Aims ................................................................................................................ 106 
3.2 Methods ................................................................................................................. 108 
3.2.1 Zebrafish lines and husbandry ..................................................................... 108 
3.2.2 Single electrode recording method............................................................... 108 
3.2.3 Imaging: ScanR ............................................................................................. 108 
3.2.4 Standardising atrium and ventricle electrode positions ............................ 109 
3.2.5 Dual electrode recording method ................................................................. 109 
3.2.6 MATLAB: Wave solution analysis .............................................................. 110 
3.2.7 Temperature control ..................................................................................... 111 
3.2.8 Statistical tests. ............................................................................................... 112 
3.3 Results .................................................................................................................... 113 
3.3.1 Atrium and ventricle signals recorded using single electrode recording 
method. .................................................................................................................... 113 
3.3.2 Atrial and ventricle recordings taken from fluorescent lines using 
standardised electrode positions. .......................................................................... 117 
3.3.3 QRS amplitude recorded in atrium / ventricle. .......................................... 124 
3.3.4 Stimulation signal used to standardise signal differences between the 2 
electrode systems .................................................................................................... 125 
3.3.4 Using Fast Fourier transform to analyse ECG changes from drug 
treatment. ................................................................................................................ 129 
3.4 Discussion .............................................................................................................. 133 
3.4.1 Preliminary look at atrium/ ventricle signals ............................................. 133 
3.4.2 Significant difference between atrium and ventricle recorded signals 
detected using fast Fourier transform analyses. .................................................. 134 
3.4.3 Standardisation of a dual electrode recording system. .............................. 135 
3.4.4 Amplitude difference in QRS complex in atrium and ventricle signals. .. 136 
3.4.5 Analysis of drug induced differences in ECG traces using fast Fourier 
transform analyses.................................................................................................. 137 
4.1 Introduction ..................................................................................................... 140 
  
4.1.1 Genetic causes of long QT syndrome. .......................................................... 141 
4.1.2 The cacna1c gene encodes the Cav1.2 protein, an L-type calcium channel 
essential for normal cardiac function. .................................................................. 143 
4.1.2.1 Structure of the alpha 1c subunit of the L-type calcium protein ....... 143 
4.1.2.2 The Cardiac action potential and excitation-contraction coupling: the 
role of Calcium. ................................................................................................... 143 
4.1.3 LQT 8 and Timothy Syndrome. ................................................................... 144 
4.1.4 Current models of Cav1.2 dysfunction and Timothy Syndrome. ............. 146 
4.1.5 Characterisation of a novel calcium channel mutant cacna1c (sa6050). .. 148 
4.1.6 Utilising the larval recording system for detecting ECG differences due to 
genetic mutation...................................................................................................... 149 
4.1.7 Aims ................................................................................................................ 150 
4.2. Methods ................................................................................................................ 151 
4.2.1 Zebrafish husbandry ..................................................................................... 151 
4.2.2 The cacna1c sa6050 mutant .......................................................................... 151 
4.2.3 Visual screening for cacna1c homozygous mutants ................................... 152 
4.2.4 Genotyping analysis performed by Sanger Institute. ................................. 153 
4.2.5 Assessment of 2 dpf analysis as a screening tool ......................................... 153 
4.2.6 ECG procedure .............................................................................................. 154 
4.2.6.1 Recording set up ..................................................................................... 154 
4.2.7 Temperature control ..................................................................................... 154 
4.2.8 ECG analysis and Statistics .......................................................................... 155 
4.2.9 Drug stocks ..................................................................................................... 155 
4.2.10 Literature search to seek candidate drugs to rescue phenotype ............. 156 
4.2.11 Chlorzoxazone LC50 bioassay.................................................................... 156 
4.2.12 Screening for asystolic events ..................................................................... 157 
4.2.13 Introducing environmental stress through high salinity and orbital 
shaking procedure. ................................................................................................. 157 
4.2.14 Statistics. ....................................................................................................... 158 
4.3. Results ................................................................................................................... 160 
4.3.1 Phenotype screening of cacna1c mutants .................................................... 160 
4.3.1.1The cacna1c sa6050 mutant .................................................................... 160 
4.3.1.2 Visual phenotype screening of the cacna1c mutant at 2 dpf. ............. 161 
4.3.1.4 Genetic analysis of the cacna1c mutant performed at Sanger Institute.
 .............................................................................................................................. 164 
  
4.3.1.3 The heart rate of the cacna1c mutant is significantly slower than wild 
type embryos. ...................................................................................................... 166 
 .................................................................................................................................. 166 
4.3.2. ECG analysis of the cacna1c mutant .......................................................... 167 
4.3.2.1 Optimisation of dual electrode recording system for cacna1c mutant 
ECG analysis. ...................................................................................................... 167 
4.3.2.2 ECG interval analysis of cacna1c mutant and sibling controls 
performed at 28oC. ............................................................................................. 171 
4.3.2.3 Selection of diverse cardiac drugs for assessment effect on cacna1c 
mutant ECG. ....................................................................................................... 173 
4.3.3 Potassium channel blocker produces additive effect to the cacna1c mutant.
 .................................................................................................................................. 174 
4.3.4 Wild type zebrafish more profoundly affected by calcium channel blocker 
than the cacna1c mutant. ....................................................................................... 177 
4.3.5 Non-selective Beta-agonist partially compensates the mutant phenotype179 
4.3.6 Non-cardiac acting control drug has no effect on the cacna1c .................. 182 
mutant. ..................................................................................................................... 182 
4.3.7 Sodium channel blocker has additive effect on the cacna1c mutant 
phenotype. ............................................................................................................... 184 
4.3.8 Selective beta 1 beta-blocker increases prolongation of cardiac cycle. .... 187 
4.3. 9 Screening for asystolic events phenotype in cacna1c mutant. .................. 189 
4.3.9.1 Visual screening and population proportions ...................................... 189 
4.3.9.2 Inducing the asystolic events phenotype in the cacna1c mutant. ....... 190 
4.3.9.3 Video analysis of the asystolic events phenotype ................................. 193 
4.3.10 Effect of chlorzoxazone treatment on the cacna1c mutant. ..................... 196 
4.3.10.1 Identification of chlorzoxazone as a candidate rescue drug. ............ 196 
4.3.10.2 Chlorzoxazone LC50 assay and dosing range.................................... 197 
4.3.10.3 Effect of chlorzoxazone as a rescue drug for the cacna1c mutant ... 200 
4.3.11 Comparison of Timothy syndrome and sa6050 zebrafish mutant. ......... 204 
4.4. Discussion ............................................................................................................. 208 
4.4.1 Visual phenotype and genetic analysis of the cacna1c mutant. ................. 208 
4.4.2. ECG analysis of the mutant phenotype ...................................................... 210 
4.4.3 Potassium channel blocker has an additive effect on the mutant phenotype.
 .................................................................................................................................. 213 
4.4.4 Calcium channel blocker produces little effect in the mutant compared to 
wild type. ................................................................................................................. 213 
4.4.5 Non-selective beta-agonist increases the heart rate and reduces QTc...... 214 
  
4.4.6 Non cardiac-acting control drug has no effect on either wild type or 
cacna1c embryos ..................................................................................................... 215 
4.4.7 Sodium channel blocker has an additive effect on cacna1c mutant. ........ 215 
4.4.8 Selective beta 1 Beta-Blocker has an additive effect on the cacna1c mutant
 .................................................................................................................................. 216 
4.4.9 The use of a set of diversely acting cardiac acting drugs is informative on 
mutation target. ...................................................................................................... 217 
4.4.10 Screening for asystolic pauses phenotype and video analysis ................. 218 
4.4.11 Chlorzoxazone treatment on the cacna1c mutant reduces frequency of 
asystolic events, reduces QTc interval and increases heart rate. ....................... 219 
4.4.12 Comparison of sa6050 mutant to published Island beat mutant ............. 220 
4.4.13 Relevance of cacna1c mutant to human disease: Timothy syndrome. ... 221 
5. Overall conclusions ................................................................................................. 224 
6. References ............................................................................................................... 230 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Acknowledgements 
I would first like to thank my supervisor Ferenc Mueller for his continued support, 
advice and encouragement throughout my studies. I would also like to thank my co-
supervisor Attila Sik for his support and guidance, particularly with understanding the 
ECG systems.  
I would like to thank all the members past and present of the Muller and Sik labs, for 
creating a great working environment.  
I would also like to thank the British Heart Foundation for funding such an interesting 
project.  
I would like to thank my husband, my parents and family, for all their support and 
encouragement, without them I would not have reached the end.  
Finally, I would like to thank my daughter, Dorothy, my constant inspiration.  
 
 
 
 
 
 
 
  
 
 
1 
 
Abstract. 
 
In the past decade, the zebrafish, Danio rerio, has risen to greater and greater 
prominence as a vertebrate model system for drug discovery and toxicity testing. 
Zebrafish larvae represent an in vivo vertebrate model, with high throughput potential 
and proven efficacy as a model of human disease and drug responses. In particular, 
zebrafish have been used for cardiotoxicity studies and cardiac arrhythmia modelling.  
This project aims to develop and optimise tools for electrocardiographic recording in 
zebrafish larvae for use in cardiotoxicity screening and human arrhythmia modelling. 
Steps were taken towards a high throughput ECG system for zebrafish larvae through 
establishing viability of non-contact capillary electrode recording and development of 
microfabricated electrode arrays capable of replacing glass capillary electrodes. In 
depth analysis of atrium and ventricle signals using wavelet analysis was performed 
and the frequency profiles for these chambers examined. 
The utility of the larval ECG recording system for characterisation of a cardiac mutant 
(cacna1c sa6050) was demonstrated through a set of drug treatments and demonstration 
of drug discovery through ECG analysis of chemical rescue of the mutant phenotype.  
Overall, the results presented in this thesis highlight the zebrafish as an effective, robust 
and reliable model for cardiac arrhythmia and assessing drug responses in vivo. 
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1.1. The human cardiac cycle and drug induced 
cardiotoxicity 
1.1.1 Human cardiac action potential, ion channels and ECG.  
The cardiac action potential is responsible for generation and propagation of electrical 
activity in the heart which drives and coordinates cardiac myocyte contraction for each 
heartbeat (Seebohm 2005). Electrical activity is initiated by pacemaker cells at the sino-
atrial node at the top of the heart and then propagated through the atria causing atrial 
contraction. The signal is paused at the atrioventricular node to allow for blood from 
the atria to empty into the ventricles and then the signal is propagated down the bundles 
of His to the Purkinje fibres where excitation spreads through the Purkinje fibres 
causing apex to base ventricular contraction (Nerbonne and Kass, 2005). Cardiac action 
potential activity is caused by carefully organised and coordinated movement of ions, 
through cardiac ion channels, generating changes in membrane potential which drives 
signal propagation. The action potential is split into 5 different phases, with different 
cardiac ion channels involved in each phase (Iaizzo, 2009). The phases are, phase 0 
(depolarisation), phase 1 (early repolarisation), phase 2 (plateau), phase 3 
(repolarisation) and phase 4 (resting membrane potential restored). These are depicted 
in figure 1.1. 
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Figure 1.1 The phases of the human cardiac action potential. Phase 4: resting 
membrane potential of ~-90mV maintained by an inward rectifying potassium current 
through channel Ki22.X. Phase 0: depolarisation by inward sodium current through 
Nav1.5 voltage gated sodium channels. Phase 1: Early repolarisation by an outward 
K+ ion current through Kv4.2. Phase 2: the plateau phase maintained by balance of 
inward Ca2+ current causing excitation coupled contraction and an outward K+ ion 
current. Phase 3: Repolarisation by voltage gated potassium channels kv11.1 and 
Kv7.1.  
 
During phase 4 the membrane potential is at -70mV which is the resting potential in 
between heartbeats. The potential is maintained by an inward rectifying potassium 
current through channel Ki22.X. When a threshold potential of ~ -70mV is reached, 
phase 0 starts. In phase 0, Sodium ion channels open and a rapid inward Na+ ion current 
flows into myocytes causing depolarisation until a membrane potential of ~ +30mV is 
reached, and the channels shut. Then in phase 1, the sodium channels have closed and 
an outward current of K+ ions drives early repolarisation. Phase 2 is the plateau phase, 
where a massive influx of Ca2+ ions into the cell triggers contraction. The plateau is 
maintained by a concurrent outward potassium current ensuring that ventricular 
contraction has finished before repolarisation occurs. Phase 3 then follows, where the 
cell undergoes repolarisation to regain the resting membrane potential. Outward 
potassium currents facilitated by voltage gated potassium channels are responsible for 
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repolarisation, namely the Ikr (kv11.1) and Kv7.1. The Ikr is the main channel 
responsible for repolarisation in phase 3 and is commonly known as the hERG (human 
ether-a-go-go) channel and deactivates at -40mV. It is also sensitive to blockade by 
various classes of drugs (Golan et al, 2011 and Iaizzo, 2009).  
The electrical activity of the action potential can be observed using an 
electrocardiogram (ECG). The ECG is a recording of all electrical activity that drives 
each heart beat and is very useful clinically for diagnosis of heart dysfunction. The 
ECG can be split down into several components, The P wave, QRS complex and T 
wave. Clinically, the duration of these are measured, namely the PR interval, QRS 
duration and QT interval. Changes in these measurements can be informative of 
aberrant electrical activity causing arrhythmia (Hughes, Tarassenko and Roberts, 2004 
and Langheinrich, Vacun and Wagner 2008). The ECG can be seen in figure 1.2.  
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Figure 1.2 The Human ECG components. P: atrial depolarisation, QRS: ventricular 
depolarisation, T ventricular repolarisation. PR interval: AV conduction time, QT 
interval: time duration of ventricular depolarisation and repolarisation.  
The P wave represents atrial depolarisation and lasts around 80-110ms. The PR 
measurement is the time between atrial and ventricular depolarisation and is seen as 
atrioventricular (AV) conduction time and is measured from the start of the P wave to 
the beginning of the QRS complex. The QRS complex denotes ventricular 
depolarisation and is the dominant wave in the ECG. Measurement between R waves 
(RR interval) is used to calculate heart rate. The T wave is ventricular repolarisation, 
this is where the resting potential is reached ready for the next cycle to start. The QT 
interval measures ventricular depolarisation and repolarisation and is measured from 
the start of the QRS complex to the end of the T wave (Wagner and Strauss, 2013).  
The human ECG can occasionally have a wave following the T wave, called the U 
P 
Q 
R 
S 
T 
QRS 
complex 
PR interval 
QT interval 
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wave, which is also a part of repolarisation in the ventricle, and when present represents 
the last phase of ventricular repolarisation and is thought to represent Purkinje fibre 
repolarisation, although this is not conclusive.  Prominent U waves are most commonly 
seen in hypokalemia. They normally have the same polarity of the T wave, but inverted 
U waves against a positive T wave have been linked to left ventricular hypertrophy and 
myocardial ischemia (Hughes, Tarassenko and Roberts, 2004 and Iaizzo, 2009 and).  
 
1.1.2 Human cardiac arrhythmia and problems surrounding therapies.  
 
Cardiac arrhythmia refers to a set of conditions where the normal sinus rhythm and 
electrical activity of the heart is aberrant. Cardiac arrhythmias are highly varied both by 
mechanism and by patient outlook. Arrhythmia is a comprehensive term for abnormal 
rhythms both regular and irregular, as well as total loss of rhythm. Different arrhythmia 
types can be described in various ways such as rate, mechanism, site of origin, and 
ECG appearance. Some can be harmless, for example, sinus tachycardia after exercise 
or when anxious. However, some can be very dangerous, for example ventricular 
fibrillation, which is a life threatening arrhythmia and is often accompanied by cardiac 
arrest, (Iaizzo, 2009).  Congenital malformations and arrhythmias vary widely in 
mechanism and severity, with over 4300 babies born with a congenital heart defect 
each year in the UK (Artman et al, 2005). They represent a significant challenge in 
terms of developing novel therapeutic agents (Macrae 2010).  
1.1.3 Cardiac toxicity and QT prolongation.  
1.1.3.1 The drug development pathway and pre-clinical testing. 
The drug development pathway can be broken down roughly into 5 stages. Drug 
discovery where candidate drugs are identified, pre-clinical testing, and then clinical 
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trials in phases 1, 2 and 3. Successful candidate drugs after this process gain approval 
and are made available on the market. Non-clinical studies start during the discovery 
phase and continue to and sometimes beyond approval. This area of testing covers a 
very wide range of areas including biological research to understand the mode of 
action, pharmacokinetics, ADME (absorption, distribution, metabolism and excretion 
of compounds), and safety pharmacology (Nurnberg & Pierre, 2017). Safety 
pharmacology covers safety testing in multiple areas including cardiotoxicity, 
reproductive toxicity, acute and repeat dosing effects, genotoxicity, teratology, and 
toxicity in all organ systems. After candidate drugs are identified, the first step is to put 
these compounds through in silico predictions and in vitro screens. Following these, in 
vivo screens are performed in mammals. The results of these tests in combination 
dictate which compounds are taken forward for GLP (good laboratory practise) safety 
assessments described above.  If these are successful, then compounds progress into the 
human clinical trial phases (Nurnberg & Pierre, 2017). The average cost for a drug to 
successfully progress through the pathway and make it to market is $2.558 billion and 
takes 10-12 years (Wenchao, 2016). Therefore, it is better to fail early due to the step-
wise increases in costs as candidate drugs progress through the drug development 
pathway. So, to reduce the rising cost of drug development, early and efficient tools to 
screen out unsuccessful candidate drugs as early as possible in the development process 
are needed. Priority of which adverse drug reactions to target is based on incidence and 
impact (Redfern et al, 2008).  
 
1.1.3.2 Cardiac toxicity  
The biggest cause of drug candidates failing during development is due to toxicity, with 
cardiotoxicity being the leading causes of drug attrition (Anyuknovsky, 2011). In total 
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cardiotoxicity accounts for 22-23% of drug failure during development (Wenchao, 
2016). Cardiotoxicity is not only the cause of drug failure to be brought to market, but 
also a main cause of drugs being removed from the market due to subsequently being 
found to cause cardiac toxicity, with 45% of drugs removed from the market between 
1970 and 2005 resulted from cardiovascular related toxicity. These late phase drug 
failures are costly both in terms of money and time and screening out these compounds 
as early as possible is crucial to reducing this cost (Wenchao, 2016).  
Cardiac toxicity can refer to many different types of adverse action on the heart with 
varying underlying mechanisms. For instance, QRS prolongation can be caused by 
blockage of the sodium channels which leads to ventricular depolarisation delay. This 
blockage can be caused by drugs such as flecainide (Harmer et al, 2011). Doxorubicin 
is an anticancer drug with serious cardiotoxicity. It affects the function of multiple 
cardiac pumps and channels and causing calcium dysregulation leading to 
mitochondrial dysfunction and apoptosis. This ultimately leads to impaired ventricular 
activity and heart failure (Brano, Zamora and Tabernero, 2010).  A leading cause of 
drug failure during development is QT prolongation through blockage of the hERG 
channel, and there is a lot of focus on utilising and improving screening methods for 
hERG channel blockers but it is important to remember that there are many other 
cardiac ion channels which when their function is perturbed causes of cardiac toxicity 
and hERG centric approaches oversimplify the problem, Safety screens have to balance 
against multiple adverse drug targets, not just for hERG interaction (Redfern et al, 
2008). 
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1.1.3.2 QT prolongation and hERG channel.  
One of the main types of cardiac toxicity is an arrhythmia termed QT prolongation, 
which is a delay in ventricular repolarisation. Long QT is named for the observed ECG 
deformation where the QT interval is prolonged with respect to normal interval range, 
figure 1.3. A long QT is a clinically significant phenotype as there is the potential for it 
to progress from long QT to a distinct polymorphic ventricular tachycardia called 
torsade des pointes (tdp). This tachycardia is dangerous and can result in syncope, 
ventricular fibrillation and cardiac arrest (Abrams and Macrae, 2014). Congenital long 
QT syndrome has several identified causal mutations and is a major cause of sudden 
cardiac death, but toxicologically, the most common cause of a long QT phenotype is 
blockage of the Kv11.1 (hERG) channel.  
As depicted in figure 1.1, the Kv11.1 channel is the main repolarisation channel. It is 
encoded by the ether-a-go-go gene which is where the human ERG (hERG) channel 
name is derived. It has a large structure with 4 identical subunits spanning the 
membrane forming the pore, each with 6 segments in each subunit. It is voltage 
sensitive, opening and shutting in response to changes in membrane potential due to the 
cardiac action potential. Blockage of the channel by drugs disturbs the flow of 
potassium ions out of the cell, slowing ventricular repolarisation. This causes the T 
wave on the ECG to be larger, hence QT prolongation (Abrams and Macrae, 2014). In 
humans the QT ranges between 350 and 480ms, with the majority of the population 
falling within this range with age and gender accounting for some of the variance, 
(SAD Foundation https://www.sads.org/library/long-qt-syndrome#.Wp59nOjFLIV, 
accessed March 2018). When the QT interval falls outside of this range, this represents 
a short QT (< 380 ms) and a long QT phenotype (<450 ms). A short QT is also 
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clinically significant and patients with inherited short QT syndrome have an increased 
risk of sudden cardiac death (Antzelevitch, 2001). 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 ECG waveforms showing normal and prolonged QT interval. Cardiac 
repolarisation is prolonged when phase 3 potassium ion channels (kv11.1) are blocked 
by drugs, causing the T wave to increase and the QT interval to be longer.  
 
The hERG channel is very susceptible to blockage by drugs and has been demonstrated 
to show concentration dependant inhibition by various drugs (Mittelstadt et al, 2007). 
Drugs are now specifically screened for hERG interaction as large numbers of 
structurally and functionally diverse drugs have been found to be hERG blockers and 
consequently have been abandoned late into drug development. These drugs include; 
antihistamines, neuroleptics, and fluoroquinolones have all been shown to interact with 
the hERG channel (Raschi et al, 2008). A most notable example is terfenadine, an 
antihistamine, which was subsequently removed from the market after people reported 
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adverse cardiac side effects after using it, and then after testing it was revealed as a 
hERG channel blocker. Particularly due to the vast diverse drug types, structures and 
function which have been found to inhibit hERG channel activity, and the fact that the 
blockage causes long QT which can develop into a potentially fatal tachyarrhythmia, 
this highlights the need for cardiotoxicity screens for drug safety as early as possible in 
drug development (Raschi et al, 2008).  
The zebrafish has emerged as a vertebrate model organism for many human disease 
states including cardiac disease, and could prove useful as an arrhythmia model for 
potential cardiac responses to new drugs.  
 
1.2. Zebrafish as a model organism for human disease 
and drug development screens.  
 
The established method for discovering novel compounds with desired medicinal 
effects is through systematic screening and isolation of positive compounds. Successful 
compounds are then put forward for drug safety testing, for toxicity, ADME and 
efficacy using in vitro and in vivo tests. In vivo models are essential for toxicity, 
efficacy and metabolism testing. The zebrafish represents an in vivo model which has 
several advantages over traditional mammalian models and the use of which would be 
in line with the three R’s: refinement, reduction and replacement of animals in research. 
They have, over recent years grown in prominence as a viable alternative to traditional 
mammalian or cell line models for drug discovery, safety screening and disease 
modelling (Johnston et al, 2017).  
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1.2.1 The Zebrafish, Danio rerio: Background.  
Danio rerio is a fresh water teleost originating from south Asia. Adult fish can grow up 
to ~6 cm and they reach sexual maturity in 3-5 months of age with a life span of 2 – 3 
years. An adult mating pair can produce 200-300 eggs per week and can be maintained 
in artificial aquaria making them a popular model organism (Santoriello and Zon, 
2012). Traditionally, they were used for developmental research due to their high 
fecundity, transparency and ex utero development. It then developed as a genetic model 
and its genome has been sequenced, and during the last couple of decades it has 
emerged as a human disease model of choice by many and is widely used for a large 
variety of different conditions covering all organ systems (Santoriello and Zon 2012). 
The central database for zebrafish is a resource covering genetic, genomic, phenotypic 
and developmental data for the zebrafish model organism for human disease modelling 
(Howe et al, 2016).  
 
1.2.2 Zebrafish embryo development 
Zebrafish have ex utero development. Single cell eggs are hatched by the females and 
fertilized by the males. The first cell division takes place approximately 20 minutes 
later. Development then progresses from a 1 cell zygote to 32/64 cell stage within 3 
hours at 28oC. Zebrafish development can be split into 8 stages from the single cell 
zygote to the early larvae at 72 hours post fertilisation (hpf). The first stage, the newly 
fertilized egg known as the zygote, undergoes the first cell division. Then the cleavage 
stage covers rapid, synchronous cell divisions 2 through 7 which is where the blastula is 
formed at stage 3. The blastula is formed by approximately 2.5 hours after fertilisation 
and this is where epiboly (cell movement) begins. Epiboly movement continues 
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through the gastrula stage, forming the tail bud. This is followed by segmentation 
where the somites and pronephros form and primary organogenesis begins, this stage 
takes development up to 24 hours post fertilisation (Poon and Brand 2013). Cardiac 
development is rapid, a rudimentary heart tube formed in the first 24 hours providing 
circulation after initiation of the heart beat at the start of the pharyngula stage (Lu et al 
2016). From 24-48 hours post fertilisation (hpf), the pharyngula stage, is where pigment 
starts to develop. Endodermal progenitors fated to become the liver are identifiable 
from 18-24hrs post fertilisation. By 48 hpf the liver expresses mature liver markers and 
continues to grow through embryonic and larval stages. Primary liver morphogenesis is 
complete by 48hpf and the liver is fully formed and functioning by 72 hpf (McGrath 
and Li, 2008). Embryos hatch from their chorion between 48-72 hpf and have some 
gross motor movement due to development of pectoral fins and fin blades (Kimmel et 
al, 1995). The zebrafish are now larvae (72 hpf-29 dpf) and continue to grow, 
completing organ development by 5dpf. At 72 hpf, development is characterised by a 
protruding jaw, marking the point where embryos can start to ingest nutrients orally as 
well as dermally, figure 1.4. Free swimming develops at 5 days post fertilisation (dpf) 
when the swim bladder inflates (Lieschke and Currie, 2007). The juvenile period lasts 
from 30-89 dpf, when the adult fins and full pigmentation has formed. Following this, 
the fish is considered an adult (Kimmel et al, 1995).  
Up until the jaw develops at around 72 hpf, embryos absorb oxygen and some nutrients 
through transdermal diffusion, until the gills form, but nearly all requirements, bar 
oxygen, are contained in the yolk sac, figure 1.4 shows the anatomy of a zebrafish 
larvae 72 hpf. The yolk sac provides all nutrients for the first 5 days of life before free 
feeding stage is reached at 5dpf. Adults have gills for oxygen uptake like all other fish 
but the embryo can absorb oxygen by transdermal diffusion (Langheinrich, 2003). 
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Figure 1.4 Anatomy of a zebrafish larva 72 hours post fertilisation (hpf). 
Despite obvious anatomical difference to humans, including a lack of long limbs, lungs, 
and an intestinal bulb instead of a stomach, zebrafish have many comparative organs 
and organ systems to human, such as liver, pancreas and heart and cardiovascular 
system with a conserved function across species (Lieschke and Currie, 2007). 
1.2.2.1 Zebrafish cardiac development.  
During zebrafish embryogenesis, similar to mammals, the heart is one of the first 
organs to develop and heart development is rapid, with a beating rudimentary heart tube 
observed at 24 hours post fertilisation (hpf) (Hu et al, 2000). This then loops, known as 
D-looping, to form a single atrium and a single ventricle (Burggren et al, 2017 and 
Stainier et al, 1996). Mesodermal heart precursors specific for atrium and ventricle 
drive heart assembly and at the 18 somite stage these come together and then fuse, 
creating a cone structure which then forms the tube by 24hpf. By 48 hpf distinct 
chambers can be observed, figure 1.5 (Burggen et al, 2017). 
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Figure 1.5 Zebrafish early heart development. Structures observed from 14 hpf to 48 
hpf. Cardiac progenitor cells from the mesoderm specific for atrium and ventricle 
emerge. These migrate and fuse to form the cone structure, and then by 24 hpf the 
beating heart tube has developed. This then undergoes cardiac D-looping to form the 
atrium and ventricle chambers observed by 48 hpf. 
 
The zebrafish conduction system is a unidirectional with a single atrium and a single 
ventricle comprising the heart. There are also two extra structures in fish to maintain a 
low pressure system, bulbus arteriosus and venus sinosus. These chambers aid 
movement of blood into and through the capillary network in the gills. Once fully 
developed, in the adult zebrafish heart, the ventricle is more conical in shape and blood 
is pumped unidirectionally, from the sinus venosus through the atrium, ventricle and 
out into the bulbus where it is then pumped into the capillary network in the gills and 
then round the body, figure 1.6 (Leong et al, 2010). The shape of the ventricle helps 
facilitate the pressure in the blood system. Hu, Yost & Clark, 2001, measured blood 
pressure gradients in the adult zebrafish. Blood pressure is a major variable in 
cardiovascular regulation in zebrafish and so pressure for systole and diastole were 
measured for the atrium and ventricle chambers and the dorsal and aortic blood vessels. 
Ventricular pressure was measured to be approximately ~2.51/0.42 mmHg (Hu, Yost & 
Clark, 2001). Larval blood pressure is lower than in adult and pressure increases with 
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size as they grow. At 5 dpf ventricular pressure was measured to be approximately 
0.42/0.003 mmHg (Hu et al, 2000).  
 
 
 
 
 
 
 
 
Figure 1.6 The adult zebrafish heart. Dashed arrows show the direction of blood flow. 
A single atrium and ventricle are joined by the sinus venosus and bulbus arteriosus 
which are used to maintain a low pressure system. Blood passes from the bulbus into a 
capillary network around the gills for oxygenation and then is pumped around the 
body. Figure taken from Leong et al, 2010.  
 
By 3dpf there is a functioning conduction system with a fully formed heart complete 
with a complex system of cardiac ion channels which display complimentary effects to 
cardiac acting drugs as some humans (Dhillon et al, 2013, Santoriello and Zon, 2012).  
 
1.2.3 Zebrafish model compared to existing in vivo models 
In vivo models are essential for efficacy, toxicity and metabolism during drug 
development, and for aiding understanding to discover new drug targets and novel 
therapies. In vivo models are traditionally rodents or dogs. These require large amounts 
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of compound and long treatment regimens which is expensive. Zebrafish only require 
small amounts of compound and rapid development would decrease these costs.  
 
1.2.3.1 Advantages of the zebrafish embryo model for drug screening 
compared to mammalian model systems. 
Zebrafish have many advantages over other animal models for use in drug development 
and in scientific research. In drug safety screening, rodents are widely used and are the 
in vivo model of choice due to their close evolutionary relationship to humans. They 
have all largely similar anatomy, conserved cellular pathways and drug metabolism, 
and drugs can be administered the same way as humans with rodents, which is a 
distinct advantage over zebrafish models. However, they are also much more expensive 
to use, and development is comparatively slow and occurs in utero and have more 
stringent restrictions and regulations surrounding their use (Lieske and Currie, 2007). 
Zebrafish advantages over mammalian models are wide-ranging. They have low 
maintenance costs compared to rodents and due to their small size as up  to 30 animals 
can be housed in a tank roughly the same size as a mouse cage (Gut et al, 2017). Their 
size also means that only small amounts of compound are needed for a study, also 
reducing cost and because of the yolk sac, embryos do not require feeding until 5 dpf. 
Zebrafish embryos are transparent, this coupled with their ex utero development means 
ease of visualisation under a microscope. This allows observation of the stages of 
development and direct observation of drug effects (Langheinrich 2003). Their rapid ex 
utero development and small size also lends them to high throughput screening 
potential. Embryos are easily housed in 12, 24 or 96 well plates for drug treatment and 
visual assessment of phenotypes.  
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It is also important to note that the use of zebrafish in place of rodents and other 
mammals contributes to the 3 Rs: refinement, reduction and replacement of animals in 
research, as zebrafish embryos are not protected in law or require a licence until they 
reach free feeding and swimming stage at ~5 dpf (Langheinrich 2003). 
Crucially, as a potential model for drug responses, they have similar toxic responses to 
humans and other mammals due to evolutionary conserved cellular pathways and 
systems. Early development is highly conserved in all vertebrates and leads to high 
similarity in pharmacology, physiology and genetics (Gut et al, 2017). They have close 
conservation with other vertebrate species, with 70% gene homology and 80% 
homology with disease causing genes in humans (Howe et al, 2013).  
Zebrafish embryos have features, in addition to those discussed above, that particularly 
lend themselves to use as an in vivo drug screen. They can absorb molecules 
transdermally which can be utilised as a drug delivery system. However, this route has 
limitations, for example; size. Compounds also need to be water soluble to be added 
into the medium surrounding larva for uptake, but zebrafish are reasonably tolerant to 
DMSO (dimethyl sulfoxide) which can be used to aid solubility of less soluble 
compounds (Sukardi et al, 2011). From 72 hpf drug uptake is also oral as the mouth 
and jaw are sufficiently developed. The liver is fully formed and functioning by 72 hpf 
also, with homologous enzymes crucial for comparative drug metabolism (McGrath 
and Li, 2008). They can survive in small volumes of water in 96 or 384 well plates 
introducing the possibility for automated drug screens on a large scale with a high 
throughput. This introduces the potential for zebrafish to be used for big-data 
approaches (Gut et al, 2017). Tissues or organs of interest can be labelled using 
fluorescent tags to aide screening. From 3 dpf the jaw develops allowing oral ingestion 
of compounds as well as transdermal absorption (Leong et al, 2010). Dimethyl 
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sulphoxide (DMSO) is used to increase solubility of poorly soluble compounds and 
zebrafish are tolerant of up to 1.5% DMSO allowing compounds with low water 
solubility to be tested by zebrafish embryos (Hallare et al 2006).  
Zebrafish exhibit high similarity to humans in terms of pharmacology, physiology, 
genetics and toxic effects to drug exposure making them an ideal model organism 
(Santoriello and Zon, 2012).  An important advantage for human disease modelling is 
that the zebrafish genome has been sequenced which means direct comparison with the 
human genome can be performed (Howe et al, 2013). The zebrafish genome has an 
additional 2 chromosome pairs and many duplicate genes, but these duplicates often 
have a different function or expression in different tissues. Often, gene duplicates in 
zebrafish are species specific with no human orthologue. Duplicate genes can be 
advantageous in cases where if one gene copy is compromised from mutation, the 
other copies may compensate and so the overall mutation effect is reduced (Howe et 
al, 2013).  
Their high fecundity is an advantage when establishing a new transgenic line as this, 
coupled with rapid development means it is much quicker and cheaper than in rodents 
(Santoriello and Zon 2012). 
 
1.2.3.2 Advantages and disadvantages of zebrafish compared to other fish 
models 
Besides zebrafish, other fish have also been used as model organisms. Carp (Cyprinus 
carpi), has historical use as a toxicological model, and perhaps is more suitable when 
greater amounts if tissue are needed or for anatomical assessment, due to its larger size. 
Puffer fish (Fugu rubripes) has been used for genetic studies by virtue of its potential to 
provide information on gene organisation and regulation and has close homology with 
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human genes despite having a genome 1/8th the size. A fish very close to zebrafish 
which has been used is the Japanese medaka (Oryzias latipes). The Tol2 element for the 
Tol2 transposon mediated mutagenesis system popular with zebrafish users was 
discovered in medaka (Leong et al, 2010). Medaka are a similar size to zebrafish, 
mature within 2 months and lay large numbers of eggs. They have provided a breadth 
of genetic and developmental model information. However, they only have a life span 
of 1 year in the lab, which is a quick turn over.  
While useful, none of these fish models can singularly allow the large variety of 
technical advantages the zebrafish does, but may, particularly medaka, work 
complementary to the zebrafish model (Hill et al, 2005).  
 
1.2.3.3 Advantages and disadvantages of zebrafish compared to other in 
vitro models for drug screening 
Zebrafish, as a vertebrate in vivo model, has advantages over in vitro screens as in vitro 
cell line testing lacks the complexity of a whole organism and therefore, loss of 
functionality compared to whole organs and organ systems when testing, for example, 
cardiotoxicity. Multiple different cell types make up organ systems and cell-cell 
interactions between cell types will be missed in a simpler test system (Driessen et al, 
2015). However, as a first response, quick test, in vitro screens are very useful and for 
many represent the current standard for single end point assays . They are cheaper than 
whole organism models, reduce animal use and do not have the stringent protocols and 
regulations attached to whole animals (Driessen et al, 2015). In addition, 
toxicogenomic in vitro approaches allow gene expression changes upon exposure to 
compounds to be monitored with a high throughput and low amounts of compound. It 
is also important to note that the cell culture serum essential for maintaining cell 
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cultures can act as a barrier to drug uptake by the cells. Serum proteins can bind to 
drugs, inhibiting them from reaching their cellular targets. In addition, the large data 
sets generated are time consuming to analyse and are often affected by normal gene 
expression variation (Pettit et al, 2010). Induced pluripotent stem cells offer distinct 
advantages over other models, both in vivo and other in vitro systems. These are cells 
derived straight from patients and therefore are genetically identical. Studies have 
shown that the use of pluripotent stem cell derived cardiomyocytes show patterns of 
cardiotoxicity; and have even been shown to be effective in arrhythmia screens (Liang 
et al, 2013 and Navarrete et al, 2013). In vitro cell based ion channel assays are 
prevalent in early toxicity screening and are extremely effective for looking at single 
ion channel interactions, for example those compounds interacting with the hERG 
channel. These assays are rapid, but only look at single ion channel interaction with a 
single endpoint. For more complex cardiovascular toxicities with multiple endpoints, a 
more integrated approach, such as a whole organism are required.   
Whilst not comprehensive enough in isolation, in vitro testing represents a large 
component of screening and is best utilised coupled with more complex whole 
organism in vivo models (Pettit et al, 2010).  These in vitro and in silico models have 
the advantage of being quick and comparatively simple to implement compared to in 
vivo models, and do not have the same restrictions, but are not comprehensive enough 
on their own to identify all cardiotoxic drugs during development.  
 
1.2.3.4 Zebrafish as a complimentary model to existing in vitro models  
For drug development, the aim would be to introduce zebrafish embryos as a vertebrate 
in vivo high throughput model, which inserts complimentary to existing screens. 
Currently in drug development, in vitro and mammalian in vivo models are used in 
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combination for drug safety screening. As a tiered system, those that pass the in vitro 
tests are put forward for mammalian testing, but there are still many costly late stage 
drug candidate failures. These could be reduced by introducing high throughput in vivo 
zebrafish screens that sit complimentary to and alongside the other screens prior to 
GLP safety assessments. This would help ensure that only prime candidates are 
advanced to the time consuming and costly in vivo mammalian screens.  
There is evidence that in vitro and zebrafish in vivo screens would work well together; 
for example, in nanoparticle safety testing. Some nanoparticles can induce oxidative 
stress and inflammation, and screening using macrophages and neutrophils (in vitro) 
and zebrafish would be greatly beneficial (Johnston et al 2017). This was taken further 
and a comparative screen testing for novel cell cycle inhibitors was performed in a 
mammalian cell line, a zebrafish cell line and zebrafish embryos. The results showed 
that the zebrafish embryo screen identified 14 compounds, not identified by the cell 
lines, and 6 of these were subsequently found to have an effect in the mammalian cells. 
This suggests a conserved effect in vertebrates. There were 3 compounds inactivated 
by the culture serum, and so no effect seen in the cell line and 1 compound was only 
effective in the zebrafish cell line and embryos suggesting a species specific effect. 
These results demonstrate that performing the same screen across multiple platforms; 
cell lines and zebrafish embryos gives a much greater amount of information than any 
one screen individually, and can be used to identify compounds that would have been 
missed without the additional inclusion of a zebrafish embryo screen (Murphy et al, 
2006). This principal can be applied across drug development and safety screening. 
Toxicity testing across cell lines and zebrafish embryos yield a greater quality of drug 
candidates to advance to mammalian in vivo tests, reducing the amount of late stage 
drug failures. This would be especially applicable to cardiotoxicity and hERG channel 
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interaction, which is the greatest cause of drug candidates being dropped from 
development.    
 
1.3 Zebrafish as a model of human cardiac conditions and 
arrhythmia. 
1.3.1 Zebrafish as a tool to evaluate cardiotoxicity 
Zebrafish have emerged as a model organism for human disease and novel drug 
development. They have a highly conserved, sequenced genome with around 70% 
homology to humans and 80% homology of disease causing genes. This makes them a 
very desirable genetic model (Milan and Macrae, 2008). There are many features of 
zebrafish which makes them ideal for a phenotype screen, for example, their small size, 
small amounts of chemical required for dosing and comparatively inexpensive 
husbandry makes them a cost effective alternative to other vertebrate systems such as 
murine models. Their ex utero development, optical transparency means that close 
observation of development and phenotype progression is possible. Fluorescent 
markers can be used to highlight areas of interest and many transgenic lines have been 
created for a wide range of uses including expressing fluorescent proteins of interest, 
analysis of enhancers, and modelling genetic abnormalities for modelling human 
disease (Milan and Macrae, 2008, Roberts et al, 2014, Kari, Rodeck and Dicker, 2007). 
Zebrafish have been used successfully for toxicological studies, as these can be 
conducted with relative ease using a 24 or 96 well plate, small amounts of compound 
and effects easily visualised due to optical transparency (Mcgrath and Li, 2008). This 
approach has led to large-scale chemical screens and mutagenic screens, creating 
zebrafish mutants modelling human diseases with visible embryonic phenotypes, for 
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example cardiovascular diseases such as cardiomyopathy and arrhythmias (Lieschke 
and Currie, 2007 and Rubinstein, 2003). Zebrafish and human cardiac 
electrophysiology share many similarities.  
 
1.3.2 Zebrafish electrophysiology  
1.3.2.1 Comparison of human, mouse and zebrafish action potentials and 
electrophysiology.  
In humans, the pacemaker cells are the source of cardiac electrical activity. Pacemaker 
cells are also found in the zebrafish which control heart rate and initiation of the 
zebrafish action potential. There are some differences in physiology; the structure of the 
vessels is simpler, and the ventricles lack Purkinje fibres and bundles of His, but the 
zebrafish have ventricular trabeculae which perform a similar function and the 
ventricles still contract apex to base the same as humans. Most notably, zebrafish only 
have one atrium and one ventricle, as opposed to the two atrium and two ventricle heart 
structure in humans (Milan and Macrae, 2008). 
 
Many orthologues of human cardiac ion channels are found in zebrafish, and 
consequently, a lot of the channels which make up the different phases of the zebrafish 
action potential are homologous. However, there are some differences. In phase 0, 
sodium channels are responsible for rapid depolarisation but in zebrafish, calcium 
channels called t type calcium channels also contribute. This is also present in 
mammals but only very early in development. Phases 2 and 3 are very much the same 
as in humans with zebrafish orthologue channels causing the voltage plateau and rapid 
repolarisation. The major difference between humans and zebrafish embryos is that the 
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zebrafish embryos lack Kv7.1 and Kv4.3 which generate the early repolarisation in 
phase 1 (Leong et al, 2010).  
Adult zebrafish have an average heart rate of 120-150bpm (beats per minute) which is 
roughly twice the speed of humans, but much closer to the human heart rate than mice, 
whose hearts beat approximately 10 times that of humans and have evolved to have a 
rapid repolarisation phase to facilitate this fast heart rate. Zebrafish, like humans have a 
slow repolarisation phase with very similar ion channels used to generate the action 
potential, as described above. Mice have a different main repolarisation channel, in 
order for fast repolarisation to happen. The main repolarisation channel in humans, the 
kv11.1 (hERG) channel, has a homologue in zebrafish (zERG) which is the main 
repolarisation channel in zebrafish (Leong et al, 2010). However, in mice, while there 
is a hERG homologue, it is not the main repolarisation channel for the murine action 
potential. This is because the current flow through this channel is too slow for the fast 
repolarisation required for the fast heart rate of the mouse. figure 1.7.  
 
 
Figure 1.7 Comparison of human, mouse and zebrafish action potentials (AP) 
A) Human action potential. Fast depolarisation and slow repolarisation with a plateau 
phase.    
B) Mouse action potential: less plateau and fast repolarisation to facilitate a fast heart 
beat 10 x that of human. IKr channel is not the dominant channel for repolarisation. 
C) Zebrafish action potential, more closely resembles the human AP with a plateau and 
slower repolarisation. IKr channel is the dominant repolarisation channel which 
allows modelling of repolarisation abnormalities such as QT prolongation from hERG 
(zERG) blockade.  
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The mouse action potential does not have much of a plateau phase and relies on fast a 
repolarisation current to facilitate the fast heart rate. The zebrafish action potential more 
closely resembles the human action potential and has a more comparable heart rate. The 
zebrafish, therefore, is arguably the better model of human cardiac repolarisation 
abnormalities than mice. 
 
1.3.2.2 The Human ECG compared to the zebrafish ECG.  
As expected, due to similar ion channels being responsible for generating the different 
phases of the human and zebrafish action potentials, the resultant ECG traces for these 
species, which measures this electrical activity, are also very similar. Like human, there 
are three main components of the ECG, the P wave, QRS complex and the T wave. 
These depict atrial and ventricular depolarisation and repolarisation in the same way the 
human ECG does, and the three main measurements commonly taken from the ECG for 
analysis; the PR interval, the RR interval and the QT interval, measured the same way 
as in human. The PR segment shows time taken for the components responsible for 
carrying the electrical current to be activated. In zebrafish this interval is shorter than in 
humans, around 30ms, as there is less delay between transference of electrical signal 
from atrium to ventricle. Also, the P wave is smaller, as there is less muscle in the 
atrium in zebrafish and the blood pumping is mainly due to the thicker ventricle 
(Artman et al, 2008 and Milan et al, 2006). In zebrafish the RR interval is shorter than 
in human, as they have a faster heart beat (Leong et al, 2010). The QT interval in 
zebrafish is comparable to human, only slightly shorter. The QTc interval is the QT 
interval corrected for heartrate and can be calculated using the Bazett’s formula 
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QTc=QT/√RR, (Wagner and Strauss, 2013). In mice, the ECG shows differences to 
human and zebrafish as a result of the differences in the action potential. Most notably, 
the QRS complex has two peaks, and a negative T wave, in addition, the whole cardiac 
cycle is around a 10th of humans, figure, 1.8.  
 
 
 
 
 
 
 
Figure 1.8 Depiction of the human, mouse and zebrafish ECG trace showing the P 
wave, QRS complex and T wave. Adapted from Leong et al 2010.  
A) Human ECG trace. 
B) Zebrafish ECG trace, close similarity with the human ECG.  
C) Mouse ECG trace, differences seen from the human trace; two peaks for QRS and 
negative T wave.  
 
Human and zebrafish, have strongly correlating ECG traces, due to similar action 
potentials (Leong et al 2010). Consequently, they respond to different cardiac acting 
drugs in the same way, and so it is possible to use zebrafish responses to predict human 
responses to cardiac drugs. This makes them a very attractive model for cardiotoxicity 
testing (McGrath and Li, 2008).  
 
1.3.3 Zebrafish as a model for Long QT syndrome  
As demonstrated, high conservation between human and zebrafish has already been 
exploited by groups using zebrafish as a model organism for disease states across 
multiple organ systems which includes cardiovascular. Adult zebrafish arrhythmia 
A B C 
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models take advantage of ion channel conservation with humans to closely model 
arrhythmic responses to drug treatments and genetic arrhythmia models. Particularly 
repolarisation abnormalities, where the potassium ion channels driving repolarisation in 
humans (the hERG channel, kv11.1) has a zebrafish orthologue zERG.  It is possible to 
use zebrafish larvae as a screen for cardiac drug safety testing. Larvae at 3dpf have 
been successfully visually assessed for the presence of bradycardia (slow heart rate) 
and AV block (conduction between atrium and ventricles impaired, so ventricle 
contraction is irregular against the atrium), when dosed with known hERG blockers 
(Bergmans et al, 2008). 
As previously stated, orthologues of the human cardiac ion channels are found in 
zebrafish, these include orthologues of hERG and Nav1.5 (Nguyen et al, 2008). The 
zebrafish zERG channel protein has 1186 amino acids and has 60% sequence 
homology to human hERG channel with 90% homology at the pore forming region. 
Both consist of 6 transmembrane domains, S1-S4 voltage sensing and S5-S6 making up 
the central ion pore (Hassel, et al, 2008), figure 1.9.  A cAMP binding site is located 
following S6 in the c terminus and this, along with the amino acids in segments 4,5 and 
6 are highly conserved with the human othologue, (Langheinrich et al, 2003).  
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Figure 1.9 The zebrafish zERG channel. A transmembrane voltage gated potassium 
channel, the main repolarisation channel in the zebrafish heart. It has 6 
transmembrane domains S1-S4 forming the voltage sensing components and S5-S6 
forming the potassium selective channel. Two domains are shown with S1-S4 in purple 
form the voltage sensing component and S5-S6 in red form the pore. In S5 and S6 there 
is a pore helix (PH), a cyclic AMP (adenosine monophosphate) binding domain 
(cAMP).   
 
The main ventricular repolarisation channel in both human and zebrafish is the hERG 
channel, known as the zERG in zebrafish and perturbance of channel activity leads to a 
prolongation of the QT interval on an ECG. This can be genetic or drug induced and is 
diagnosed in humans as long QT syndrome. The QT interval comprises ventricular 
depolarisation (QRS) and repolarisation (T wave). When this occurs, there can be a 
predisposition to arrhythmia, and Torsades de pointes (TdP) which is a life threatening 
tachycardia characterised by the QRS twisting around the isoelectric baseline, 
(Chaudhari et al, 2013). This can lead to sudden cardiac death. It has been 
demonstrated that known hERG blockers have the same effect (QT prolongation) in 
zebrafish, making them an ideal model to screen for adverse cardiotoxicity hERG 
blockers in an in vivo vertebrate large scale chemical screen (Arnaout et al,2007).  
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1.3.4 Current cardiac models 
1.3.4.1 In vitro and in silico cardiac models 
Pluri-potent stem cells derived from human cardiac tissues have been implemented as 
in vitro models for testing cardiotoxicity (Navarrete et al 2013). They currently 
constitute an important part of cardiotoxicity testing, alongside in vivo models. Human 
pluripotent stem cell lines derived from the myocytes of healthy and arrhythmic hearts 
(hiPSC-CMs) have been used to generate single cell level drug response profiles of 
different arrhythmia types against healthy hiPSC-CMs. Hereditary arrhythmic cell lines 
included Long QT syndrome, dilated cardiomyopathy and hypertrophic 
cardiomyopathy. This library exhibited increased susceptibility to cardiac drugs, with 
differing responses, highlighting that use of such cell lines may be predictive of drug 
treatment responses (Liang et al, 2013). An in vitro hERG channel assay has been 
widely implicated to combat the prevalence of hERG channel blockers discovered late 
into development and have shown good predictive value at predicting compound 
interactions. The current gold standard for identifying hERG interaction is by a high 
throughput in vitro whole cell patch clamp assay. This approach is very successful for 
identifying compounds which interact with the hERG channel accurately and is capable 
of producing data for hundreds of compounds a week. However, these ion channel 
assays are single end point and more complex compound interactions and toxicities can 
not be assessed through these approaches. Zebrafish larvae present a multi-end point 
model but while there is high throughput potential, manual handling and orientation of 
embryos needs to be removed in order to compete with the throughput of in vitro assays 
(Redfern, et al, 2008). Kramer et al, 2013, reported higher predictive value using MICE 
(multiple ion channel effects) models, with a reduction in false positives and false 
negatives, so may represent an alternative in vitro test (Kramer et al, 2013). However, 
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in vivo testing where all channels of relevance are expressed as are interconnects and 
external influences provides a more accurate and complete picture of cardiac toxicity 
than testing for individual channel responses alone. This is where the zebrafish could be 
used, as a more rapid alternative to mammalian systems.   
In silico testing are predictive computational models using collected knowledge of 
known drug responses to different drugs, their structure and uses this to predict 
responses to novel compounds. Aronov et al, 2005, used this approach to create an in 
silico model to screen for potential hERG blockers. The problem with trying to predict 
hERG blockers, is that many compounds with diverse drug action and structures have 
been found to interact with and inhibit hERG channel function, making it a difficult and 
complex task to predict without further testing. However, homology modelling and 
QSAR methods, have shown good results.  
In silico testing has also been performed for analysis of patients with long QT 
syndrome. Similar to the study performed by Liang et al, 2013, this study evaluated the 
utility of a computer model to perform a risk assessment of cardiac-acting drugs given 
to patients with type 1 long QT syndrome. They successfully demonstrated modelling 
of type 1 LQT repolarisation and drug responses using multivariate analysis (Hoefen et 
al, 2012).  
In silico and in vitro testing are extremely useful to narrow down drug candidate pools, 
but cannot be used in isolation with 100% accuracy. These tests must be utilised in 
combination with in vivo models, and zebrafish provide a viable, cheaper alternative to 
mammalian models.  
 
32 
 
1.3.4.2 In vivo models: mammalian 
Traditionally, in drug development, successful candidate drugs that progress past in 
silico and in vitro tests are then put forward for mammalian testing in mice and rats. 
These tests cover toxicity testing (including; cardiac, hepatic, reproductive, respiratory) 
and long term dose studies. These studies are vital for bridging the gap between bench 
top research and the clinic. This translational phase relies on validated and predictive 
mammalian models such as mice and rats (Denayer, Stöhr and Roy, 2014).  
 In vivo mammalian models can be used to be predictive of novel drug responses, due to 
the large body of data amassed from decades of standardized protocols, but different 
model systems are needed to be pieced together to create a full picture, for example; 
cell-based ion channel assays, in vivo assessment of conductivity, physiology and 
electrophysiology all contribute a different aspect of this multifaceted disease, and no 
single model encompasses all these aspects (Denayer, Stöhr and Roy, 2014). 
Mammalian models continue to provide valuable insights into cardiovascular disease 
and arrhythmia (Smith et al, 2016 and Green et al, 2016). For example; hypertrophic 
cardiomyopathy, where the heart muscle becomes enlarged and inefficient at pumping 
blood through the heart and around the body and lungs, is commonly modelled using 
mammalian systems. This is a progressive disease, ultimately leading to heart failure 
and as such is an important area of interest for discovering novel therapeutics (Green et 
al, 2016). Green et al, 2016, identified a novel compound which inhibits the 
hypercontractility associated with the early disease state, by binding to myosin and 
inhibiting hypercontractility activity when administered to mice (Green et al, 2016). 
Mouse mutant models are also used, for example SCN5A-linked Lenègres disease. 
SCN5A is the main sodium channel in the heart, and mutations in this channel are 
linked to age related arrhythmias and myocardial fibrosis (Royer et al, 2005). Study of 
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models such as this further understanding of these disease states and help to identify 
drug targets for intervention. 
Study of cardiac arrest has been performed in a number of mammalian model species 
including; mice, rat, rabbit and canines, where cardiac arrest was induced using 
electrical pacing to the heart, and different characteristics including toxicology, 
asphyxia and myocardial infarction were assessed as well as drug intervention, 
ventilations and compressions noted. Animal models of cardiac arrest test potential new 
interventions and are widely used for cardiac arrest research (Vognsen et al, 2017). 
 Preclinical testing is a requirement of regulation authorities for a candidate drug to be 
put forward from bench research into the drug development pathway. Standard 
preclinical testing covers a wide range of areas including: acute, repeat dosing, 
genotoxicity, reproductive toxicity, teratology and safety pharmacology. It provides 
valuable data and insight into its potential performance in clinical trials and is vital to 
improve chances of the drugs success both in terms of efficacy and safety (Denayer, 
Stöhr and Roy, 2014). Due to the vast cost involved in detailed animal model studies, 
the use of a valid, cost-effective alternative, such as zebrafish represents a viable, 
substitute for some of these pre-clinical testing models.  
 
1.3.5 Current Cardiac zebrafish cardiac models 
1.3.5.1 Adult zebrafish cardiac models  
1.3.5.1.1 Adult zebrafish cardiac disease modelling.    
The zebrafish heart anatomy is different to human, but despite these differences have 
been used successfully for cardiac modelling (Menke et al, 2011, Gut et al, 2017). 
There are many examples of cardiomyopathy in adult zebrafish, including genetic, 
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chemical and anaemia induced models which also concomitantly uses high resolution 
imaging and fluorescence (Gut et al, 2017, Reischauer et al 2014 and Ding et al, 2016). 
Reischauer et al, created a transgenic line with actin binding GFP to visualise in 4D and 
in vivo, the myofilament dynamics in early heart development of the zebrafish. They 
then used this line to identify erbb2 signalling which has a role in myofibril 
organisation and inhibition of erbb2 causes dysregulation of the myofibrils and 
cardiomyopathy. Using the dominant-negative erbb2 transgene, a model of 
cardiomyopathy in adult zebrafish was created (Reischauer et al, 2014). Ding et al, 
2016 also identified a gene with cardiomyopathy susceptibility using a transposon 
mutagenesis screen. 44 other transgenic lines indicating a potential role in cardiac 
regulation were also identified (Ding et al, 2016). There are many other examples 
where zebrafish have been used to identify genes and pathways involved in cardiac 
failure and developed into useful models yielding important insights into this major 
cardiac disease problem. There are advantages to using zebrafish to model congenital 
heart disease (CHD). In humans, severe defects ultimately lead to heart failure. 
Modelling this progression in zebrafish can be useful as the oxygen requirement for 
early stage development in zebrafish larvae is fulfilled by dermal absorption. However, 
due to differences in size and anatomy, zebrafish heart failure can present differently to 
human analogues, even with the same underlying cause (Brown et al, 2016). In 
zebrafish, heart failure disease progression begins with gradually decreasing 
contractility causing abnormal changes in heart size, shape and function (Brown et al, 
2016).  
Zebrafish are also a major organism of interest in scientific research due to their ability 
to regenerate cardiac tissue. In humans if heart muscle dies due to ischemic attack then 
that becomes scar tissue, reducing the overall efficiency of the heart. Eventually with 
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repeat attacks, heart goes into heart failure from the lack of working muscle and from 
compensating for the burden of scar tissue and loss of muscle. If we can learn from the 
zebrafish and be able to regenerate tissue to functional cardiac muscle it would be a 
major leap forward in combatting heart disease (Gonzalez-Rosa et al, 2017). As well as 
whole organism studies, in vitro studies have also been used to study chronotropic 
effects of serotonin in zebrafish heart. Extracted zebrafish hearts, were dosed with 
serotonin and examined using ECG, physiology and pharmacology approaches to 
investigate 5-HT pathways. ECGs showed that 5-HT pathways act through the heart 
lowering heart rate, demonstrating the use of zebrafish in autonomic cardiac control 
(Stoyek et al, 2017). Some cardiac techniques developed are adaptable for adult and 
larval zebrafish. Hoage, Ding and Xu, 2012, developed a red blood flow rate assay 
using a transparent transgenic line with a red fluorescent heart to study cardiac 
functions in adult and embryonic zebrafish. The transparency coupled with the 
fluorescent heart facilitate ease of visualisation of the beating heart in adult fish 
allowing observation of cardiac function non-invasively. This line can be observed 
from 24 hours when the heart beat commences throughout development until adulthood 
and beyond (Hoage, Ding and Xu, 2012).  
 
1.3.5.1.2 Adult zebrafish cardiac arrhythmia models 
Milan et al 2006, first demonstrated the in vivo ECG recording system for adult 
zebrafish and demonstrated its use for measuring QT prolongation from drug treatment. 
This opened the door for further development of adult recording systems and these 
systems have been used to study a variety of arrhythmias in zebrafish. Hassel, 2008, 
created a mutant line with a short QT phenotype, named Reggae (m230), which is a 
mutation in the zERG channel. Using ECG analysis, the mutation was found to cause 
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premature channel activation and deficient inactivation resulting in shortened 
repolarisation phase and the short QT phenotype. Sun et al 2009, took a similar 
recording approach to analyse the ECGs of zebrafish adults pre and post ventricular 
amputation. The system first described by Milan et al 2006 was optimised by 
Chaudhari et al 2013, standardising the immobilisation method, perfusion system and 
acclimatisation period. More recently, Liu et al 2016 published a surface recording 
protocol for adult zebrafish, using 2 electrode probes. Prior to recording, scale layers 
were removed from the area covering the heart and pre-opening the pericardial sac. The 
zebrafish mutant, breakdance, was electrocardiographically characterised using this 
method. Breakdance, has a mutation in the zERG channel, and as a result has a QT 
prolongation. Multi-electrode approaches have also been developed; Yu et al, 2012 
used microfabricated multi-electrode arrays inserted into the chest so that they were in 
direct contact with the epicardium. Comparison of these results against intracardial 
calcium transient signals recorded from excised hearts showed synchrony, 
demonstrating the utility of the microarrays for real time study of heart activity in small 
animals. While this is described as a surface recording, there is still considerable 
preparation, removing outer scale layers and inserting the electrode probes 0.5mm into 
the muscle layer of the chest (Liu et al, 2016). These are invasive and time-consuming 
procedures, which would not readily adapt to a high throughput screen.  
There have been alternative methods developed for adult zebrafish ECG analysis using 
flexible microelectrode arrays for topical recording (Zhang et al 2014 and Zhang et al, 
2015). Use of microfabrication, allowed development of flexible electronics to cover 
the atrium and the ventricle from the fish surface (Zhang et al, 2014). Zhang et al, 2015 
developed microsensor jackets for ECG recording. Using these devices, heart rate and 
QT responses to phenotype response to ventricular resection and amiodarone treatment 
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(a cardiac drug) were measured. The advantages of this model are that anaesthetic is not 
required, and the recording process is non-invasive. However, it is not known what the 
effect of wearing the weight of the jacket will have on the zebrafish and the stress 
caused to the animal during the application of the electrode jacket, and while wearing it 
(Zhang et al, 2015).  
In vitro approaches have also been used for arrhythmia studies, Tsai et al, 2011 
described a zebrafish adult heart recording protocol as a platform for pharma-testing. 
Extracted adult zebrafish hearts were examined using micro-electrodes and optical 
mapping. While ECGs resembled human ECG traces, there was variation introduced by 
explanting the hearts for recording, where the P and T waves were not always the same 
polarity as the QRS complex (P, 40% T, 55% of the time not the same polarity as 
QRS). Inverted T waves and P waves can be an indication of arrhythmia in humans but 
also of benign conditions from (Tsai et al, 2011).  Isolated adult hearts have also been 
used to map electrical activity optically using a voltage sensitive dye (RH-237) to 
visualise the potentiometric response and blebbistatin to uncouple cardiac contraction 
from electrical activity to remove motion artefact (Lin et al, 2014). Using this 
approach, heart rate and action potential variation was monitored in response to a 
temperature range (Lin et al, 2014). These approaches, while excellent for small scale 
experiments, and have some potential for scaling up, lack the complexity of a whole 
organism response to drug treatment. Also, explanting the hearts can introduce artefacts 
not seen in typical in vivo heart ECGs. As the zebrafish embryo is readily adaptable for 
high throughput approaches, as a whole vertebrate organism, this is preferable to an 
isolated heart model for a pharmaceutical setting.  
Development of adult ECG recording systems represents a huge step forward for 
detailed cardiac monitoring of drug responses but is still a largely invasive procedure 
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with limited capacity for development into a high throughput system which would be a 
requirement for pharmaceutical screening. A similar platform in zebrafish embryos 
would capture the advantages of the zebrafish model and high resolution data of ECG 
monitoring with high throughput capability.  
 
1.3.5.2 The Zebrafish embryo as a cardiac model.  
1.3.5.2.1 Zebrafish embryo genetic approachs . 
As zebrafish do not have embryonic stem cells, antisense technologies, such as 
morpholinos have been used to achieve gene knockdown for study and assessment of 
drug responses. Morpholinos are oligonucleotides that block transcription or splicing 
resulting in no gene product. They are effective at knocking down gene function but are 
linked to non-phenotypic general off-target side effects such as oedema in the 
pericardial sac and necrosis, and so very strict experiment protocols are required when 
using them (Poon and Brand, 2013). Other methods include ENU mutagenesis, Tol2 
transposons and TALENs.  ENU mutagenesis, employed by the The Wellcome Sanger 
Institute for the zebrafish mutation project they undertook, which has yielded hundreds 
of mutant lines for study of genetic mutation phenotypes applicable to a huge variety of 
human disease states across all organ systems (Busch-Nentwich, et al, 2013). The Tol2 
transposon has been highly successful for the creation of transgenic fluorescent marker 
lines for a multitude of tissues and organs for study. For example; Tol2 transposon 
technology was used to create cardiac enhancer trap lines in zebrafish as a novel tool 
for studying cardiac development and disease. The resultant lines could be used for 
examining cardiac contractility and function in 4D under a confocal microscope, Poon 
et al, 2010. The TALEN (transcriptor activator-like effector nucleases) approach is a 
popular technique for creating mutants in genes of interest, to generate zebrafish 
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models of human genetic diseases (Roberts et al, 2014). More recently, the 
CRISPR/cas9 technology has been utilised in zebrafish, rapidly becoming the technique 
of choice for genome editing as it is more straight forward than Tol2 or TALEN, and 
has already been used successfully for the creation of mutations and transgenic lines 
(Hruscha et al, 2013).  
 
1.3.5.2.2 Zebrafish embryo cardiac drug screens and arrhythmia models. 
Many cardiac mutant lines have been used in drug response studies and have 
demonstrated that zebrafish can be used for novel drug discovery of cardiac drugs 
(Kebler, Rottbauer and Just, 2015 and Asnani and Peterson, 2014).  The advantages of 
using zebrafish embryos (as discussed 1.2.3) means that they are readily adaptable for 
drug screens. Only small volumes of drug solution are required for dosage and embryos 
can be easily maintained in a 96 well plate. This approach has been utilised for 
adaptation to a high-throughput model for zebrafish larvae as both a chemical and 
genetic screen (Pardo-Martin et al, 2010). This allows automated transference and 
orientation of zebrafish larvae for high resolution imaging at a cellular level in three 
dimensions (Pardo-Martin 2010). However, this loading process is limited to imaging 
analysis, and still performs imaging on individual larvae consecutively, rather than 
multiple fish simultaneously, which would be optimal.  
Multiple studies have shown that zebrafish show similar cardiac effects seen in 
zebrafish larvae to known cardiac acting drugs in human (Gut et al,2017, Alzuade et al 
2016, D’Amico et al, 2012 and Milan et al, 2003). Milan et al 2003, demonstrated that 
drugs which cause repolarisation abnormalities in humans, cause bradycardia in 
zebrafish larvae. Bradycardia is known to be an effect of Ikr channel (kv11.1 hERG) 
inhibition. This was a simple, but high throughput assay, highlighting the potential use 
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of zebrafish embryos in cardiac drug safety testing for repolarisation inhibitors, such as 
hERG blockers. Cardiotoxicity responses have been tested in zebrafish embryos, using 
visual assessment for bradycardia and AV block (D’Amico et al, 2011). Drug response 
analysis of known hERG blockers (n=6) and other cardiac acting drugs (n=7) was 
assessed in zebrafish larvae and found to exhibit a range of phenotypes including; AV 
block, bradycardia, ventricular fibrillation and death (Alzuade et al 2016). While this is 
strong evidence for a conserved cardiac drug response between zebrafish and human, to 
fully characterise these responses, assessment by electrocardiographic means would be 
required to further to validate zebrafish embryos as a model of human arrhythmia.   
 
1.3.5.2.3 Zebrafish embryo ECG development and other technologies for 
cardiac assessment.  
Further to visual observations of arrhythmia and cardiac dysfunction such as those 
described in Milan et al 2003, larval ECG procedures, along with other technologies 
such as echo scans for larvae have been developed (Milan et al 2003, Dhillon et al 2013 
and Fuad, Kaslin and Wlodkowic 2018). 
Recently, a rapid, lab-on-a-chip imaging protocol for micro-echocardiography was 
developed for assessment of cardiovascular activity (Fuad, Kaslin and Wlodkowic, 
2018). They describe a millifluidic system, an imaging platform where embryos are 
immobilised using suction rather than agarose and prototypes created rapidly using 3D 
printing of moulds using SLA (stereolithography) and subsequent replica moulding in 
poly(dimethylsiloxane). This created a platform that removed the need for painstaking 
orientation and agarose-imbedding of embryos for imaging, increasing throughput and 
automation. It also improves the capacity for drug testing while on the platform; drug 
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delivery is not hampered by diffusion through agarose. Imaging was also performed 
using an automated system, producing programmable time-resolved video data. Larvae 
were anaesthetised for 5 minutes in MS-222, loaded, and left to acclimatize for 15 
minutes prior to data collection, videos were recorded in colour, 60 frames per second 
and drug treatments lasted 30 minutes. Each chip had the capacity for up to 10 larvae. 
While representing a major step forward to automated zebrafish cardiac analysis, 
currently, only heart rate analysis has been reported using this device. More high 
resolution data, such as that from an ECG recording is needed to analyse phenotypes; 
for example QT prolongation from hERG channel blockade. However, using a platform 
such as the millifluidic system alongside integrated electrode arrays may be the 
solution.  
An electrographical method for recording heart activity in zebrafish embryos was first 
described by Forouhar et al 2004. Pre-pulled glass capillaries, commonly used for 
extracellular recording were utilised, filled with conductive solution and manipulated 
and positioned onto 5dpf embryos using micromanipulators. Embryos were treated with 
PTU (phenylthiourea) to prevent pigment formation and were anaesthetised in 0.01% 
MS-222 (ethyl 3-aminobenzoate methanesulfonate). The resulting ECG traces, 
identified P and R waves, but the distinct PQRST wave pattern observed in adult traces 
was missing.  
Dhillon et al 2013, optimised this single glass capillary electrode recording system for 
zebrafish embryos. Parameters investigated included; temperature, electrode placement 
and larval developmental stage. The results displayed clear PQRST wave pattern, and 
QT prolongation drug responses to known hERG blockers including terfenadine. While 
requiring further optimisation of parameters, this represented a key step in establishing 
a larval ECG protocol, but major adaptations would be required for high throughput 
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use, and single recordings mean collecting a whole data set is time-consuming (Dhillon 
et al, 2013).  
 
1.3.6 Comparison of mammalian and zebrafish drug screens. 
Mammalian models such as mouse and rat are widely used and established in the 
pharmaceutical industry and as a result, there are decades of information and data on 
these models, which is helpful for predicting responses. Also, this data comes from 
standardised protocols and husbandry which makes comparison of results across 
different labs more accurate. The zebrafish model’s validity would benefit greatly in 
similar standardisation; and that would open up pharmaceutical companies to being 
more receptive to make the necessary adjustments to implement a fish model into their 
screening procedures. As close evolutionary species to human, they are a natural choice 
with high gene homology and drug responses to humans (Planchart et al, 2016). As 
well as electrophysiological advantages of using a vertebrate model with a similar heart 
beat and action potential to human, as opposed to the murine system with a fast heart 
rate and adapted action potential facilitating this, zebrafish embryos have the advantage 
of being readily adaptable to high throughput platforms (Leong et al, 2010). 
Due to the many advantages discussed in this chapter, zebrafish have risen in 
prominence in recent years with ever increasing numbers of screens and platforms for 
use of zebrafish in drug discovery and development published. It has been postulated 
for some time, with a wealth of evidence that zebrafish could be used to predict drug 
toxicity (McGrath and Li, 2008). The question of the utility of zebrafish embryos as a 
high throughput toxicity assay for pharmaceutical development was addressed by 
Redfern et al, 2008. It is an established fact that early safety screens are required to try 
and address the fall in new successful drugs brought to the market. Those that do 
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succeed have to shoulder the financial responsibility of those that failed before it. This 
is substantial, as a reported 9 out of 10 candidate drugs fail before they reach market. 
This number could be reduced if new early screening tools, such as zebrafish embryos 
were employed (Redfern et al 2008). As discussed previously, a leading cause of drug 
candidate failure is cardiac toxicity through the hERG channel interaction. Zebrafish 
larvae can be used to detect hERG channel blockers, with high accuracy, causing 
cardiotoxic hERG blockers to be screened out early, saving funds. In addition, the 
hERG channel is not the only ion channel adversely affected by drugs, and use of an 
early in vivo screen such as zebrafish would screen for adverse effects across multiple 
adverse drug targets. Comparison of zebrafish front loading compatible assays with in 
vitro screens, identifies potential screens for cardiac, gut, renal and visual function 
zebrafish screens which may out perform their in vitro counterparts (Redfern et al, 
2004). The attraction of zebrafish larvae as a model comes down to the ability of 
having an in vivo vertebrate model with high conservation with human on a high 
throughput platform (Goldsmith et al 2004). It is a model that can be utilised using 
existing toxicological endpoints, across morphology, physiology and behaviour assays 
(Kari, Rodeck and Dicker, 2007). In addition, advances in technology, for example in 
embryo manipulation and imaging, mean that robust platforms now exist for hosting 
high throughput zebrafish assays (Pardo-Martin et al, 2010, Yanik et al, 2016 and 
Roper, Simonich and Tanguay, 2018). However, there are obstacles to the 
implementation of high throughput zebrafish screens; firstly, inconsistency in 
husbandry practise, including variance in diet and feeding regimes. Diet is the biggest 
environmental factor and impacts on cellular signalling and has been shown to impact 
on the offspring’s transcriptome. Secondly, toxicity assays require standardisation and 
validation. Protocol differences across laboratories include chemical purity, exposure 
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regimen, number of animals per well, all of which influence on chemical uptake 
(Planchart et al, 2016). Thirdly, inadequate description of zebrafish strains. In 
mammalian research, it has been clearly demonstrated that different strains will have 
different underlying physiology and therefore different chemical responses. Therefore, 
choice of strain and clear reporting on which strain has been used for a study is 
important. And lastly, disease monitoring remains insufficient. Zebrafish, like 
mammals are susceptible to infections which impacts on health and egg production 
(Planchart et al, 2016).  
In addition, for many potential users, there are problems surrounding compound uptake. 
Zebrafish are dosed by being exposed to drug concentrations in the surrounding 
medium and responses measured. This assumes efficient drug uptake and metabolism 
alongside organ system development in the larval zebrafish. With using larvae, 
compound uptake relies solely on transdermal absorption until 72 hpf where some can 
be taken orally as the jaw develops (Langheinrich, 2003). This limits compounds 
pharmacology; for example, size and solubility, to ensure uptake into the larva. This 
raises questions about how exposure concentration relates to the dose achieved in the 
animal and how this is compares to dosing in other models. There are also uncertainties 
over how metabolically active these animals are, particularly given concurrent organ 
system development taking place, which impacts on (active) drug exposure. These 
considerations mean it is difficult to accurately determine the final dose achieved. 
Standardisation and consideration of these elements would go a long way to facilitate 
direct comparison between laboratory results and gain further support of the zebrafish 
as a model for use in pharmaceutical drug development. Even so, companies remain 
sceptical about how translatable certain physiology and biochemistry is and so 
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extensive validation studies are required to prove the reliability and effectiveness of the 
zebrafish model (Redfern et al, 2008).   
As well as drug safety screening, zebrafish have also been used successfully to identify 
novel therapeutic compounds (Goldsmith et al, 2004, Zon and Peterson, 2005 and Kari, 
Rodeck and Dicker, 2007). Zebrafish are an accepted model for chemical safety 
assessments by regulatory agents, removing the barrier for their use in chemical screens 
(Johnston et al, 2017). Even with this body of evidence, the pharmaceutical company 
are still reluctant to invest in new screens, potentially using zebrafish embryos. This 
may be as although recent data suggests that zebrafish may be able to bridge the gap 
between in vitro models and in vivo mammalian models there are still hurdles to 
overcome before zebrafish can truly be instilled into drug development screening 
protocols (Sukardi et al, 2011 and Planchart et al, 2016).  
 
1.3.7. Project Aims  
This project proposes a high throughput zebrafish embryo ECG recording system for 
cardiac toxicity screening and identification of novel therapeutic compounds. This 
study focused on developing the zebrafish embryo as an arrhythmia model using high 
resolution ECG recordings in vivo of the larval heart. This chapter evaluates current 
models against zebrafish and concludes that the zebrafish, may be the next logical step 
for pharmacology screens, particularly for cardiac toxicity. A zebrafish embryo ECG 
recording system has been successfully demonstrated. Further optimization of this 
system and making steps towards adapting it for high throughput capability has the 
potential to change the way cardiac toxicity is detected in candidate drugs (Dhillon et 
al, 2013). Early exclusion of hERG blockers, for example, is crucial to streamline the 
drug development process and reduce the financial burden on successful drugs brought 
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to market as well as guaranteeing patient safety.  Platforms using analysis tools such as 
the automated system described in (Hughes, Tarassenko and Roberts, 2004) removes 
the potential bottleneck of data such approaches would create and produce standardised 
data readouts of heart rate and ECG parameters, (unpublished data Barrett et al 2015).  
Compared to other arrhythmia analysis approaches, ECG produces high resolution, 
comprehensive data showing a detailed picture of cardiac function.  
The aim of this study is to demonstrate the utility of an ECG recording system for 
cardiac arrhythmia in zebrafish embryos both by drug induction and from arrhythmic 
zebrafish lines. This could be a significant, informative tool for both drug discovery and 
cardiac toxicity testing.  
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2. ECG PARAMETER OPTIMISATION: 
• Investigation into the potential effect of anaesthetic on 
larval zebrafish heart rate and QTc.  
• Investigation into the effect of electrode distance on ECG 
recording in zebrafish larvae. 
• Optimisation of ECG parameters for the development of a 
high throughput recording system. 
 
All work pertaining to the ECG experiments for non-contact recordings and the effect 
of anaesthetic in this chapter were performed by me solely. The microfabricated 
electrodes were designed and manufactured by Richard Barratt. The twisted pair 
electrodes were made by him and myself. The testing of the microfabricated electrodes 
were performed by myself (mainly) and in collaboration with Richard Barrett.  
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2.1. Introduction 
2.1.1 Parameter development and optimisation of the single electrode 
zebrafish ECG recording system.  
A protocol for larval zebrafish ECG recording was developed by Dhillon et al 2013. 
This protocol established that recording electrical activity from the developing larval 
zebrafish heart was not only possible but potentially presented a viable alternative to 
more invasive and time consuming techniques using mammalian animal systems. 
Dhillon et al 2013 investigated a number of parameters to optimise the recording 
procedure and to investigate the effect of these parameters on larval heart activity and 
the recording protocol. These included; temperature, embryo development stage and 
electrode position across the heart. In this work, parameters were taken and developed 
further to optimise for more detailed recordings and to make progress towards a high 
throughput system.  
 
2.1.1.1 The effect of temperature on the ECG parameters recorded. 
Temperature is an important parameter to investigate as it is well established that 
increasing temperature increases heart rate in mammals (Deutschman et al,1994). 
Dhillon et al established that this was also true for the larval zebrafish heart and that 
this also impacted on ECG parameter measurements such as QT. Therefore, it is 
important to control temperature for the duration of the recording and keep it constant. 
While the ideal temperature for zebrafish temperature is 28.5oC, practically, this was 
difficult to control and maintain throughout the recording while keeping the system 
electrically quiet to reduce interference with the recording signal. Therefore, the 
majority of recordings for Dhillon et al, 2013 were performed at room temperature. 
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However, it would be more optimal and more informative of the normal zebrafish ECG 
signal to record from the heart at the natural environmental zebrafish temperature of 
28.5oC. At this temperature, as established by Dhillon et al, 2013, the heart rate is 
higher and QTc lower that when recorded at room temperature. This means that they 
will be considered bradycardic at a heart rate much faster than humans when in their 
normal environment and establishing what is normal for zebrafish is important for then 
being able to determine and study the larval zebrafish heart when abnormal, either due 
to external environmental factors such as drug treatments, or due to genetic mutations.  
 
2.1.1.2 Optimal larval zebrafish development stage for ECG recording. 
The larval heart develops rapidly so to standardise the recording protocol the larval 
development stage needed to be kept consistent. Due to licence restrictions it was 
necessary to keep under 5 dpf. Dhillon et al concluded that the optimal development 
stage was 3 dpf (days post fertilisation). This was the stage ultimately decided upon for 
the recordings collected for this project. This is because at this stage, the rudimentary 
heart tube had looped and developed into the two distinct chambers, atrium and 
ventricle, with co-ordinated contraction due to ion channels established. By 48 hpf the 
heart and cardiovascular system is fully functional with all ion channels formed and in 
place (McGrath and Li, 2008). At this stage it is still early enough to maximise 
facilitation to high throughput development. In addition, performing the experiments at 
3 dpf created a better weekly throughput for these experiments, maximising the amount 
of data collected.  
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2.1.1.3 Electrode position on the larval zebrafish heart. 
Dhillon et al investigated the effect of recording at different positions across the heart, 
and found that there was no significant difference in ECG parameter measurements e.g. 
QT. Different positions consistently recorded comparable ECG parameter 
measurements but that it was easier to record different parameters and see a complete 
PQRST signal waveform with the electrode positioned centrally on the heart at the AV 
canal (similar to mammalian atrio-ventricular junction). At this position PQRST 
waveform was easier to detect and clearly recorded with a favourable signal: noise 
ratio. However, it would be more useful to record electrical activity from the two 
chambers of the zebrafish heart separately, to improve signal quality and increase the 
amount of data obtained from these recordings. This is because, while the AV canal is 
the optimal position to record a full ECG with PQRST waveforms using a single 
electrode, recording from more positions simultaneously, specifically individual atrium 
and ventricle recordings would increase the likelihood of detecting the smaller, atrium 
signals which corresponds to the P wave in a typical ECG. Also, the ability to record 
with more than one electrode has the advantage of moving the zebrafish recording 
system to more closely resemble the 12 lead human diagnostic ECG. This allows 
greater sensitivity and resolution of the ECG data, making it a more useful tool for 
clinical research. Being able to record and identify separate atrium and ventricle signals 
will also increase the diagnostic ability of the recording system when applying cardiac 
drugs that target different parts of the cardiac cycle.  
 
2.1.1.4 Immobilising agents to facilitate ECG recording. 
In order to position and record from zebrafish larvae, it is necessary to immobilise them 
for compliance and to prevent motion artefact in the recording. The established single 
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electrode recording system used MS-222 at 0.3 mg/ml to sedate the larvae in order to 
manipulate the larvae, position the electrode and obtain recordings. This is the standard 
method for immobilising zebrafish for ease of manipulation, (Kimmel et al 1994). 
Humans under general anaesthesia can experience heart rate variability (HRV) due to 
increased vagal/autonomic nervous system activity. This results in supressed heart rate, 
blood pressure, breathing and gastro-intestinal tract movement (Deutschman, et al 
1994). One of the main considerations in Dhillon et al was the immobilising method to 
facilitate the recordings. It was important to establish an efficient immobilising method 
and two immobilising agents were compared; ethyl 3-aminobenzoate methanesulfonate 
(MS-222) and tubocurarine. It was concluded there was no difference in ECG 
parameters between these two agents. However, to truly test whether the use of 
immobilising agents has a significant effect on the ECG parameters, recordings from 
anaesthetised embryos need to be compared to recordings taken from non-anaesthetised 
embryos. One of the main aims in this study was to establish the effect of commonly 
used anaesthetic MS-222, on the heart rate and ECG parameter measurements at the 
concentration that is used on larval zebrafish for ECG recording. To do this, a method 
of immobilisation without the use of anaesthetic needed to be developed. 
 
2.1.1.5 Parameter development summary 
Overall, there are further developments that could be made to optimise the recording 
system, hence further parameter development and optimisation would improve both the 
quality of the data recorded and expand on the potential usage of the recording system. 
Throughout the duration of this project improvements and developments to the 
recording system in these areas were devised and implemented into the recording set 
up. These included a temperature controlled recording plate allowing recordings at 
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28.5oC, a dual electrode recording system to allow signals to be recorded from the 
atrium and ventricle simultaneously and a method for recording from non-anaesthetised 
embryos.  This chapter will discuss the development of a system to record from non-
anaesthetised embryos to investigate the effect of MS-222 on the heart rate and ECG 
parameters at the concentration used for ECG recording.  
 
2.1.2 Optimisation of parameters with the later goal of high 
throughput recording 
One of the principal aims in this project is to make steps towards a high-throughput 
recording system for larval zebrafish ECG. The single electrode recording system 
produces high resolution signals for analysis of heart activity. However, there were two 
rate-limiting factors that affected the throughput of the recordings. Firstly, the system 
only has the capacity to record individual zebrafish larvae in turn, whereas the 
established method for drug treatments on zebrafish larvae used 96 well plates and 
microscopy to analyse the drug effect (McGrath and Li, 2008), therefore have a much 
greater capacity. However, ECG data has higher resolution, so greater depth of cardiac 
data can be obtained, therefore it is preferable. Secondly, it is a laborious and 
meticulous process to correctly position the electrode on the heart for ECG recording. 
This means that it is a long, time consuming process to record an entire data set. In 
order to move towards a higher throughput recording system these issues would need to 
be addressed first.  
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2.1.2.1 High throughput parameter testing: non-contact recording 
A major factor affecting the throughput is the time-consuming process of positioning 
the electrode across the heart. The position of the electrode on the heart greatly impacts 
on the size, shape and quality of the ECG recording signal making it necessary to 
painstakingly position the electrode to the optimal position across the heart. This is in 
order to obtain a full, clear, high quality ECG with PQRST waveforms. In particular, 
the P wave which is the atrial component of the ECG is more difficult to pick up unless 
correctly positioned. The dominant waveform, the QRS complex is much easier to 
detect as well as the T wave as these are the ventricle components. The size of the 
larval zebrafish heart at 3 dpf is approximately 100µm across, so positioning must be 
accurate to within a few microns in order to detect both atrium and ventricle signal 
components. This makes positioning the most time-consuming step in the recording 
process and a potential barrier to high throughput recording. One possible solution to 
this problem would be to record ECG signal from a position slightly away from the 
heart, removing the need for painstaking micron-accurate positioning on the surface 
area over the heart. Dhillon et al, 2013 showed measurements for QTc prolongation, an 
arrhythmia effecting the ventricle, can accurately be measured consistently across the 
heart. Therefore, as detecting the P wave is position sensitive, to establish whether 
recording at a distance from heart was possible, QRS and T wave signals were 
prioritized so that a measurement of QT could be taken. To investigate the possibility of 
a system using this technique, the established single electrode recording system was 
adapted to establish whether it was possible to record quality, QRST, ECG signal from 
non-contact positions and, if successful, to measure this distance. 
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2.1.2.2 High throughput parameter testing: development of new reusable, 
metal electrodes. 
The glass capillary electrodes used for the current single electrode recording system are 
fragile, prone to blockage and damage and as such are replaced frequently. To move to 
a higher throughput system, these glass electrodes would need to be changed for a more 
durable, less fragile and more reusable electrode, without compromising the high 
resolution recordings the glass electrodes yield. This would also introduce the potential 
for multichannel recording, and the possibility to increase the number of zebrafish 
recorded simultaneously which in turn would also increase the throughput.  
Upgrading the glass capillary electrodes to a metal bespoke electrode design introduced 
some challenges to overcome with impedance in the electrical circuit. There was a need 
to think carefully about how the signal is transferred in the capillary and how that 
changes when a metal electrode is used.  The electrical signal in the zebrafish heart is 
~5-30µV. This is a very small signal and to detect it the electrode needs to be very 
sensitive, with a low impedance (>1MOhmat 10Hz), otherwise the signal will not be 
seen. Glass capillary electrodes have a low impedance as the signal travels from the 
heart through the capillary tip and to the chloridised silver wire through the potassium 
chloride solution that fills the capillary. The signal is then transferred to the wire over a 
very large surface area (the surface area of the wire inside the capillary) and this keeps 
the impedance low and the signal only has to travel through a resistance circuit due to 
direct current flow (DC). Metal electrode signal transfer differs significantly. In these 
electrodes (both microfabricated and twisted pair) this signal transfer happens at the 
electrode tip, at the surface of the heart. This means that the surface area is much 
smaller than the surface area available in glass capillary along the silver wire, therefore 
the impedance is much larger. If the impedance is too high the signal cannot be 
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recorded. The tip has to be plated to increase the surface area, reducing the impedance 
to under the threshold impedance of (>1MOhmat 10Hz. 
 
2.1.3 Aims 
• To investigate the effect of anaesthetic on the heart rate and ECG signal. To 
determine this accurately, a comparison needs to be made between an 
anaesthetic and non-anaesthetic recording. Therefore, a method for ECG 
recording from non-anaesthetized embryos must be devised. To do this, the 
embryos must be immobilised for ECG without anaesthetic.   
• To establish whether contact is required for successful recording of ECG or 
whether it is possible to record from a non-contact position, and how far from 
the embryo this can be done.  If recording can be taken from further away from 
the zebrafish, this will aid development of a high throughput system by 
removing the need to accurately position electrodes.  
• To investigate alternative materials and designs for more durable, reusable and 
less fragile electrodes capable of recording ECG from larval zebrafish to aide 
development of a high throughput recording system.  
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2.2 Methods 
2.2.1 Zebrafish Husbandry and embryo collection 
For all experiments wild-type AB zebrafish embryos were used. All zebrafish were 
handled according to the UK animal (Scientific Procedures) Act of 1986 with 
appropriate home office licensing. Adult zebrafish were maintained using standard 
conditions in a flow-through system of aerated, charcoal filtered tap water with a 12 
hour light/dark cycle (Techniplast; UK). 
Breeding pairs were set up in separate breeding tanks, filled with system water and left 
over night. Embryos were collected the following morning and transferred into petri 
dishes containing E3 medium (2.2.11) and incubated at 28 oC until 3 dpf.  
If pigment free embryos were required, the E3 medium contained 0.2mM 
Phenylthiourea which inhibits melanogenesis. This concentration was used as higher 
concentrations can cause toxicity. Pigment free embryos were used in trials of 
Microfabricated electrode prototypes to help visualise the heart in the pipette tip set up 
but were not used for any formal ECG data collection recording.  
 
2.2.2 Single electrode glass capillary recording procedure 
For all experiments, unless otherwise stated (non MS-222 experiments) the zebrafish 
embryos were anaesthetised for immobilisation in MS-222 at 0.3 mg/ml (Sigma).  
2.2.2.1 Making glass capillary electrodes 
A borosilicate glass micropipette (P84, world Precision Instruments) was pulled on a 
micropipette capillary puller (Sutter instruments P-80, Brown flaming micropipette 
puller) to give a 2 µm tip and then filled using MicroFil with 3 M potassium acetate 
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solution (Sigma) coloured with methylene blue (Sigma) for ease of visualisation under 
the microscope  
 
2.2.2.2 ECG Recording procedure  
To perform an ECG recording, 3 dpf embryos were positioned and orientated on a pre-
made, specially designed recording plate. Agarose (molecular grade agarose (Bioline) 
was set with a hand-made mould to create grooves, in a standard petri dish (100mm x 
15mm) (Fisher Scientific) containing 9 ml of E3 with 0.3 mg/ml MS-222. The plate 
was then positioned under a Nikon SMZ600 microscope and the embryo orientated 
ventrally in a groove, to give the best view of the heart. Temperature is monitored for 
the duration of the recording to prevent changes in temperature affecting the heart rate. 
Temperature was monitored using Cryocon 22C (cryogenic control systems) and 
recordings performed at room temperature. This whole set up sat inside a Faraday cage 
to ground and minimise electrical noise. 
The electrode tip, was positioned at the AV canal on the skin surface of the zebrafish 
which is between the atrium and the ventricle using a micromanipulator (Narishige) and 
a motor arm (Inchworm, Burleigh). 
 A chloridised silver wire with a complimentary pin soldered to one end was inserted 
into the capillary and connects, via the pin to the amplifier (NPI electronics, for 
settings: 2.2.2.3) and the signal is then passed through a filter, Humbug (Quest 
Scientific) to minimise background noise. The analogue signal was then processed 
through Powerlab (ADInstruments), an analogue digital converter, and displayed on the 
computer screen using compatible software Labchart (ADInstruments). A second, 
reference, electrode was positioned in the recording plate at a distance away from the 
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fish to complete the circuit. Inchworm (Burleigh), allows incremental adjustments of 
the position (4 µm steps) until a detailed, stable ECG signal was achieved then the 
recording was started. Detailed ECG refers to all features (PQRST) visible in the 
recording. Schematic of recording set up set out in figure 2.1. 
 
Figure 2.1 Schematic of the recording set up for the single electrode recording system.   
 
2.2.2.3 NPI Amplifier. 
A single point amplifier, with applied filter settings to keep the impedance of the 
system lower. For settings; see table 6.1 (appendices). These filter settings were fixed 
to allow the maximum amount of data to go through to Powerlab (ADInstruments). 
Here in Labchart (ADInstruments) more restrictive filter settings were applied, table 6.1 
(appendices), to more easily visualise the ECG signal.   
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2.2.3 Non -contact recording system development: Glass block 
recording set up and bent electrodes. 
2.2.3.1 Glass block set up 
To allow an electrode to come in flat perpendicular to the embryo, but still have a 
groove to stably orientate the embryo, a glass block with a carved cross and a thin 
coating of agar was used mounted in a 14 cm petri dish (Fisher Scientific). A zebrafish 
larva (3dpf) is positioned at the intersection of the cross. The rest of the set up follows 
as the procedure outlined in 3.2b with the reference wire positioned behind the embryo 
and the bent glass capillary electrode approaches the embryo from the groove in front. 
 
2.2.3.2 Bending glass capillary electrodes. 
Bending the electrodes allowed the electrode to approach the embryo perpendicularly 
and visualise when the point of contact occurs. To create a bent electrode, once the 
borosilicate glass capillary had been pulled (Sutter instruments P-80, Brown flaming 
micropipette puller) it was bent to 30 o using a Microforge (MF 830, Narsighe) 
according to the scale in the eye piece lens. The electrode was then filled with 3M 
potassium acetate (Sigma) and used as normal.   
 
2.2.4 Method for ECG recording from non-anaesthetized embryos. 
Embryos were immobilised for non-anaesthetized ECG recording using agarose. 
Embryos were mounted in 1% low melting point agarose (Sigma Aldrich) in a 4 cm 
petri dish (Fisher Scientific). Zebrafish larvae aged 3dpf were indicidually pipetted into 
small petri dishes, the excess liquid removed and a drop of molten agarose added. The 
agarose was allowed to cool to 30oC before a drop was placed over the larva. This was 
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sufficient to immobilise the embryos effectively. This was then left to set. After being 
set, 3 ml of E3 embryo medium was added to the plate and the section of agarose 
around the heart was removed using forceps. This was to stop the glass capillary 
electrode from clogging up with gel during positioning and recording, which would 
affect the measurement. Control experiments where embryos were mounted in agarose 
and anaesthetised, the embryos were pretreated in 0.3mg/ml MS-222 (Ethyl – 
3aminobenzoate methanesulfonate, Sigma Aldrich) and then mounted the same way.  
 
2.2.5 Microfabricated electrode manufacture and micropipette tip 
recording set up to aid zebrafish orientation. 
2.2.5.1 Microfabricated Probes 
The microfabricated electrodes were designed and produced for this project by Dr 
Richard Barrett. A layer of gold metal was evaporated onto a layer of plastic and a top 
coat of plastic overlaid. A 10µm tip was then laser cut out from the plastic to expose the 
gold. The opposite end would then be wired up with complimentary gold pins to allow 
the electrode to be attached to the amplifier, Tucker Davis Technologies. The process 
allows very specific 2D designs to be created.   
The electrodes are then plated by being placed in chloroplatanic acid (platinum plating 
solution) and applying a negative current relative to a silver ground electrode. The 
plating process was necessary to lower the impedance of the electrode to below 1 M 
Ohm at 10 Hz, without this low impedance, the ECG recording could not be achieved 
using these electrodes. The glass capillary electrodes are very low impedance as the 
potassium solution creates a salt bridge keeping the impedance low, and stable, over a 
frequency range.  
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2.2.5.2 Micropipette Tip set up. 
Zebrafish larvae are pre-treated in MS-222 (ethyl-3aminobenzoate methanesulfonate) at 
0.3 mg/ml) for 10 minutes. The embryo was then collected up using a Pasteur pipette, 
and inserted, up to the yolksac/pericardial sac boundary into a disposable micropipette 
tip (50 µm). The pipette tip was then secured to a micromanipulator and lowered into a 
petri dish containing 0.3 % MS-222 in E3 medium, total volume 9ml using E3 medium. 
The microfabricated probe was attached to the motor arm and lowered into the petri 
dish next to the embryo. The embryo position was then adjusted using the 
micromanipulator until positioned underneath the microfabricated probe in a contact, 
recording position. Orientating the embryo to the microfabricated device created a more 
stable contact between the two for a recording to be taken.  
 
2.2.6 Multichannel System 
Multichannel recording was performed using the TDT multichannel recording system 
(Tucker – Davies Technologies). The same grooved agar plate was used for recording 
as 3.2b. The electrode (glass capillary, twisted pair or microfabricated electrode) is 
connected to a 16 channel headstage (Tucker Davis Technologies). This headstage had 
16 inputs, a reference and a ground electrode. The headstage connected to a pre-
amplifier (PZ2-256, S3 z series, Tucker Davis Technologies) which has a 256 channel 
capacity. The signal is digitised in the processor (RZ2 BioAmp Processor, S3 z series, 
Tucker Davis Technologies). TDT uses Open WorkBench (Open WorkBench 2.12, the 
user interface of OpenEx Suite, TDT) software to visualise the signal and perform some 
analysis. This software allows programs to be designed to manipulate the signal as best 
fits your project. These include filter settings, analogue output to Labchart, recording 
blocks can be exported to Matlab, and recording channel and reference channel 
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selection for differential recordings. For continuity, all TDT recordings analysed in this 
chapter were analysed in Labchart (Powerlab), so direct comparison with glass 
capillary electrode recordings, also analysed in Labchart, could be done.  
 
2.2.7 Production of twisted pair electrodes. 
Twisted pair electrodes are created using long lengths of wire folded in half and twisted 
together along the entire length. The folded end was cut and soldered complimentary 
pins to the recording system, for this study, the multichannel Tucker-Davis 
Technologies system. A wide range of twisted pair electrodes were made, using 
different wire materials and diameters with different plating material combinations.  
 
2.2.8 Labchart analysis 
For all glass capillary recordings, the signal was visualised using Labchart (Powerlab). 
Labchart is the complimentary software to the Powerlab analogue-digital converter 
used for these experiments. The TDT recorded signals were output to Powerlab so that 
these recordings could also be analysed in Labchart. Labchart allows filters to be 
applied to the raw signal for better visualisation of the signal.  
Sections can be highlighted for analysis and then the built in analysis software locates 
the ‘R’ peaks and marks them along the recording trace. Manual manipulation ensured 
this was accurate and any outliers where the ’R’ peaks were not correctly identified 
were excluded from the parameter measurement. These labelled cardiac cycles were 
then and overlaid to produce average cardiac cycle from the selected section and from 
this the R-R, QRS, QT and QTc ECG parameters and the heart rate were calculated.  
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2.2.9 Statistical analysis 
The p-values to determine statistical significance of the anaesthetic and non-
anaesthetised groups were calculated. Firstly, normality tests, Shapiro-Wilk  and 
Anderson-Darling, were performed which showed normal distribution for all the data 
groups. Therefore a parametric paired, two-tailed t test was then performed to 
determine statistical significance between the groups. They were also each tested 
against the control group in the same way.  
 
2.2.10 Drug stocks 
Drug treatments were routinely used to confirm the efficacy of new recording set ups 
and protocols. For each new recording set up a recording was performed with a glass 
capillary electrode and a drug treatment (terfenadine or verapamil) applied. This was to 
ensure that a QT interval change could be recorded and analysed using each set up. 
This verified the quality of the recording was acceptable for measuring drug induced 
arrhythmias throughout electrode development. Terfenadine has been demonstrated 
previously to produce a QT prolongation and this was measured in each electrode 
development (Dhillon et al, 2013). Drug stocks were made up in E3 medium. 
Terfenadine (Sigma) was prepared in 10 mM stock in E3 and DMSO (10 % Sigma 
Aldrich), to aide solubility. Stocks were diluted using E3 and the final concentration of 
DMSO on the recording plate was less than 2 % for both concentrations (0.5µM and 
5µM). 
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2.2.11 E3 Medium protocol 
 
 1 x E3 50 x E3 
5.0 mM NaCl (58.44) 0.292g    14.6g 
0.17mM KCl (74.55)   0.013g   0.65g 
0.33mM CaCl (147.02)    0.044g    2.20g 
0.33mM MgSO4 (246.5) 0.081g    4.05g 
 
2.2.12 PTU Phenylthiourea 
 
Standard dilution 0.2mM solution made up using E3 medium. 
 
Table 2.2 NPI amplifier and labchart settings 
 
NPI amplifier Gain 1000 
Band pass filter Low:0.3 Hz  
High 2 K Hz  
Labchart Raw data No calculation 
Wide band pass 
filter 
Low 0.3 Hz High 20 
Hz 
Narrow band pass 
filter 
Low 0.3  Hz High 
10 Hz 
Sample rate 4 k/s  
(1 k/s when used 
with the 
multichannel 
system, TDT: 3.9 
 
Table2.2: NPI Amplifier settings used for glass capillary recordings 
 
65 
 
2.3. Results 
2.3.1 Investigations to determine if anaesthetic affects heart rate and 
QTc. 
It was important to investigate whether there is an anaesthetic effect on the larval 
zebrafish heart rate and ECG parameters, such as QTc, because it could potentially 
compromise results. Dhillon et al 2013 compared MS-222 (an anaesthetic) and 
tubocurarine (a neuromuscular block) as immobilising agents, but did not compare 
these measurements against ECG’s taken from non-anaesthetised embryos. At high 
concentrations these compounds will affect heart rate, MS-222 decreases heart rate and 
tubocurarine increases heart rate so it was important to compare against ECG 
measurements taken from zebrafish larvae without any chemical immobilising agent. 
Therefore, comparison of anaesthetized embryo recordings and non-anaesthetized 
embryo recording was necessary to determine the effect of anaesthetic on the heart rate 
and ECG parameters, recordings using MS-222 as an immobilising agent needed to be 
compared to recordings taken from non-anaesthetized zebrafish embryos. However, the 
embryos still had to be effectively immobilised to perform an ECG. This was achieved 
by mounting embryos in 1 % low melting point agarose This is shown in figure 2.2. 
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Figure 2.2 Schematic showing the embryo embedded in 1% low melting point agar and 
the section of agar removed to allow the electrode access to the heart without getting 
clogged up by the agar. 
 
 
Following n=5 trial experiments using this technique, an additional step was included. 
Once the embryos were mounted and the electrode positioned, the trace was started but 
not recorded for measurement for a further 2 minutes. This is because a fast heart rate is 
induced through embryo manipulation and electrode positioning, not seen when the 
zebrafish is sedated using anaesthetic. This delay was to allow the heart rate to stabilise 
so that a true baseline recorded, at rest, could be taken for comparison against 
anaesthetised recordings. 5-minute measurements from non-anaesthetised embryos 
(n=24) were recorded using this method. For comparison, anaesthetised embryos were 
Heart 
Head 
Tail 
1% Low 
melting point 
agar 
Electrode 
Petri dish 
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also recorded using this method. These were anaesthetised in 0.3 mg/ml MS-222 for 10 
minutes prior to mounting in agarose.  These 2 data groups were also compared to 
measurements taken using the standard set up, where the embryos are anaesthetised and 
not mounted in agarose (n=24).  
The results show there is no significant difference in QTc between mounted embryos 
with and without MS-222 (p value = 0.623) and no difference between mounted and 
unmounted (p value = 0.710). The heart rate is not significantly lower when under 
anaesthetic, (p value = 0.508), as shown in figure 2.3.  
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Figure 2.3 Effect of 0.3mg/ml MS-222 on the heart rate and QTc interval of 3dpf 
zebrafish heart.  
A) Average heart rate of a 3 dpf zebrafish embryo mounted in L.M.P. agarose with and 
without anaesthetic (MS-222). Ctrl is the average heart rate of 3 dpf zebrafish embryo 
not in mounted agarose and under anaesthetic.  
B) For the same groups, average QTc interval. C.  Raw ECG recording from a non-
anaesthetized 3 dpf zebrafish embryo. D. Filtered ECG using a narrow band pass filter 
Low: 0.3 Hz, High: 10 Hz. 
 
Therefore, conclude that 0.3mg/ml MS-222 does not significantly affect the heart rate 
and QTc of 3 dpf zebrafish larvae. In conclusion, while non-anaesthetic recording 
would be preferable, the set up is time consuming and greatly reduces throughput. The 
use of MS-222 dosage for immobilisation for ECG recording can continue to be used 
without affecting ECG recording parameters.   
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2.3.2 Zebrafish larvae ECG recording from a non-contact position. 
The recording procedure for larval zebrafish ECG recording is labour intensive, 
meticulous and lengthy. In particular, positioning the electrode accurately for detailed 
PQRST ECG signal is the rate limiting step, and reduces the recording throughput. For 
high throughput ECG recording it is important to remove the necessity to accurately 
position the electrode for a signal to be obtained, if the amount of time to position was 
reduced, this would increase the throughput significantly. Therefore, studies were 
carried out to determine whether it is possible to record ECG without touching the 
embryo and the maximum distance away from the heart successful recording could be 
achieved. This was carried out using a glass capillary electrode and calibrated motor 
arm to measure the distance. This could then be used as a parameter to build into a high 
throughput set up. 
 
2.3.2.1 Development of alternative electrode set up for non-contact 
recording. 
2.3.2.1.1: Preliminary experiments highlighting the issues with standard 
setup. 
Initial experiments, to determine whether recording from a non-contact position was 
possible, were performed using the established single electrode recording procedure. 
These preliminary experiments to investigate this simply started from the recording 
position at the AV canal and then took incremental steps back from that position using 
the inchworm (Berleigh). The steps were calibrated to 4 µm so that a distance from the 
number of steps could be calculated. There were problems with this approach as 
although the electrode was moving away from the recording position, it was still 
moving across the heart due to the angle the electrode approached the heart at, so the 
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amplitude of signal fluctuated as the electrode moved across the heart in and out of 
recording positions. This meant that it was not possible to tell clearly when or if the 
electrode was no longer touching the pericardial sac due to the angle of observation 
from the microscope in this set up, and therefore any measurement of distance away 
from the heart could not be reliably measured, see Figure 2.4. 
 
 
 
 
 
 
 
 
 
Figure 2.4 Schematic to demonstrate the problem encountered by using the single 
electrode recording system for non-contact recording. As the electrode moved back on 
the motor arm it also travelled across the heart causing the signal amplitude to 
fluctuate making it difficult to determine when it had left the surface of the pericardial 
sac and to measure the distance. On the standard system the electrode comes in at a 
30o angle. In order to see clearly, the set up was changed so that the electrode could 
come in at a 90o angle to the embryo from a top down perspective through the 
microscope.  
 
 In order to see clearly when the electrode left the surface of the pericardial sac a 
change to the set up was needed to allow visualisation of this with ease. For this to 
happen the electrode needed to approach the embryo at a 90o from the top down 
microscope view.    
Top down view from microscope 
Electrode 
90
0
 
Head Pericardial sac 
30
o
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2.3.2.1.2: Optimisation of visualisation of electrode set up for distance 
recording. 
It was clear from these preliminary experiments that to perform and confirm a non-
contact recording, the set up needed to clearly show the edge of the pericardial sac and 
the electrode tip at a 90o angle to the top down microscope view. As this is a 90o angle 
from the microscope view, so as to visualise when the electrode is on or off the heart, 
the electrode needed to come in alongside the embryo rather than from above it. 
Incremental steps away from this position can then be used to calculate the distance 
from the embryo that an ECG signal could still be recorded.  
To arrange the set up for a position at 90o to the pericardial sac, the glass capillary 
electrodes needed to be bent. The angle from which the electrode approaches the 
embryo was calculated to be 30o to the horizontal axis therefore the electrodes needed 
to be bent to 30o to compensate. Pulled borosilicate capillaries were bent to 30o using 
the Narsighe microforge. To facilitate using these new electrodes, a new recording plate 
using a carved glass block was created. The glass block used in the setup has a cross 
carved into it. This design means that when an embryo is positioned at the intersection 
of the cross, the recording electrode can approach the heart from one channel and the 
recording electrode can sit behind the embryo, resulting in the electrode travelling 
through the embryo, which improves the signal strength. This set up, detailed in figure 
2.5, allowed the electrode to be positioned at in a recording position just touching the 
pericardial sac and then move the electrode in 4 µm steps back until the ECG signal is 
lost.  
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Figure 2.5. Development of set up for non-contact recording. 
A) A schematic of the glass block set up showing where the embryo is positioned and 
the bent electrode and reference electrode as seen from view angle.  
B) Image of the embryo and electrodes in the set up. From this orientation it is easily 
visible when the electrode is on or off the heart. 
 
2.3.2.2 Non-contact recording achieved and visualised using alternative 
electrode shape and positioning. 
2.3.2.2.1 Non-contract recording achieved and confirmed with high 
resolution imaging. 
The set up described above was used and this orientation allowed the recording 
electrodes to be positioned at a 90o angle to the pericardial sac. Incremental steps at 
4µm allowed the distance from the embryo from which an ECG signal was still 
recorded to be quantified. Using this recording set up, an ECG signal was recorded 
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from a non-contact position, confirmed by high resolution imaging of the electrode 
position, see Figure 2.6. The larvae in figure 4.5 had a haemorrhage just below the 
heart, due to prolonged positioning on the glass block. Larval zebrafish ECG recording 
from a non-contact recording position with glass capillary electrodes has not been 
previously reported, and represents a significant step towards a high throughput system.   
 
 
 
 
 
 
Figure 2.6 Non-contact ECG recording achieved at 16µM from embryo surface.  
A) 3 dpf embryo positioned in non-contact set up where the 30o bent electrode 
approaches the embryo at 90o. This embryo has a haemorrhage below the heart due to 
prolonged positioning on the glass block. This is observed top down through the 
microscope. Electrode is positioned ≈16 µm away.  
B) close up of the gap between the pericardial sac and the electrode tip shown in ‘A’. 
ECG was recorded from this position n=5. 
 
The ECG recording was considered successful as a clear QRS wave and T wave can be 
seen which means QT interval can be measured from signal recorded at this distance, 
figure 2.7. 
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Figure 2.7 10second section of signal recorded at 16µm away from the edge of the 
pericardial sac.  
A) Raw data direct from the analogue-digital converter and amplifier into labchart.  
B) Raw signal filtered with band width filter 0.5 -30 Hz.  
 
The distance measured between the electrode tip and the pericardial sac was measured 
to be 16 µm. This is a significant result, potentially reducing the need for careful 
electrode positioning. This is important for development of a high throughput method. 
2.3.1.2.2 Signal: noise ratio calculated for non-contact positions. 
The signal obtained from this position at 16µm away from the heart was smaller and 
less detailed than signals obtained from a contact position at the AV canal, which was 
expected. The amplitude of the signal decreased as distance from the heart increased. 
Signal waveforms were displayed as functions of amplitude and frequency in 
Amplitude vs Frequency spectra.  figure 2.8.  
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Figure 2.8. Signal amplitudes plotted against frequency to produce Amplitude vs 
Frequency spectrum. This displays all signal waveforms from a section of recording as 
the amplitude vs frequency (Hz) for each waveform  
A) Amplitude vs frequency spectrum for ‘position zero’, the position where the 
electrode is just touching the heart.  
B) Spectrum for position measured 16µm away from heart. Amplitude has decreased 
when further away from the heart. The ECG components of the recording are at lower 
frequencies, the first few spikes. The top amplitude (R wave) has decreased when 
recording at 16µm away from the heart. 
 
Background noise at a frequency of 40 and 50 Hz is mostly mains noise. As signal 
amplitude decreases, it becomes more difficult to identify the ECG signal from the 
noise signal. Even with a low-pass filter at 30Hz, not all noise was eliminated. A 
spectrum of signal amplitude against frequency was taken at 5 positions (distances) 
with respect to the embryo heart. Position ‘zero’ was the when the electrode was just 
touching the pericardial sac, the other 4 positions were in 4 µm steps away from that 
position; 4, 8, 12, 16 and 20 µm.  The signal: noise ratio could be calculated from these 
and the amplitude of signal and noise plotted, see figure 2.9.  
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Figure 2.9 Comparison of signal and noise amplitudes at different positions. Signal 
amplitude decreases as distance from the heart increases. Noise amplitude, compared 
to signal amplitude, remained fairly constant but noise levels can vary between 
recordings, independently from electrode position from the heart.  
A) Signal Amplitude against position from the heart (blue) Noise signal levels at each 
distance from the heart (orange) n= 3 for each position, however a reliable signal for 
position 20 was only achieved 1 out of 5 attempts, due to noise levels.  
B) Slight variance in SNR from position 0-8 microns but then the SNR falls consistently 
with increasing distance from the heart. 
 
A reliable reproducible recording (n=3) was achieved for positions 4 – 16, however a 
clear, distinct ECG signal could only be achieved from position 20 once in 5 attempts 
due to high levels of noise and low signal amplitude.  
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Therefore, it can be concluded that recording from a non-contact position is possible at 
a distance of up to 16 µm. QT was visible at this distance, figure 2.9A, therefore, 
recording from this distance could be used for analysis of QTc interval. The signal: 
noise ratios for the recordings were calculated using signal amplitudes from the embryo 
recordings and from recordings taken without an embryo present. These were plotted, 
figure 2.9B. This highlighted that as signal amplitudes decreased as distance from the 
heart increased, but noise levels were comparatively constant and the noise range was 
independent of the positional changes. Noise levels can vary a lot depending on 
conditions, so repeat recordings were on the same day and time to minimise 
environmental effects.   
 
2.3.3 Investigations into alternative materials for microelectrode ECG 
recording of larval zebrafish ECG. 
In order to develop the single electrode recording system into a high throughput system, 
changes to the recording set up were needed. One of the biggest changes to the 
equipment set up was that the glass capillary electrodes would need to be changed for 
electrodes which could be reused and were less prone to breakage. They would need to 
be durable and less fragile so they would not need to be changed each day or in 
between recordings. In addition to this, they would need to maintain the high resolution 
signal of the glass capillary electrodes so that the signal quality was not compromised. 
Two different types of metal-based electrodes were trialled: twisted pair electrodes and 
microfabricated electrodes. Design and manufacture of twisted pair and microfabricated 
electrodes were done by Dr Richard Barrett.  
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2.3.3.1 Metal electrode development: twisted pair electrodes. 
 The first attempts to move away from the glass electrode system were twisted pair 
electrodes. These provided a tool to test various metals and plating materials at 
different diameters. A major advantage of the design of these electrodes is that they 
create 2 channel electrodes so recordings from 2 positions could be taken, or 
alternatively a differential recording using these 2 channels could be performed which 
reduced some of the noise, allowing clearer ECG signals to be recorded. Table 2.1 
shows the combinations of metals, plating material and diameters that were trialled for 
twisted pair electrodes. 
Wire 
Material 
Plating 
metal 
Radiu
s µM 
Signal Y/N Comment 
Platinum  platinum 50 N Wide diameter means 
the heart is entirely 
covered removing the 
need for specific 
positioning but also 
averages any signal out. 
no usable signal 
achieved in n=5 attempts 
Tungsten platinum 12 Y but not 
repeatable 
due to 
unstable 
plating. 
Small diameter allows 
for accurate positioning 
across the heart but 
platinum doesn’t plate 
tungsten very well. So 
the impedance is low 
enough (<1 M Ohm at 
10 Hz) but is not very 
stable and crumbles off 
when in contact with 
larvae. 
n=3 recordings achieved 
but needed to be replated 
after each attempt due to 
unstable plating. 
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Table 2.1: Overview of different metals, diameters and plating material combinations 
used to create twisted pair electrodes for dual ECG signal of 3dpf zebrafish larvae. 
Includes comments on how successful each trial electrode pair was. Successful 
electrodes, such as stainless steel plated with platinum were taken forward for testing 
for potential to record drug induced long QT syndrome using terfenadine treatment.  
 
The electrodes were considered successful if a clear PQRST could be seen in the signal 
recorded, figure 2.10A,B. Successful trials were then taken forward to test whether the 
electrodes were sensitive enough and had high enough resolution to record changes due 
to drug treatment. This was tested by treating embryos with 5µM terfenadine to induce 
long QT syndrome whilst recording from the twisted pair electrode. Terfenadine is 
known to produce an increase in QTc following treatment and this was observable by 
the 25µm stainless steel wire platinum plated twisted pair, meaning that trial was 
successful, see figure 2.10C, D. 
 
 
Tungsten gold 12 N Gold plates tungsten 
better, however the 
plating process is slow 
and the impedance not 
low enough to record a 
signal. 
Stainless 
steel 
platinum 25 Y 3 repeats taken. 
Electrodes record good 
clear signal using a 
differential style 
recording. However the 
diameter is large and 
position is still crucial 
for an analyzable 
recording with visible 
PQRST parameters. 
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Figure 2.10. Comparison of poor and good signal quality from twisted pair electrodes. 
A) Poor quality signal from tungsten platinum plated electrode. PQRST cannot be 
determined despite a clear R wave.  
B) ECG signal from a stainless steel wire electrode plated with platinum. These 
electrodes produced clear signal, with PQRST easily visualised. 
C) ECG trace with labelled PQRST for pre treatment.   
D) ECG trace labelled PQRST post 5µM terfenadine treatment, QT interval has 
lengthened.  
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This is consistent with glass capillary electrode recording of terfenadine indicating that 
these electrodes can be used to produce the same result as the glass capillary electrodes. 
However, these are very time consuming to produce and can only be made one at a 
time. 
 
2.3.3.2 Metal electrode development: microfabricated electrodes 
Following the success of the twisted pair electrode another metal electrode type was 
trialled. These were microfabricated electrodes. An advantage of these is the production 
process allows multiple electrodes to be made in one batch, so less time is spent 
manufacturing the electrodes, and more time available for recording. These were 
microfabricated SU-8 probes meaning they are gold electrodes coated in an insulating 
plastic and plated with gold on the exposed electrode recording surface area (10µm 
diameter). Microfabricated electrode designs were developed and created by Richard 
Barrett (Post Doc electrical engineer) and then put forward for testing on 3 dpf 
zebrafish embryos.  
These electrodes are much larger and more flexible than the glass capillary electrodes 
and so they were difficult to position on the embryo in the grooved agar recording 
plate. Their flexibility meant that the probe bent away from the embryo when it came 
into contact with the grooved agar plate, figure 2.11, or if the electrode was managed to 
be positioned on the heart, the contact was not stable enough to be maintained 
throughout a recording. The embryo needed to be secured into position to keep the 
contact needed for recording.  
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Figure 2.11 Development of the micropipette set up. The grooved agar recording plate 
is not suitable for recording with the microfabricated SU-8 probes as they are more 
flexible than the glass capillary electrodes and bend away from the embryo when they 
touch the agar.  
A) Glass capillary electrode is rigid and can easily approach the embryo in the 
grooved agar plate. It doesn’t bend away and contact and positioning on the embryo 
for ECG recording is possible.  
B) Microfabricated SU-8 probes are very flexible and so when they hit the top of the 
grooves in the agar plate they bend away from the embryo at the bottom of the groove. 
The set up needs to be adjusted so that the embryo and the microfabricated electrode 
can be manipulated for correct positioning for an ECG measurement to be recorded. 
 
It was therefore necessary to develop a different way of positioning the electrodes to 
establish and maintain stable contact between the electrode and the embryo.  
The embryo was placed in a disposable micropipette tip and attached to a 
micromanipulator to allow greater ease of manipulation of the embryos orientation with 
respect to the probe to aid the positioning of the electrodes. The embryo is held 
securely, but not too firmly, in the end of a disposable micropipette tip. This is then 
secured onto a micromanipulator and submerged in a petri dish of E3 solution, allowing 
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electrode 
is much 
more rigid 
SU-8 probe 
bends along 
the shaft 
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the embryo position to be adjusted. The microfabricated probe is then also lowered into 
solution within the frame of the microscope and the embryo positioned according to the 
probe rather than being stationary, figure, 2.12A. 
 
 
 
 
 
 
 
Figure 2.12 Confirmation that the set up using the micropipette to position the embryo 
does not compromise the recording quality and ECG recording with changes due to 
drug treatment can be recorded using this set up.  
A) Glass electrode test in pipette set up, glass electrode positioned on 3 dpf embryo 
heart.  
B) Recording from glass electrode in pipette set up before and after 5 µM terfenadine, 
n=3. 
 
This new set up was tested using a glass capillary electrode, and the signal confirmed as 
ECG using 5µM terfenadine drug treatment, which induces an increase in QT interval 
of ~30% , n=3 figure 2.12B. This step was used as a control for all new set ups to 
ensure signal quality was maintained. Using this recording set up, it was possible to 
position embryos and microfabricated electrode in a stable recording position, figure 
2.13B. From this stable position an ECG signal from a single microfabricated channel 
was achieved, figure 2.13E. This signal had clear QRS complex and T wave so the 
signal was confirmed as ECG and had sufficient quality for QT analysis. As positioning 
B A 
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was still time-consuming and meticulous, and the microfabricated SU-8 probes were 
much larger than the glass capillary electrodes, some embryos treated with 0.2mM PTU 
(phenylthiourea). This inhibits melanogenesis to prevent pigment developing to try and 
increase visibility of the heart with the larger electrodes, figure 2.13A. This was tried in 
the grooved agar plate and later in the pipette tip set up, but had little effect in reducing 
the time required to position the electrode, so this step was dropped. 
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Figure 2.13 Microfabricated SU-8 electrodes successfully recording from 3dpf 
zebrafish larvae.  
A) MF electrode positioned on zebrafish larvae treated with PTU (phenylthiourea)in 
recording plate N=3 Embryo positioned in grooved agar plate, Video still image which 
showed how the electrode was not stably positioned and moved over the heart and 
eventually off the embryo as the recording progressed.  
B) Microfabricated  electrode positioned in pipette tip to aide electrode positioning and 
embryo orientation.. The surrounding plastic with the gold core is visible.   
C) second embryo inside pipette tip, this time inserted more firmly into the holder. Can 
see the flexibility of the electrode probe.   
D) A close up of the electrode tip. Shows flat design.  
E) Successful PQRST recording achieved using the SU-8 probes in this recording 
setup. This signal has a band pass filter of 0.1-30Hz. P wave is present but not as clear 
as the other waveforms in this recording.  
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Not all trials with the SU-8 probes were successful and it was thought that this was 
down to impedance and maintaining a low impedance. Probes were tested for 
impedance after plating and before testing, to make sure the impedance was low 
enough (>1Mohm at 10Hz). Then the impedance was retested after a recording was 
attempted whether an ECG signal was obtained or not. This showed that unsuccessful 
probes had impedance values higher than 1 Mohm (mega ohm) at 10Hz after a 
recording attempt and this is too high to record zebrafish ECG. This instability of 
plating also impacted on repeat recordings using the same probe. As this was a crucial 
requirement of high-throughput electrodes this needed to be resolved. The electrodes 
are plated following fabrication to increase the surface area on the exposed electrode tip 
without increasing the footprint. This is so that the impedance is lowered, so that 
recording the small electrical signal from the zebrafish heart is possible, and that the 
area on the heart the device is recording from is kept to within 10µm, so the signal is 
not averaged across a large area, loosing detail from the recording. To address the 
impedance issue; the plating process was analysed. The probes are plated by suspension 
in an acidic gold solution and a current applied causing dissociated gold ions to be 
deposited onto the SU-8 probe acting as the cathode.  
Alternative plating materials were researched and conductive polymer called PEDOT 
(poly(3,4-ethylenedioxythiophene)) was chosen. PEDOT is positively charged 
(PEDOT). This composite has both electrical and ionic conductivity, which has been 
shown to be effective in biological recordings of the peripheral nervous system in rats 
(Frost et al, 2012). In this study PEDOT plated electrodes had a significantly higher 
charge capacity and lower impedance than the needle needle electrode allowing signal 
to be recorded from few simultaneously firing neurons (Frost et al, 2012). Therefore, 
applying this plating strategy to the SU-8 probes, was predicted to yield similarly 
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positive results. It was also decided that to improve the stability of the plating, a low 
current was applied so that the plating was built up in layers, which produced more a 
stable plated layer. The final design of the probes had a layer of gold plating first and 
then plated with PEDOT over the top. These were more successful and resulted in clear 
usable signal in repeat recordings from the probe, clearly displaying an advantage to 
this plating approach over other materials trialled.  
Having established that ECG recording was possible in 3dpf zebrafish larvae using 
metal microfabricated electrodes with high throughput potential, the designs for the 
probes were changed to increase the channel number. As the design process is so 
flexible in a 2D space this meant that 4 channel devices with only a small (20µm) 
distance between them was possible. Therefore, all four channels could be positioned 
over the heart to record ECG from 4 locations. The 4 channel device was similar in size 
and shape to the single channel electrode, but flat at the tip to allow 4 exposed 
electrodes to fit, figure, 2.14.A. 
 
 
 
 
 
 
 
 
88 
 
- 
  
 
 
 
 
 
 
 
 
 
 
Figure 2.14 The 4 channel microfabricated electrode design and recording signal from 
one of these channels from a dechorionated 3dpf zebrafish embryo.  
A) The tip of the 4 channel device design. Red arrows show location the exposed 
electrode recording points.  
B) 4 channel device positioned on a dechorionated 3 dpf zebrafish heart.  
C) Higher magnification of the microfabricated device positioned on the embryos heart 
Position used for successful ECG recording of 3 dpf zebrafish larvae n=5.  
D) Average waveforms before drug treatment.  
E) Average waveforms 20mins after 5µM terfenadine treatment.  
 
Successful repeat recordings were achieved with the 4 channel device (n=5) and the 
ability to place 4 channels on the heart simultaneously meant that positioning was much 
easier. As the tip of the device was larger, with 4 gold wires connecting running up the 
shaft to connect the four electrode recording spots, the device was less flexible, 
allowing positioning in the grooved agar plate. This also meant that positioning was 
easier and quicker, as the 4 channels covered the heart increasing the through put of the 
recording, figure 2.13B,C. These recording were also of sufficient quality to record and 
analyse differences due to drug treatment. QT prolongation was induced by 5µM 
D E 
A B C 
89 
 
terfenadine treatment and measured 20mins after dose, figure 2.14.D,E. 
For n=3 recordings, an ECG recording signal was recorded from all 4 channels, figure, 
2.15. However, the background noise for these recordings varied. For further 
development, reducing this noise would be key to ensuring clear ECG recordings from 
multiple channels.  
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Figure 2.15. Section of recorded ECG signal taken from recording using the 4 channel 
device. Device was positioned on a dechorionated 3 dpf zebrafish larvae. All 4 
channels recorded ECG signal and the traces are overlaid to show amplitude 
differences from the different locations on the heart. Signals recorded from different 
locations on the heart will show different amplitudes depending on position relative to 
the heart electrical signal.  
 
This is a significant result as multichannel microfabricated electrode recordings for 
larval zebrafish has not been previously reported and represents a significant 
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technological step towards a high throughput system. This result shows this possibility 
of replacing the less durable glass electrodes with reusable microfabricated 
multichannel electrodes. This opens the door for differential recordings, and also moves 
towards a model more similar to the 12 lead ECG performed on humans which would 
be advantageous as more direct comparison could be possible.  
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2.4 Discussion 
2.4.1 0.3mg/ml MS-222 does not significantly affect the heart rate and 
QTc interval of 3dpf zebrafish larvae.  
Effective immobilisation of the zebrafish embryos is imperative for successful ECG 
recording. To ensure a stable recording, the electrode position needs to be secure, and 
fixed to prevent movement artefact. Dhillon et al 2013, compared two chemical 
immobilisers, Ethyl 3-aminobenzoate methanesulfonate (MS-222), a commonly used 
anaesthetic for zebrafish work, and Tubocurarine, a neuromuscular block. It was 
concluded that there was no significant difference to the QT interval from compared 
recordings using these two immobilising agents and MS-222 was routinely used for 
recordings. However, to truly establish whether the use of anaesthetic had an effect on 
the ECG signal, recordings using MS-222 needed to be compared to recordings 
obtained without the use of anaesthetic. In particular, it was important to establish that 
the concentration of MS-222 used to immobilise the embryos for ECG was not 
affecting the heart rate or QTc interval. It is well documented that anaesthesia, at a 
high enough concentration, will lower the heart rate in humans, and it was crucial to 
establish if this was the case at 0.3mg/ml concentration of MS-222 and if so to what 
degree in the zebrafish. If significant, heart rate and QTc values could be normalised 
against this change. To compare anaesthetised and non-anaesthetised embryos, the 
embryos were immobilised in a bed of agarose. Once the fish were mounted and the 
agar had set, it was important to let the fish settle after handling. Without this step the 
heart rate at the beginning of the recording was much higher due to the stress of 
handling. So, it was important to let them acclimatize before positioning the electrode. 
93 
 
N=8 MS-222 treated and non-treated embryos were mounted for comparison and also 
compared to recordings from MS-222 treated and unmounted embryos.  
Analysis of stable ECG recordings revealed no significant difference between 
anaesthetised and non-anaesthetised embryos, at 0.3 mg/ml. This means that no 
normalising factor is required for future measurements and the immobilising method 
using 0.3mg/ml in the grooved agar plates was sufficient for detailed ECG recordings 
without effecting the heart rate and QTc interval.  
 
2.4.2 Non-contact recording from zebrafish larvae is possible and a 
maximum distance of 16µM can be reached. 
A principal aim of this study was to make steps towards, and to investigate the 
feasibility of specific parameters required for, a high throughput recording system for 
larval zebrafish ECG. The most time consuming part of the glass capillary single 
electrode recording process is the positioning of the electrode on the heart. It is an 
intricate and highly skilled job and the removal of this step would greatly increase the 
throughput of these recordings. One way in which this might be achieved is the ability 
to record at a distance from the heart. So that if the electrode is within a certain distance 
away from the heart, a reliable ECG signal can be recorded. In addition to this 
advantage, recording at a distance would also decrease the amount of embryo 
manipulation required, which would also save time, and increase throughput.  
Initial experiments used the existing set up with embryos aligned in the grooved ager 
plates, but due to the angle at which the electrode met the embryo with respect to the 
view from the microscope, visibility of the exact point where the electrode left the heart 
was difficult. In order to test whether non-contact recording was possible with the 
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borosilicate glass capillaries a different recording stage and electrode shape was 
required to be able to observe the electrode approaching the heart at a 90o angle from 
the top view microscope. Usually the electrode approaches the embryo at a 30o angle. 
Bending the electrode by 30 degrees allowed it to come in at 90 degrees to the top 
down microscope view, so that the point at which the embryo is just touching (position 
zero) vs not touching (positions 1-6) were easily visualized. The carved glass stage was 
also designed for visibility and to orientate the embryo while providing a flat channel 
for the electrode. Using this alternative electrode set up allowed signal to be recorded 
from accurately measured distances of up to 20 µm away from the heart. The signal 
noise ratio at each of these distances was calculated. The SNR is a calculated 
measurement to compare desired signal against levels of noise in a recording system. It 
can be calculated using average power of signal and noise, or mean signal amplitudes 
over time. In this instance average signal amplitudes at each distance relative to the 
heart were used to calculate SNR. This was possible as the impedance was the same for 
both signal and noise. The calculation for SNR is the square of the amplitude ratio 
(Signal/noise), figure 2.19A. The SNR is usually represented as a decibel, on a 
logarithmic scale and was calculated using the formula in figure 2.19B. 
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Figure 2.15 Formula used for calculating SNR (signal noise ratio) and signal noise 
ratio in decibels. P= average power over time. A= mean amplitude over time. SNR 
calculation for signal recorded at increasing distances from the heart average 
amplitudes(mV) were used. SNR is usually displayed as a logarithmic decibel, 
calculated using formula B. 
 
A distance of 16 µm away from the heart reliably produced a measurable ECG signal 
with a clear QT interval for analysis. Signal was also achieved at a distance of 20µm 
away from the heart, but this was only possible n=1 out of 5 attempts due to a very low 
signal noise ratio (SNR). The low signal noise ratio means that the ECG signal is not 
very visible above the noise, and therefore makes it very difficult to record detailed 
ECG from which QT analysis could be performed. The SNR varied more between 0 
and 8 microns due to varying noise levels, with a comparably lower noise level 
recorded at 8 microns than at any other distance. This is most likely due to external 
factors for those particular recordings and not difference in recording technique. To 
reduce variances in environmental noise factors such as other electrical equipment in 
adjacent labs, the recordings were taken at the same time and day, when the lab was 
quiet. Recorded noise amplitudes ranged between 0.0001 and 0.0002 and variance was 
independent of distance, there was no distance dependent trend observed. Conversely, 
signal amplitude decreased as distance from the larval heart increased. A reliable ECG 
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signal was recorded up to 16µm away from the heart with identifiable R and T wave so 
QT analysis is possible, which is in line with high throughput requirements. 
 While this is an important result for the development of a high throughput recording 
system it is likely that such a system would not utilise glass electrodes as they are 
fragile, prone to breakage and blockage. In order to design a system which uses non-
contact ECG recording this would have to be tested in a similar way to test the viability 
of such a system.  
 
2.4.3 Recording ECG from 3 dpf Zebrafish larvae using twisted pair and 
microfabricated metal electrodes: a move towards a high throughput 
system. 
The single electrode recording system described in Dhillon et al 2013, produces high 
resolution recordings from 3dpf larval zebrafish. These can be used for analysis of 
normal heart rate activity at this development stage and also to record heart responses 
to different drug treatments. While this is a very useful tool, this recording system is 
limited by the rate at which whole data sets can be produced as these recordings can 
only be performed singularly. A principle aim of this project was to make steps to move 
away from a single electrode recording system to a multichannel system in order to 
increase the throughput.  
Designing new electrodes which did not depend on glass capillaries posed a problem 
due to the scale of the zebrafish larvae at 3dpf (approx. 3mm head to tail). The glass 
capillary electrodes have an impedance independent from frequency and as such have a 
low impedance of less than 1Mohm (mega ohm). The zebrafish has cardiac electrical 
signal in the range of 5-30uV and as such, the new non-glass electrodes also need to be 
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have an impedance of ~1Mohm a 10Hz in order to record this signal. However, this 
needed to be achieved without increasing the size of the electrodes (glass capillary tip 
size 2uM) as this will increase the recording area of the zebrafish heart (which is 
approx. 100uM in diameter) and the resulting signal will be averaged across a large 
area and so detail will be lost. An averaged ECG signal would lose detail such as the p 
wave, which is difficult to capture. To keep the high resolution data obtained from the 
glass capillary recording the new non-glass electrodes needed to be less than 10microns 
in diameter. 
 
2.4.3.1 Measurable QTc differences can be recorded using metal twisted pair 
electrodes. 
The twisted pair electrode design has significant advantages on glass capillary 
electrodes. Firstly, they adhere to the requirements for high-throughput electrodes, they 
are durable and reusable, and with the right combination of metal, diameter and plating 
material, they can record detailed ECG signal with PQRST waveforms. Secondly, due 
to the nature of their design, they are 2 channel electrodes which allows a signal to be 
recorded from 2 places. This could be a dual recording on the heart, or a differential 
recording where the signal recorded from the channel positioned away from the heart is 
subtracted from the channel positioned on the heart. This subtracts addition noise not 
filtered out, potentially making it easier to ‘clean up’ the signal and obtain a clear, 
detailed ECG with PQRST waveforms. This was achieved using stainless steel twisted 
pair with a 25µm radius and plated with platinum. With a 25µm radius and stable 
plating, the impedance was low enough (>1Mohm at 10Hz) for a detailed ECG with 
PQRST waveforms to be recorded. This level of detail matches the glass capillary 
recordings, and therefore can be used as an alternative. 
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Using this successful twisted pair electrode, a recording was performed where the 
zebrafish larvae were dosed with 5µM of terfenadine to induce QT prolongation, to test 
whether this ECG change due to drug treatment could be measured using this electrode. 
The result showed the 30% increase in QTc measurement, first established by glass 
capillary recording, showing that these electrodes yield the same quality of 
measurement. This result shows that these electrodes could potentially be used as part 
of a high throughput system for recording ECGs in zebrafish larvae.  
A drawback of these electrodes is that they are time consuming to produce and plate. 
Each has to be made individually, whereas the microfabricated electrodes can be batch 
made. The design for the single microfabricated electrodes produced 40 electrodes per 
batch. Each batch took 2 weeks to make, and then were individually plated ready for 
testing. This was much quicker than creating individual twisted pair electrodes. Also, 
long term, these would require fairly consistent repeat plating to keep the impedance 
low enough, and they were maximum 2 channels, as there was no room on the 
recording plate to add any further electrodes. It was extremely difficult to try and 
position both channels on the heart for a dual recording and this was only possible with 
the lower radius metals such as the tungsten with 12µm radius, but this was difficult to 
plate and keep the impedance low enough for recording. This means that these twisted 
pair electrodes are predominantly single channel devices, therefore, do not lend 
themselves for use in high throughput systems with multichannel recording. In 
conclusion, the microfabricated electrodes were more versatile, as bespoke designs 
tailored for this specific project were created, and had the potential for more than 2 
channels, such as the specially designed 4channel device.     
Throughput this chapter different recording approaches have been applied in order to 
develop further the single electrode recording system described in Dhillon et al, 2013. 
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This is the first time metal electrode devices have been reported for use on zebrafish 
larvae and the first time reported recording from unanaesthetised embryos and from a 
non-contact position. All of which represent novel recording approaches developed as 
part of this work. As described above (2.4.3.1), recording from metal devices represents 
a significant challenge, but is vital to the development of a high throughput device.  
 
2.4.4 ECG signal can be recorded from microfabricated electrodes; a 
potential electrode type for high throughput recording. 
As previously described, moving from a single electrode recording system to a 
multichannel recording system will increase the throughput of zebrafish larval ECG 
recordings. Work with twisted pair electrodes concluded that while initially it was 
thought that these could serve as 2 channel devices, practically they were too bulky to 
facilitate this.  Following on from the work with twisted pair electrodes, 
microfabricated electrodes were trialled. These were more expensive initially to 
produce as the bespoke designed ‘masts’ required for creating the designs, produced 
externally were expensive. After this step, the rest of the manufacturing process was 
performed by Dr Richard Barrett, a post-doc electrical engineer on the project.  
The bespoke electrode mast design process opens the door for multichannel devices. 
The design process is extremely flexible in a 2D space so very individualised electrodes 
can be created. Multichannel electrodes would aid the development of a high 
throughput system as you could position the electrode over the heart, very easily and 
quickly, knowing that with multichannel at least one of the electrodes on the device 
would be in a position to record ECG. This removes the need for painstaking electrode 
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positioning, increasing the throughput. Also, if positioned on the device close enough 
together, there is the potential for ECG recording across multiple channels.  
The first microfabricated electrodes were single channel devices to test the feasibility of 
using these electrodes to record the small electrical signal (5-30µV) of the 3 dpf larval 
zebrafish heart. The microfabricated electrodes created were SU-8 probes, these are 
gold electrodes coated in an insulating layer of plastic, top and bottom. A 10µm 
electrode tip is left exposed as the recording area which is plated with gold to increase 
surface area to achieve the low impedance required for zebrafish ECG recording 
(>1Mohm at 10Hz) without increasing the recording area footprint which would 
average the signal over a larger area of the heart reducing detail in the recording.  
These initial devices were difficult to work with due to their flexibility and required a 
different approach to allow greater embryo manipulation to position the electrodes on 
the heart, firmly. This was resolved by using a disposable electrode tip attached to a 
micromanipulator and using this setup, recording from these single channel 
microfabricated recording devices was achieved. However, there was a problem with 
replication and not every device created, despite being from the same batch and 
identical treatment, performed the same. Impedance measurements taken after plating, 
before and after recordings showed that the impedance values didn’t stay low after 
positioning on the embryo. This led to time being wasted consistently re-plating 
individual electrodes in order to be able to test them for recording ECG. Also, a major 
requirement for high throughput electrodes as a departure from the glass capillary 
electrodes is that they need to be reusable. In order for the microfabricated electrodes to 
be developed for high throughput recording, this plating unreliability needed to be 
resolved. Different plating materials were researched and a conductive polymer, 
PEDOT was chosen. PEDOT has proven success in biological recordings. Frost et al, 
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2012 demonstrated the use of PEDOT in peripheral nervous system recordings in rats 
with PEDOT plated electrodes performing better than alternatives. This is because 
PEDOT plated electrodes have a higher charge capacity and a low impedance. The 
higher charge capacity helps the signal transfer at the electrode tip from the zebrafish 
pericardial sac surface to the electrode. A low impedance is required to record the small 
electrical signal of the zebrafish heart, and the lower impedance of the PEDOT plating 
greatly helps to record. It is also much more stable and so the impedance stays low, 
allowing repeat recordings with the same electrode without having to re-plate. 
Reusability is a requirement for high throughput electrodes, so it was important ensure 
that with the electrode design and plating protocol this was achieved. The final plating 
protocol used a layer of gold plating and a layer of PEDOT plating on top. However, 
positioning still took time with extra help for embryo orientation and establishing stable 
contact needed using the pipette tip set up. Also, despite a vast improvement with the 
PEDOT plating, the signal quality was still not at the standard as the glass capillary 
electrode, however, the signal quality was sufficient to be able to detect the QRS, R 
wave and T wave, so QT analysis is possible from recordings using these electrodes.  
Once effective, reliable metal microfabricated electrodes had been established, the next 
step was to upscale this result from single channel electrodes to multichannel. This was 
the next important requirement for high throughput recording. With more channels, the 
laborious, meticulous electrode positioning would not be necessary, as increasing the 
number of channels on the electrode increases the chance of 1 of those electrodes 
recording ECG signal without having to take extra time and care to place the electrodes 
precisely. Using the same design process as the single electrodes, a 4 channel device 
was designed and created and was plated with gold and PEDOT as per the successful 
single electrode devices. This device was successfully used to record detailed ECG 
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signal (n=3). This is a very important and novel result for the development of a high 
throughput channel, recording signal that is detailed enough for analysis of drug 
treatments is a big step towards a high throughput system. Although only a very small 
sample size this is a proof of concept result which demonstrates the potential of a high 
throughput zebrafish larvae ECG recording device for hERG channel cardiotoxicity and 
novel drug screen therapies.  
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3. Characteristic analysis of the electrocardiograph signals 
from the chambers of a 3dpf zebrafish heart using Fourier 
transform analyses. 
 
All ECG work and analyses pertaining to this chapter was performed by myself. In 
silico modelling work performed by James Crowcombe.  
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3.1 Introduction  
3.1.1 The Human 12 lead ECG procedure 
Diagnosis of a multitude of human cardiac conditions depends, at least in part, on a 12 
lead ECG recording as a standard method for determining cardiac dysfunction. This is 
because it is a robust, high resolution and informative tool for observing the electrical 
activity in the heart. The 10 electrode, 12 lead standard ECG procedure gives a detailed 
picture of electrical activity and, therefore, is highly informative in a disease state. 
Depending on which electrode/lead abnormalities are showing, in conjunction with 
which section of the ECG is affected can suggest different arrhythmia conditions as 
well as indicating an atrial or ventricle problem. For example: QT prolongation can be 
diagnosed by examining Leads II, V5 or V6 and analysing a section of cardiac cycles 
(Nachimuthu, Assar and Schussler, 2012).  Currently, it is not possible to replicate this 
on the larval zebrafish due to the small scale of the zebrafish larvae. However, it would 
be useful to determine if there are measurable differences in the atrium and ventricle 
signals which could then be used, in a cardiac disease state to identify chamber specific 
arrhythmias in larval zebrafish. This will aid development of the zebrafish as an 
arrhythmia model for human arrhythmias and further understanding of the larval 
zebrafish heart.     
 
3.1.2 Atrium and ventricle specific signals 
Atria and ventricles have distinct differences in transcription profiles, resulting in 
chamber-specific differences in structure, ion channel expression and electrophysical 
properties. This reflects their different functions and can lead to chamber-specific 
induced or in inherited arrhythmias. As a result of these specialised transcription 
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profiles, atria and ventricles can show differences in responses to drug treatment 
(Tabibiazar et al, 2003). There are many examples of arrhythmias which are chamber 
specific to either the atrium or ventricle, for example atrial and ventricle specific 
fibrillation, chamber specific re-entrant arrhythmias and ventricular tachycardia. Even 
ion channels can have chamber specific expression patterns and therefore associated 
arrhythmias can be isolated to specific chambers, for example; T-type calcium channels 
which in adulthood are predominantly not expressed in ventricles but are present and 
have a role in sinoatrial node function, facilitating pacemaker cells depolarisation 
(Betzenhauser, Pit and Antzelevitch, 2015).  
Zebrafish also display chamber specific differences in responses to drugs, for example 
Langheinrich, Vacun and Wagner, 2003 showed chamber-specific bradycardias in 
response to drug treatment. Known hERG blockers induced 2:1 atrioventricular block 
where the ventricle beats half as often as the atrium (Langheinrich, Vacun and Wagner, 
2003) and also induced QTc prolongation (Dhillon et al, 2013). Some zebrafish 
mutants such as Reggae which displays a sinoatrial exit block and a short QT also 
feature chamber specific phenotypes (Hassel et al, 2008) and several mutants have been 
created which show silent chambers (Rottbauer et al,2001, Milan and Macrae, 2008).  
To expand the potential use of the zebrafish larvae as an arrhythmia model system, 
investigations were conducted to examine whether the atrium and ventricle signals 
could be identified and isolated. This would mean that atrial and ventricle specific 
arrhythmias could be examined in this model.  
 
106 
 
3.1.3 Analysis of ECG using wavelet transformations. 
An ECG electrocardiographic signal, is a recording of the electrical activity of the 
heart. This activity is a change in voltage potential where myocyte cells depolarize and 
repolarize, facilitated by movement of positively charged ions across the cell 
membrane, causing the voltage potential across the membrane to change from minus 70 
to plus 30 and back again. This voltage change is propagated in synchrony across the 
heart, driving coordinated myocyte contraction and relaxation. The wave of change in 
voltage potential across the heart can be measured by an electrode, producing an ECG 
trace which records voltage (V) against time (s). The waveforms this creates, the P 
wave, QRS complex and the T wave, occur at different frequencies (Hz). Wavelet 
analysis, where a fast Fourier transform is applied to waveforms and displays them as 
components of frequency (Hz), power (µV2) and time (s). A fast Fourier transformation 
is a calculation to decompose the signal into composite parts. This gives different 
information than standard trace analysis, where the ECG is analysed in terms of interval 
duration (Saritha, Sukanya and Murthy, 2008). Further wavelet analysis can also 
produce 3D spectrograms which show frequency/power relationships across time. 
These analyses may provide an alternative approach to quantifying responses from drug 
treatment, as well as also proving useful for analysing signals from noisy recordings, 
where it is difficult to visually identify clear PQRST waveforms without further 
analysis (Lilly, 2017). 
 
3.1.4 Aims 
 
This study aimed to investigate whether it was possible to record atrium and ventricle 
signals separately and distinguish individual features for these chambers, similarly to 
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human ECG. This was to establish ‘normal’ functionality parameters for the two 
chambers to then be able to identify when these parameters are abnormal, such as in a 
disease state. Therefore ECG could be used diagnostically for identifying atrium and 
ventricle specific arrhythmias in the zebrafish larvae. This could then be extrapolated to 
human conditions, if relevant, and provide novel zebrafish drug screening tools for 
chamber specific arrhythmias.  
The  aims  are: 
• To establish whether accurate recording from atrium and ventricle chambers 
could be taken and whether the differences between these signals could be 
determined.  
• To analyse these signals using fast Fourier transform techniques and wavelet 
analyses. 
• To establish a dual electrode recording system for zebrafish larvae with 
appropriate controls to allow simultaneous recording from 2 electrodes 
positioned on the heart.  
• To establish whether ECG differences due to drug treatment could be detected 
using these techniques.  
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3.2 Methods 
3.2.1 Zebrafish lines and husbandry 
All zebrafish were handled according to the UK animal (Scientific Procedures) Act of 
1986. Wild type AB fish were used for preliminary single electrode experiments and 
thereafter chamber specific fluorescent lines (Tg:VMHC-red and Tg:AMHC_cherry-
NTR) were used (Zhang et al, 2013, obtained lines from this lab, slightly different to 
the paper when requested through the author). These lines were also used for imaging 
the fish. Dual electrode recordings used wild type AB zebrafish.  
 
3.2.2 Single electrode recording method 
Same procedure as described in section 2.2.2.  
 
3.2.3 Imaging: ScanR 
The Olympus ScanR high content screening microscope (Olympus) was used to image 
the two transgenic lines (Tg:VMHC-red and Tg:AMHC_cherry-NTR). Low-resolution 
prescreen data was acquired using a single z-slice per embryo and channel using a 2.5× 
(N.A. = 0.08) objective. Embryos were imaged with a 4× (N.A. = 0.13) (60 z slices, Δz 
= 10 µm). This was repeated with the RFP channel to capture fluorescence.  
Images were then processed, formatted and overlaid in Image J (Java-based processing 
program, NIH). Maximum projection images were produced and then overlaid  to 
produce an image of the 2 fluorescent chambers for optimisation of electrode 
positioning. A grid was placed over the image to guide electrode placement of 
electrodes.  
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3.2.4 Standardising atrium and ventricle electrode positions 
In silico modelling work performed by James Crowcome was used to predict the 
optimum positions for recording atrium and ventricle recordings (Crowcombe et al, 
2016). This work created a 3D rendering of the 3 dpf zebrafish larva and mapped 
electrical currents across the heart to create a 3D finite electrical model of the ECG 
signal of a larval zebrafish at 3 dpf (Crowcombe et al, 2016). This electrical map 
predicted where signal amplitudes from the 2 chambers were largest and most distinct.  
To facilitate putting these predicted positions into practise, an image using fluorescent 
lines was created and a grid overlaid. Atrium recordings were taken from G8 and 
ventricle recordings taken from E7, see figure 3.1. 
 
Figure 3.1: Grid overlaying ScanR image with ventral view of 3dpf embryo with a 
fluorescent heart. Columns run A-J and Rows run 1-10. Atrium recording position, G8, 
ventricle recording position E7.  
 
3.2.5 Dual electrode recording method  
The recording system used for these experiments is the multichannel system by Tucker 
Davis Technologies (TDT system).  The setup is the same as for the single electrode 
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recording protocol, but there is a micromanipulator, motor arm and electrode capillary 
set up on both sides of the recording petri dish, the left side measured the ventricle and 
the right measured the atrium. Each of these recording arms are attached to a 16 
channel headstage (TDT). This headstage allows 16 inputs plus 2 reference and ground 
electrodes. The headstage is connected to a pre amplifier (PZ2-256, S3 z series, TDT) 
which can have up to 256 separate channels and the signal is then digitised in the 
processor (RZ2 BioAmp Processor, S3 z series, TDT). The signal is then displayed 
using Open WorkBench (Open WorkBench 2.12, the user interface of OpenEx Suite, 
TDT). Programs can be designed within this software to allow effective manipulation 
of the signal. These include filter settings, analogue output to Labchart and recording 
channel and reference channel selection for differential recordings. The signal is 
recorded in blocks which can be transferred to MatLab for analysis. Signals are 
analysed in MatLab using Wave Solution. Analogue signals were also output to 
Powerlab for Labchart analysis as per 2.2.8.  
 
3.2.6 MATLAB: Wave solution analysis 
As well as labchart analysis performed as per 2.2.8, 1 minute segments of raw data 
were taken from Labchart and converted to MATLAB ((MATLAB R2010a, 
MathWorks) files for analysis using Wave Solution. Wave Solution is custom written 
analysis software created by Richard Csercsa and Andor Magony that can be used to 
evaluate electrophysiological signals. Data were resampled at 500Hz to reduce 
processing requirements for analysis. A band-pass filter of 1-30Hz was applied before 
analysis to eliminate large noise artefacts occurring at 50Hz. This is also the same band 
pass filter applied in Labchart filter settings, for continuity. A fast Fourier transform 
was applied to each section, allowing calculation of the power of the signal over time at 
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different frequencies. This enabled analysis of the data through periodograms 
(graphical representations of the spectral density of the signal across different 
frequencies, plotting frequency (Hz) against power (uV2)) and spectrograms (3D graphs 
representing time, frequency and power on the X, Y and Z axes respectively). This was 
used to analyse power/frequency differences between atrium and ventricle, and to 
determine how the power of the signal changes before and after drug treatment. 3D 
spectrogram graphs were created by sampling 10 second sections from the recording 
for analysis. The FFT calculation then reproduced this section coloured for highlighting 
higher and lower power frequency areas in the recording. Periodograms had 100 
smoothing points applied and Spectral density colour maps were optimised using 
standardised index number settings (blue marker: 2, turquoise marker: 18, yellow 
marker: 37, red marker: 55) for ease of visualisation of the higher and lower power 
areas.  
 
3.2.7 Temperature control 
All recordings were taken at a temperature between 24.5. and 25.5 degrees Celsius. 
Temperature affects heart rate, and by extension the ECG interval measurements. Steps 
were taken to try to monitor and control temperature, but finding a solution which did 
not impact on electrical noise was difficult, any equipment required for heating, 
controlling and monitoring temperature would need to be inside the Faraday cage, 
therefore introducing more electrical noise in proximity to the electrodes. For this 
reason, the recording area inside the Faraday cage was heated using a radiator to 25.5oC 
and then switched off for the recording. The Faraday cage was insulated against heat 
loss by covering the cage in tin foil, with a retractable flap at the front to allow access 
for positioning. The radiator was switched off prior to recording to limit noise. The 
112 
 
temperature during the recording was monitored using a temperature probe (ATC 1000 
DC temperature controller, World Precision Instruments). When the temperature dipped 
below 24.5 oC, the recording was stopped and the recording area reheated.  
3.2.8 Statistical tests. 
Data sets were tested for normality using Shapiro-Wilk and Anderson-Darling tests. 
Normal distribution plots were also used to check and validate these results.  
The normalised frequency values for the 3 periodogram peaks taken from the atrium 
and ventricle fluorescent lines (Tg:VMHC-red and Tg:AMHC_cherry-NTR) were 
analysed for significance using Mann-Whitney and Wilcoxon tests.   
Comparison of atrium and ventricle amplitudes from both single and dual electrode 
experiments were tested for significance using Wilcoxon paired-signed test. 
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3.3 Results 
Atrium and ventricle recordings were taken to determine firstly, if it was possible to 
distinctly record signals from these chambers, secondly if there is a difference between 
atrium and ventricle signals, and thirdly to try and quantify this difference and apply 
appropriate statistical tests to determine whether the difference was significant.  
 
3.3.1 Atrium and ventricle signals recorded using single electrode 
recording method.  
 The first preliminary experiment to observe atrium and ventricle recordings, used the 
established single glass electrode recording system and took sequential atrium and 
ventricle recordings from n= 18 wild type embryos (AB strain). This was performed 
using a single glass electrode positioned first on the atrium for 5 minutes followed by a 
5 minute recording from the ventricle. This allowed analysis of the atrium and ventricle 
signals from the same embryo using the existing single electrode recording method and 
an instant direct comparison between the two signals could be made.  
These recordings were analysed for average cardiac cycle wave morphology to see if 
there were distinct characteristics between these two groups of recordings, figure 3.2.  
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Figure 3.2 Example atrium (A) and ventricles (B) signals for 5 3dpf embryos (E1-E5) 
recorded using the single electrode recording system. Some overall patterns observed 
for atrium and ventricle but not conserved for all embryos. Variation in amplitude and 
morphology. N=18 embryos analysed in total. Figure shows matching chamber signals 
from 5 embryos as examples from the n=18 performed in total.  
 A) n= 5Atrium recorded signals  
B) n= 5Ventricle recorded signals 
 
There were no consistent morphological distinctions between atrium and ventricle 
recorded signal across all embryos; there were some overall patterns but none that were 
shared by all embryos. However, signal shape is in part dependant on electrode position 
B A 
E1 
E2 
E3 
E4 
E5 
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so it was thought that standardising and controlling electrode placement and position 
may produce clearer similarities between repeat recordings. Minute long sections of 
each recording were extracted as MATLAB files and analysed using MATLAB 
programme Wave Solution developed by Andor Mahony and Richard Csercsa. This 
programme applies a fast Fourier transform to the signal to produce periodograms and 
spectrograms, which displays signals as components of frequency, time and power. 
This displays the ECG signals as components of frequency/Hz, power/µV2 and time/s. 
Spectrogram analysis of the atrium and ventricle recordings from the n=18 embryos 
was carried out to look at power frequency patterns, figure 3.3. These analyses give 
information about the frequencies which make up the components of the ECG and 
action potentials of the larval zebrafish heart.  
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Figure 3.3 ECG signals displayed as components of time, frequency and power, Power 
frequency spectrums are a different way to look at ECG signals and analyse the 
frequencies of the PQRST waveforms. Colour on all charts represents Power 
density/µV2. Higher power is towards the red end of the spectrum, lower power towards 
the blue. 
A) n=18 Atrium signal Power spectral density maps collated together in rows 1 row = 
1 recording signal  
B) )n=18 ventricle signal power spectral density maps collated together in rows 1 row 
= 1 recording signal  
Rows between A and B correspond to the same embryo.  
C) 4 example atrium signals and spectrograms: X axis: time/s Y axis: Frequency/ Hz. 
D)4 example ventricle signals and spectrograms: X axis: time/s Y axis: Frequency/ Hz. 
Example atrium and ventricle traces taken from same embryos (n=4).  
 
Stacked power density spectrogram analyses showed that there were repeated bands of 
high power at certain frequencies, throughout all n=18 recordings for atrium and 
ventricle, figure 3.3 A,B. Individual spectrograms for each recording showed these 
higher power frequency bands corresponded to waveforms of the ECG, figure 3.3 C,D.   
Analysis of these spectra showed potential repeatable differences between the atrium 
and ventricle signals, indicating a difference could be quantified. To analyse these 
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potential repeatable differences in more detail further refinement of the experimental 
procedure is needed to standardise the electrode positions to reduce the variation 
between repeats.  
 
3.3.2 Atrial and ventricle recordings taken from fluorescent lines using 
standardised electrode positions. 
To develop the protocol further, it was necessary to standardise the positions used for 
atrium and ventricle recordings. To make sure the atrial and ventricle positions for 
recordings were consistent, a grid was overlaid on an image of a 3dpf larval heart. 
Specific atrial and ventricle fluorescent transgenic lines were used to more accurately 
map the electrode position on the heart. This was used in reference for positioning the 
electrode on all the embryos. The grid can be seen in figure 3.4A. In silico modelling 
predictions, performed by James Crowcombe, were used to determine the optimal 
positions for recording the atrium and ventricle separately, figure 3.4 B (Crowcombe et 
al, 2016). The two positions were chosen as they lie at the extremes of the heart and are 
therefore the best positions to obtain atrial/ventricle signals in isolation. To analyse the 
potential difference seen from the preliminary experiments further, atrium and ventricle 
recordings were taken, n= 20 AMHC atrial and n= 20 VMHC ventricle at specific 
positions taken from a grid formation over a 3 dpf larval zebrafish heart.  
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Fig 3.4: Determining atrium and ventricle electrode recording positions using 
computational modelling of zebrafish heart. 
A) Computational modelling (in silico) work mapping electrical activity on the surface 
of the larval zebrafish heart, produced  by James Crowcombe (Crowcombe et al, 2016). 
This predicted the positions for atrium and ventricle recording electrodes by selecting 
position where signal amplitude for that chamber was greatest. Blue and green circles 
mark the predicted positions for atrium (blue) and ventricle (green).  
B) Grid reference used for positions of the atrium and ventricle recordings. Image 
produced by overlaying ScanR images of Tg(AMHC:mcherry-NTR) and 
Tg(VMHC:red).Black lines represent electrodes.  
 
Atrium and ventricle signals were recorded as single electrode recordings using the 
Tg(AMHC:mcherry-NTR) for atrium recordings and Tg(VMHC:red) for ventricle 
recordings. The temperature was monitored throughout all the recordings and 
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controlled such that the temperature was within a temperature range of 24.5 and 25.5 oC 
for all recordings.  2-3 minute recordings were taken and 1 minute sections were then 
extracted as MATLAB files for analysis.  Each recording, n=20 atrium and n=20 
ventricle, were analysed by applying a fast Fourier transform and from this a 
periodogram showing frequency/power peaks, figure 3.5 A and spectrograms 
displaying 10s sections of recording as 3D maps of frequency and power / time, figure 
3.5B. Spectrographic analyses were also collected and stacked for atrium and ventricle 
recordings for direct comparison, figure 3.5 C, D. These sections were also analysed 
using Labchart to obtain R-R intervals used for analysis, figure 3.5E.   
Comparison of each of these analyses showed cross correlation. The bands of high 
power observed in the stacked spectrograms for all n=20 atrium and n=20 ventricle 
recordings corresponded with the peaks observed from the periodograms. For example, 
the first high frequency band (boxed in red, figure 3.5 C, D) corresponds with the first 
peak on the periodogram. Also, in the 3D spectrograms showing 10s sections of 
recording as frequency and power against time, the high power areas (in red/orange 
from the colour scale, figure 3.5B), correlate with the waveforms of the ECG, most 
notably, the R peak (QRS complex). A secondary wave of lower frequency is also 
observable, which could represent the T wave, reading off a frequency value off these 
graphs is difficult as it is difficult to accurately determine the point of highest power, 
but the dark red (highest power on colour scale) appears to be under 5Hz, which 
correlates with the other analyses. Variation of frequency between repeat atrium and 
ventricle recordings can be seen from the stacked spectrograms, where the first peak for 
each falls within the red box, but this covers a frequency range of 0-5 Hz.  
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Fig 3.5. Spectrographic and Labchart analyses of atrium and ventricle recorded ECG 
signals from 3dpf heart using fluorescent transgenic lines Tg(AMHC:mcherry-NTR) for 
atrium recordings and Tg(VMHC:red) for ventricle recordings (n= 20 AMHC atrial 
and n= 20 VMHC ventricle) from grid references E7(ventricle) and G8 (atrium.)  
A) Example periodogram, frequency values for the first 3 peaks from each recording 
taken for analysis. The first 3 peaks were the most consistent across recordings. Taken 
from a ventricle recording. 
B) Example Spectrogram for 10s of signal expressed as time, frequency and power. 
Areas of high power (red/orange) correlate with the R peaks and other ECG features. 
Taken from a ventricle recording. 
C) n=20 stacked spectrograms of frequency/power for atrium recordings.  
D) n=20 stacked spectrograms of frequency/power for ventricle recordings.  
C&D) The red box highlights the range of frequencies for the first peak observed in the 
periodograms for each recording. 
E) Example Labchart average waveform morphology analysis to look at ECG intervals, 
such as RR interval. 
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There were no noticeable differences between the transgenic lines used and the traces 
recorded from wild type embryos, use of the transgenic line was to aid positioning only 
and had no effect on the ECG.  
Analysis of the spectrograms and signal patterns between atrium and ventricle 
recordings, figure 3.5 C,D showed that there may be repeatable frequency differences, 
indicating the difference can be quantified through frequency analysis. To quantify this 
signal difference, the frequency values for the first big three peaks of the periodograms 
were taken, three were chosen as most of the recordings showed 3 peaks, so this looked 
to be the most reproducible pattern, figure 3.5, A. Frequency values were taken from 
the periodograms rather than the other analyses as these gave exact frequency readouts, 
and as such are more accurate and less prone to error than the reading of frequency 
values off  the other spectrographic analyses charts. These frequency values were 
extracted from the periodograms and normalised against the heart rate, calculated in 
Labchart, to remove frequency differences due to changes in heart rate. The averaged 
normalised frequency points for each peak, for atrium and ventricle are seen in figure 
3.6. The general  trend, is as expected: frequency decreases as RR interval increases 
(heart rate decreases).  
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Figure 3.6. Averaged  frequency peaks against RR interval normalised with respect to 
heart rate. Taken from n=20 atrium and n=20 ventricle periodograms. 
A) Normalised frequency vs RR interval for the averaged 3 peaks for atrium.  
B) Normalised frequency vs RR interval for the averaged 3 peaks for ventricle.  
Taken from n=20 Tg(AMHC:mcherry-NTR) for atrium recordings and n=20 
Tg(VMHC:red) for ventricle recordings.  
 
One anomaly was observed from the readings from peak 3 where one embryo didn’t fit 
the trend line. In this embryo the frequency was lower than expected with respect to 
heart rate. This anomaly was still there after normalising against heart rate.   
The normalised frequency values were then plotted in a histogram format to determine 
distribution and it was found that the distribution was not normal, and a Mann-Whitney 
and Wilcoxon tests applied. The atrium and ventricle frequency differences for all three 
peaks are significant with ventricle signals consistently producing lower frequency 
peaks, figure 3.7.  
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Figure 3.7 Mean Frequency values for Atrium and Ventricle for each Peak, normalised 
against heart rate.  
A) Chart shows atrium vs ventricle periodogram peak frequency values, normalised 
against heart rate. There is a statistically significant difference between atrium and 
ventricle for all 3 frequency peaks.  
B) Table shows the frequency range for each peak prior to normalising against heart 
rate: ventricle frequencies are consistently lower than the atrium measured frequencies 
across all three peaks.  
Taken from n=20 Tg(AMHC:mcherry-NTR) for atrium recordings and n=20 
Tg(VMHC:red) for ventricle recordings. 
 
This demonstrates that there are separate frequency ranges for atrium and ventricle 
signals, which are consistent across n=20 repeats.   
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3.3.3 QRS amplitude recorded in atrium / ventricle.  
Further in silico work (performed by James Crowcombe) modelling the larval zebrafish 
heart predicted that we should see a 25% increase (1.3X larger) R wave amplitude 
height in the ventricle compared to the atrium. It is potentially easier to see this in 
recordings from the same embryo, which is why the recordings produced in 3.3.1 were 
used where atrium and ventricle recordings were taken from the same wild type embryo 
consecutively. The recordings were analysed in Labchart: producing an overlaid 
average wave form for a selection of data and P,Q,R,S,T intervals assigned. The 
resulting intervals and amplitude heights were recorded for each embryo for both 
atrium and ventricle, figure 3.8. 
 
Figure 3.8. Analysis of  R peak amplitude recorded from the atrium and ventricle of 
3dpf larval zebrafish heart. Amplitude differences between the two chambers were 
predicted. R peak amplitude was larger in the ventricle than in the atrium across all 
recordings, however due to the variation in amplitudes recorded, the error bars were 
large and so the results were not significant. N=18 wild type 3 dpf embryos. Error 
bars: standard deviation.  
 
As figure 3.8 shows, the QRS amplitude for the ventricle was consistently larger than 
in the atrium, but the range of amplitudes across the data set meant that the error bars 
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(standard deviation) were large, and so the result was not significant. Due to multiple 
factors affecting amplitude height, this is not a reliable approach for analysing atrium 
and ventricle signal differences. The first step to reducing variation in recordings for 
atrium and ventricle analysis would be to record from these chambers simultaneously.  
 
3.3.4 Stimulation signal used to standardise signal differences 
between the 2 electrode systems 
Thus far, the recording method used for ECG recording was the previously established 
single glass capillary electrode system. The best way to directly compare the ECG 
signals recorded from atrium and ventricle positioned electrodes is to record them 
simultaneously. To facilitate this, a second recording station complete with electrode 
holder and inchworm motor arm was installed into the system with both electrode arms 
connected to a multichannel channel pre amp (Tucker Davis Technologies). To 
standardise the electrode settings in both electrode recording arms it is important to 
control the electrode properties, position and distance. Using identical pulled 
borosilicate glass capillaries with the same taper, tip diameter and length to control the 
electrode properties and  in  addition to  the chloridised silver wire used to connect the 
electrode to the pre amp was kept to 4 cm and 3 minutes chloridisation for consistency. 
Electrode placement was controlled using an inchworm motor arm attached to each 
electrode and the positions used were the in silico modelling derived atrium and 
ventricle positions previously described (E7 ventricle, G8 atrium). To confirm that the 
signal from each electrode arm set ups were consistent, a stimulation signal was sent 
between the electrodes in both directions and recorded. Two recordings were taken; the 
first, stimulation signal sent from the left and recorded in the right and then sent from 
the right and recorded in the left. The signal sent was of a set voltage and amplitude, so 
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therefore the difference seen in the receiving electrode used to normalise the cardiac 
signal. The difference in the signal was taken as the difference in R wave amplitude, 
which is measured in mV, figure 3.9.  
 
 
 
 
 
 
 
 
 
Figure 3.9. Standardisation of 2 electrode arms for dual recording of atrium and 
ventricle signals. Stimulation signals at set voltage and amplitude were sent from the 
left electrode and recorded in the right and from the right electrode and recorded in the 
left. Signal received on the left is 0.000135µV higher than the right, therefore right side  
(atrium) is 0.0001325 bigger than left (ventricle) electrode so ventricle R amplitude is 
multiplied by the difference (0.000235/0.000368). This difference  was applied to dual 
electrode embryo recordings to standardise and normalise the two electrode signals. 
N=8 wild type3 dpf embryos.  
  
This stimulation control of sending artificial signal of known current (1 mV) between 
two recording electrodes, allowed the difference between the two electrode arms to be 
used to correct heart recorded ECG signal. For subsequent dual ECG recordings; the 
electrodes were positioned, then the stimulation control was performed, the dual heart 
signal was recorded and the stimulation repeated. These were performed in triplicate, 
and averaged, corrected amplitudes used for results, figure 3.10 B.  
Having standardised and normalised the dual electrode system, signals from the atrium 
and ventricle were recorded simultaneously. This allowed direct comparison in real 
Left 
(ventricle) 
Right 
(atrium) 
Average 
L→R: 
0.000235µV 
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LR: 
0.000368µV 
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time of the signals recorded from these two positions. The signals were overlaid to 
analyse signal morphology differences, and a larger amplitude was measured in the 
ventricle signal, figure 3.10A. Labchart analysis measured R peak amplitude, and these 
were corrected by electrode stimulation control difference. Recordings of n=8 wild type 
3 dpf embryos, each recording with stimulation control done in triplicate were averaged 
and the results plotted, figure 3.10B. This experimental approach showed a significant 
difference between atrium and ventricle signal R peak amplitudes and variation 
between recordings reduced. Periodograms and 3D spectrograms of these signals were 
created from 1 minute extracted sections and compared. Periodograms, figure 3.10C, E 
and 3D spectrograms, figure 3.10D,F were created for the dual signal shown in 
figure3.10A. These also showed the frequency differences described in 3.3.2, 
corroborating that result. Ventricle signals showed lower frequencies, and also lower 
power than atrium signals.  
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Figure 3.10. Dual recording of atrium and ventricle signals in the wild type 3 dpf 
larval zebrafish heart, and analyses. N=8 
A) Overlaid signals: Blue: channel 1 (left-side, ventricle) Green channel 2 (right-side, 
atrium) Red Stimulation channel. Amplitude difference between atrium and ventricle R 
amplitude observed. 
B) Amplitude difference between atrium and ventricle signals is significant. Error bars: 
standard deviation.  
C) Periodogram of atrium signal from dual signal shown in A)  
D)3D spectrogram analysis of atrium signal from dual signal shown in A). 
E) Periodogram of ventricle signal from dual signal shown in A)  
F)3D spectrogram ventricle of signal from dual signal shown in A). 
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3.3.4 Using Fast Fourier transform to analyse ECG changes from drug 
treatment.  
Further to the frequency spectrum analysis shown in 3.3.2, it was investigated as to 
whether the heart rate and QT differences from drug treatment could be measured using 
Fourier transform calculations and therefore the changes leading to QT prolongation 
can be viewed as changes in frequency and power. ECG recordings for before and after 
5µM terfenadine were performed in wild type 3 dpf embryos (n=4) and fast Fourier 
transform applied. Clear shifts in high power bands to lower frequencies were observed 
after drug treatments, figure 3.11.  
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Figure 3.11. Spectrogram and periodogram analyses of before and after 5µM 
terfenadine treatment. These results were measured from the single electrode system, 
positioned at the AV junction between the atrium and ventricle. N=4 wild type 3dpf 
embryos. 
A) Spectrogram showing shift in frequency power to lower frequencies after drug 
treatment. Top row, before 5µm terfenadine and bottom row, 20 mins post treatment.  
B) Comparative periodogram mapping frequency and power shows a shift to lower 
frequency after terfenadine treatment. 
C) Periodogram before drug treatment and D) Periodogram after drug treatment C&D 
used to create the comparative periodogram chart.   
 
To extend this result further, a dual electrode recording with 5µM terfenadine treatment 
was performed (n=4 wild type 3 dpf embryos). Terfenadine treatment also showed 
differences in response between atrium and ventricle, figure 3.12.  
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Figure 3.12 Analysis of atrium and ventricle signals recorded simultaneously pre and 
post 5µM terfenadine treatment in wild type 3 dpf embryos n=4.  
A) Spectrogram showing shift in frequency from before drug treatment (top row) to 
after drug treatment (bottom row) for atrium signal.  
Periodogram shows a difference before B) and after C) drug treatment and in atrium 
signal responses 
D) Spectrogram showing shift in frequency from before drug treatment (top row) to 
after drug treatment (bottom row) for ventricle signal.  
Periodogram shows a difference before E) and after F) drug treatment and in atrium 
signal responses. 
G) Signals show shift in frequency patterns post treatment and there is a marked 
increase in power in the ventricle signal post treatment.  
 
 
Stacked spectrograms showing pre and post terfenadine treatment were created for 
atrium figure 3.12A and ventricle figure 3.12D. Both showed shifts in high power 
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bands to lower frequency after drug treatment. This was also reflected in the 
periodograms created for pre and post treatment for atrium figure 3.12 B, C and 
ventricle figure3.12 E,F. The chart shown in figure 3.12 G, also demonstrates this 
frequency shift but also shows a marked increase in power in the ventricle recorded 
electrode, indicating a difference in atrium and ventricle response. A bigger difference 
in the ventricle electrode for a QT prolongating drug such as terfenadine would make 
sense, as QT prolongation affects ventricular repolarisation and therefore the ventricle 
should have a more marked response compared to the atrium. Therefore, this is a 
demonstration of an ECG recorded chamber specific difference analysed by frequency 
analysis. This analysis approach is automatable, making it a potential method for 
analysing ECG drug treatment response and may also indicate chamber-specific 
responses.  
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3.4 Discussion 
This chapter aimed to analyse atrium and ventricle signals in the larval zebrafish heart 
and determine if there was any difference between signals recorded at the atrium and 
ventricle, and to quantify this difference. Several approaches were utilised for analysis, 
including single and dual recorded signals, ECG morphology, Fourier transform and 
wavelet analyses, and signal amplitude. Standardisation of electrode position and 
stimulation controls allowed confirmation of significant differences between atrium and 
ventricle signals by frequency analysis and by signal amplitude. Wavelet analysis was 
also applied to signals recorded pre and post drug treatment to determine whether 
differences caused by drug treatment could be analysed using these approaches. 
Frequency shifts post drug treatment could possibly be used for quantifying drug 
treatment effects and this type of analysis would more easily be automated than ECG 
interval measurements.  
 
3.4.1 Preliminary look at atrium/ ventricle signals 
Atrium and ventricle recordings were taken consecutively from n=18 3 dpf embryos to 
determine firstly, if there is a difference between atrium and ventricle signals and 
secondly to try and quantify this difference and apply appropriate statistical tests to 
determine whether the difference was significant. These signals were then analysed for 
the shape of the ECG cardiac cycle. There was a large amount of variation and 75% of 
embryos showed similar patterns for atrium and ventricle signals indicating there are 
possibly specific characteristics for atrium and ventricle recordings. However, there 
were no consistent patterns present in all embryos. Signal morphology is in part 
dependant on the position of the electrode on the heart, so it became important to 
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standardise the electrode positions for the atrium and ventricle electrodes to improve 
the quality and comparability of repeat recordings between embryos.  
To analysis these signals further, 1 minute sections were extracted as MATLAB files 
and analysed in Wave Solution. Fast Fourier transform analyses were applied to these 
sections and displayed as frequency power spectrograms and periodograms. This also 
suggested differences between atrium and ventricle ECG signals, with similar high 
power frequency bands, indicating that analysis of the ECG waveform frequencies 
would highlight atrium and ventricle differences. It was predicted that atrium and 
ventricle frequency profiles would be distinct enough for statistical significance, but 
further refinement of the recording procedure was required to reduce inconsistency 
between repeats and reduce the frequency range observed between recordings. It was 
decided that combining in silico modelling work with a grid format would standardise 
the electrode position for the following experiments.  
 
3.4.2 Significant difference between atrium and ventricle recorded 
signals detected using fast Fourier transform analyses. 
Following on from the preliminary experiment, atrium and ventricle signals were 
recorded using the transgenic lines fluorescent for atrium Tg(AMHC:mcherry-NTR) 
and ventricle Tg(VMHC:red), electrode positions standardised for consistency. Wavelet 
analysis producing periodograms and spectrograms for these recordings were produced 
and frequency peaks taken for analysis. Statistically significant differences were 
observed between periodogram peaks suggests distinct frequency ranges for atrium and 
ventricle recorded signals, with ventricular frequencies consistently lower than atrium 
across all three peaks.  This correlates with the ECG parameter measurements: PR 
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interval 0.12 – 0.2s, QRS 0.04 – 0.12s and QT <0.42s This suggests that on these 
spectra analyses, the QT interval which corresponds to ventricular repolarisation, is the 
largest wave, and as such would have the lowest frequency. The PR interval, which is 
the atrial component in the ECG atrial depolarisation, has the shortest interval, and so 
would have the highest frequency. In humans, similar patterns are seen and waveform 
features of time and frequency components can be used to detect arrhythmic 
waveforms, for example; the frequency of ventricular fibrillation is between 4-7Hz. 
Spectra and power spectra vary with arrhythmia, as seen here with analysis of zebrafish 
ECGs (Lin, 2008).  
This type of electrophysiological signal analysis is important as it is possible it can be 
used as part of an automated signal analysis software for the development of high-
throughput system. The end goal of this project is to produce a high throughput ECG 
recording system for zebrafish embryos, and part of this is to have implemented an 
online software analysis system to decrease analysis time. However, these analyses 
should not be in place of more established signal analysis methods, where the ECG 
cardiac cycle is averaged across the recording and ECG interval times (P-R, QRS, QT) 
are determined. They can be used in combination to extract more information from the 
recording.   
 
3.4.3 Standardisation of a dual electrode recording system. 
Introducing a second recording arm for simultaneous electrode recording from 2 
positions on the 3 dpf larval heart represents a significant step forward and opens up 
possibilities for more in-depth analysis of the larval zebrafish heart activity. 
Particularly, using this system, significant differences in amplitude between the atrium 
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and ventricle R peaks were measured. Standardisation of the electrodes using the 
stimulation control is necessary as the voltage being measured and compared is so 
small from the embryonic zebrafish and this maximises the sensitivity to pick up these 
small changes in voltage/frequency/time when the ECG changes in response to external 
stimulus such as drug treatment. Using this system may also increase sensitivity for 
recording accurate PQRST differences, particularly atrial differences, as positioning for 
a clear P wave is the most time-consuming step in the set up process, as it is the 
smallest wave and the most difficult to obtain a reliable reading.  
 
3.4.4 Amplitude difference in QRS complex in atrium and ventricle 
signals. 
Amplitude can vary greatly depending on a number of factors including; position across 
the heart, distance from the heart (how much electrode is pressed onto the heart using 
the inchworm), stage (older embryos have a larger heart) and therefore a larger, more 
easily recorded signal. The initial experiment for QRS amplitude analysis re-analysed 
previous recordings, recorded during 3.3.1 (preliminary experiment). These recordings 
had a range of amplitudes too great for a significant difference to be calculated for both 
atrium and ventricle results. So, in order to investigate this parameter further this 
variation needed to be reduced. In order to do this, the atrium and ventricle signals 
needed to be recorded simultaneously. Development and standardisation of a dual 
electrode recording system allowed a significant difference in QRS amplitude height to 
be recorded and analysed. Dual recorded signals showed a 23% increase in amplitude 
height in the ventricle compared to the atrium signal. This corresponds with the 
predicted amplitude variance made from the in silico modelling at 25%. In humans, 
there are distinct differences between atrial and ventricular action potentials and 
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different amplitude differences from recorded ECG signals in zebrafish may indicate a 
similar distinctness in zebrafish. 
This experiment was less to do with comparison of atrium and ventricle and more to do 
with differences in recording position. The amplitudes taken from these recordings 
were the dominant peaks, i.e. the QRS which corresponds to ventricular depolarisation. 
Being the dominant wave, it covers the smaller amplitude atrial repolarisation wave 
which occurs at the same time. In human, differences in amplitude height can denote 
arrhythmia. For example, increased amplitude height in children has been linked as a 
precursor symptom predictive of sudden cardiac death later on. This amplitude can 
differ in different leads. Human ECG procedure is a 12 lead process. It is the amplitude 
in the limb leads which has been identified as a marker for sudden cardiac death with a 
sensitivity of 94% (Osten-Smith et al, 2010). Having demonstrated that the recording 
procedures developed here are sensitive enough to detect amplitude differences 
between recording positions, these markers could be studied in this model.  
 
3.4.5 Analysis of drug induced differences in ECG traces using fast 
Fourier transform analyses. 
Investigations into whether ECG changes from drug treatment were detectable using 
Fourier transform and whether these changes could be attributed to atrium or ventricle 
differences due to the drug treatment. This was performed to see if an alternative form 
of analysis was possible, to use as an alternative or alongside ECG parameter 
measurements. Terfenadine is a drug known to cause QT prolongation and a reduction 
in heart rate, as such it was predicted that this should reduce the frequency seen in the 
periodogram ECG frequency peaks post treatment. ECG recordings pre and post 
treatment were analysed using wavelet analysis and periodogram and spectrogram 
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analyses were performed. The results showed a shift in frequency to lower frequencies 
post terfenadine treatment. A prolonged QT interval has a larger T wave than normal 
and would therefore be a lower frequency than a normal T wave. The lower frequency 
ECG waves recorded post terfenadine treatment would indicate the waves are wider, 
hence the lower frequency (Hz). This could be interpreted as a QT prolongation, 
consistent with the known effect of terfenadine on the QT. In addition, terfenadine 
treatment showed an overall increase in power after drug treatment and showed clear 
differences between atrium and ventricle recordings. A more marked difference was 
measured in the ventricle, which corresponds to QT prolongation (ventricle 
repolarisation), again consistent with known effect of terfenadine.  This result 
highlights another potential approach for analysing ECG response to drug treatment and 
measuring chamber-specific responses, but further investigation would be required, 
with a larger sample size and a range of atrium and ventricle acting drugs to trial. In 
addition, using this type of analysis for ECG recordings is more easily adaptable for use 
in a high throughput system.  
Use of this approach using wavelet analysis to quantify ECG changes in response to 
drug treatment could be useful, as it would be easier to automate for a high throughput 
system than ECG parameter measurement which has a large ‘human judgement’ 
component where the averaged and compiled cardiac cycles have the PQRST points 
placed on the averaged cycle. However, during the course of this project, an automated 
system for PR and QTc interval analysis was developed. As this is the more comparable 
and more standardised ECG analysis approach, this was pursued instead of further 
development of wavelet analysis of ECG drug treatment responses (Barrett et al, 2016 - 
as yet unpublished). 
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4. Investigations to test the sensitivity of the ECG recording 
system for the analysis of arrhythmic mutants: Phenotypic 
characterisation of an L-type calcium channel mutant. 
 
 
 
 
All work pertaining to testing the ECG recording system for dual vs single electrode 
recording system for mutant analysis, the analysis of ECG phenotype of cacna1c 
mutant compared to wild type, comparison of drug treatment response for the 5 cardiac 
acting drugs and control drug was performed solely by me. Genetic analysis of selected 
2dpf cacna1c clutches were performed by Sanger Institute. Chlorzoxazone treatment 
and video analysis was performed in collaboration with Ben Wilkinson. Salinity and 
orbital shaker experiments were performed in collaboration with Edina Garai. 
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4.1 Introduction 
 So far work in this study has concentrated on measuring the effects of cardiac-acting 
drugs on the larval zebrafish ECG. This chapter will focus on establishing the use of the 
larval zebrafish ECG system for measuring the differences caused by mutation.  
There are several advantages for using zebrafish as a genetic model of disease, beyond 
the advantages of its small size, ocular transparency and ex utero development. The 
zebrafish genome is sequenced and transgenic lines can easily be created for extremely 
diverse uses and mimicking a wide variety of human disease states (Santoriello and 
Zon, 2012, Vornanen and Hassinen, 2016). In particular, there has been massive 
advancement in the use of zebrafish as a model of cardiovascular disease and 
arrhythmia (Brown et al, 2016, Asnani and Peterson, 2014). Like other animal models, 
zebrafish undergo manipulations to develop cardiovascular diseases which are similar 
to human for study. Models of different components with contrasting mechanisms can 
be produced to allow study into various types of cardiovascular disease state. This 
allows insight into the human disease process. These include thrombosis, 
arteriogenesis, inflammation, cardiomyopathy and cardiac regeneration (Chi et al, 
2008). The relative ease of creating mutant and transgenic lines in zebrafish through 
transposon-mediated systems has led to the generation of many cardiovascular lines for 
study. Injection of constructs into freshly fertilized eggs has created a wide range of 
transgenic zebrafish lines to facilitate study, including many cardiovascular lines 
(Santoriello and Zon, 2012). As previously discussed, there is high conservation 
between human and zebrafish, with zebrafish orthologues of all the main human cardiac 
ion channels, facilitating genetic models centred on ion channel derived arrhythmia to 
be created (Alday, et al, 2014).  The creation of a wide variety of cardiac disease 
transgenic lines has greatly aided the study of human cardiac disease conditions 
141 
 
including cardiac arrhythmia. Cardiac arrhythmia is defined as the perturbance of 
normal heart rhythm or rate away from normal sinus rhythm. This can occur in many 
different forms with many different causes. Therefore, transgenic lines created in 
zebrafish to model arrhythmia are also very diverse in their underlying genetics (Poon 
et al, 2013). 
This chapter looks at modelling repolarisation abnormalities such as long QT syndrome 
as a result of genetic manipulation as opposed to drug treatment.  
 
4.1.1 Genetic causes of long QT syndrome. 
This study has focused on long QT syndrome in zebrafish, both drug induced and as a 
result of genetic manipulation. This is because it is an easily observed ECG phenotype, 
arising from aberrant cardiac ion channel function causing perturbance of the cardiac 
action potential. Long QT syndrome is a heterogeneous group of conditions with 
multifactorial causes (Abrams and Macrae, 2014). While it can arise from certain 
cardiac acting drugs, in particular hERG channel blockers (kv11.1), it more commonly 
arises as a congenital condition, and many causal genetic mutations have been 
identified.  Some of these are listed in table 4.1. LQTS is split into difference types 
depending on the mutation causing the long QT, most commonly, loss of function 
mutations in potassium channels (Schwartz, Crotti and Insolia, 2012). 
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LQT 
TYPE 
Gene Protein 
LQT 1 KCNQ1 I
Ks
 K
+
 channel α subunit 
LQT 2 KCNH2 (herg) I
Kr
 K
+
 channel α subunit (kv11.1) 
LQT 3 SCN5A I
Na
 Na
+
 channel α subunit 
LQT 4 ANKB Ankyrin-B 
LQT 5 KCNE1 I
Ks
 K
+
 channel β subunit  
LQT 6 KCNE2 I
Kr
 K
+
 channel β subunit 
LQT 7 KCNJ2 I
Kr2.1
 K
+
 channel α subunit 
LQT 8 CACNA1c Cav1.2 calcium channel α subunit 
 
Table 4.1 Adapted from Hedley et al 2009 and Schwartz, Crotti and Insolia 2012.  
Table shows the nomenclature, gene name and protein for each genetic mutation 
reported to cause the main 8 forms of long QT.  
 
While loss of function mutation in potassium channels are the most common mutations 
linked to LQT, gain of function mutations in sodium channel (Brugada) and calcium 
channels (Timothy syndrome) are also linked to forms of long QT syndrome (Hedley et 
al, 2009).  The zebrafish mutant selected for this study is an L-type calcium channel 
mutant with a progressive severe cardiac phenotype developed by 5 dpf, ultimately 
leading to heart failure. This was suspected to display a pronounced arrhythmia, 
including a long QT by 2-3dpf for ECG analysis. Therefore LQT 8 was the focus as this  
arises from a calcium channel mutation in the Cav1.2 L-type calcium channel.  
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4.1.2 The cacna1c gene encodes the Cav1.2 protein, an L-type calcium 
channel essential for normal cardiac function. 
4.1.2.1 Structure of the alpha 1c subunit of the L-type calcium protein  
The cacna1c gene encodes the alpha 1C subunit of an L-type calcium channel. L-type 
calcium channels are heteromeric proteins consisting of an alpha 1 subunit alongside 
other alpha, beta and gamma subunits. The alpha unit consists of a voltage sensor, the 
calcium ion selectivity pore and dihydropyridine drug binding sites (Rottbauer, et al, 
2001). It has 4 transmembrane domains (I-IV) each made up of 6 transmembrane 
segments (S1-S6) with cytosolic N and C termini.  
It has an important role in the cardiac action potential, the channel opens in phase 3 and 
the influx of calcium into the cardiac myocyte triggers the cell to contract (Splawski et 
al, 2004).  
Overall structure is highly conserved between human and zebrafish with both 
containing the same 4 transmembrane domains each with 6 segments including the 
highly conserved positively charged S4 segment (Rottbauer, et al, 2001).  
 
4.1.2.2 The Cardiac action potential and excitation-contraction coupling: the 
role of Calcium.  
As previously described in detail, the cardiac action potential, which drives each heart 
beat has four phases, with different cardiac ion channels involved at each phase. 
Disturbance of any of these channels can cause arrhythmia, and several are linked to 
different types of Long QT syndrome (LQTS) (Seebohm, 2005).  
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The cardiac action potential causes cardiomyocyte contraction through excitation-
contraction coupling, a highly synchronised process linking the action potential to 
ventricular contraction through movement of ions (Reuter, 1984). L-type calcium 
channels are essential in this process, it is the movement of calcium ions during phase 2 
of the action potential (plateau phase) which triggers the myocyte to contract and then 
relaxes when calcium moves back out of the cell. This pulse of calcium ions into and 
out of the myocyte cytoplasm is what causes each heartbeat and synchronous 
propagation of the action potential through the ventricle, thereby resulting in apex to 
base contraction of the whole ventricle. Therefore, calcium movement, and by 
extension the calcium channels that facilitate calcium movement during the cardiac 
action potential are vital to normal sinus rhythm (Rottbauer et al, 2001). It important to 
notes some differences between ECC in human and zebrafish. In mammals, 
sarcoplasmic reticulum (SR) Ca2+ release is the main source of calcium in the cell for 
transient calcium movement causing contraction/relaxation. In zebrafish, the SR is less 
complex as in higher animals and has a reduced capacity to store and release Ca2+. This 
means that the SR calcium release is less important in zebrafish ECC, although still 
present and functional (Verkerk and Remme, 2012). Zebrafish have both T-type and L-
type calcium currents and use of L-type calcium channel blockers have shown the 
importance of the L-type calcium current for normal action potential duration 
(Nemtsas, 2010).   
 
4.1.3 LQT 8 and Timothy Syndrome.  
Long QT syndrome 8 is caused by a missense gain of function mutation in the cacna1c 
gene, encoding the alpha 1c subunit of L-type calcium channel Cav1.2 (Splawski et al, 
2004). This is the main calcium channel in the human and zebrafish cardiac action 
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potential and also has important roles in development (Vornanen and Hassinen, 2016). 
This LQTS8 mutation is diagnosed clinically as Timothy syndrome (Liao and Soong, 
2009). Timothy syndrome is a rare multi-system disorder resulting from a point 
mutation in the cacna1c gene encoding the Cav1.2 protein. This is the alpha 1C subunit 
of an L-type voltage-dependant calcium channel (Splawski et al, 2004). This condition 
has an autosomal dominant inheritance pattern, but less severe cases can result from 
somatic mosaicism. Timothy syndrome is caused by recurrent de novo Cav1.2 missense 
mutation G406R located on exon 8 and alternative splice variant exon 8a, both 
encoding transmembrane segment S6 of domain 1 at the c terminus end, with the splice 
variant 8a being the most common form diagnosed clinically (Dufendach, et al, 2013). 
Mutation G402S located on exon 8 has also been described. In humans, the splice form 
containing exon 8 has higher expression in heart and brain tissues (Splawski et al, 
2005). The different mutations and locations denote variances in the disease, and can 
range from autosomal dominant to maternal mosaicism.  The mutation causes the 
inward depolarising Ca2+ current to be maintained, with near complete loss of voltage 
dependence left functioning. L-type calcium channels are involved in a wide range of 
systems; including major roles in development, maintaining normal cardiac rhythm and 
neurological function (Splawski et al, 2005). As a result of L-type calcium channel 
diverse function, Timothy syndrome has a widely varied group of symptoms across 
multiple systems. L-type calcium channels are highly expressed in the brain and 
therefore, there are neurological symptoms including, cognitive impairment, autism and 
seizures. Another characteristic symptom which is useful diagnostically is syndactyly, 
which can be corrected surgically. Overall, Timothy phenotypes span the heart, skin, 
eyes, teeth, immune system and brain (Splawski, 2004).    
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4.1.4 Current models of Cav1.2 dysfunction and Timothy Syndrome. 
There are two previously reported zebrafish mutants of this channel report mutations in 
the S5 and S6 segment resulting in a truncated protein at these points, figure 4.1.  
 
 
Figure 4.1. Adapted from Rottbaurer et al, 2001. Figure shows the structure of the 4 
domains each with 6 transmemebrane spanning segments. Labelled in pink and blue 
are the locations of the 2 published mutations, each resulting in a truncated protein 
with loss of function.  
 
This produces a very severe cardiac phenotype with an under developed and silent 
ventricle by 3 dpf and are therefore expected to be foetal fatal mutations in human 
(Rottbauer et al, 2009). The atrium in this mutant is structurally normal, but the 
ventricle is smaller in sizes than typical and has fewer myocytes, indicating L-type 
calcium channel role in normal cardiac development (Verkerk and Remme, 2012). The 
cacna1c mutant chosen (sa6050) has not been used for publication prior to this study. 
The cacna1c sa6050, has a less severe phenotype, with an arrhythmic but beating heart 
at 3dpf. Therefore, it may be a better model for human calcium channelopathies 
observed clinically. This mutant, however, does highlight how essential the L-type 
calcium channel is for normal heart function and development. Total loss of function 
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has a devastating impact on normal heart rhythm and cardiac development (Rottbauer 
et al, 2009).  
Mice have been use to map the Cav1.2 cellular distribution in Timothy syndrome and 
expression was found throughout the brain. Including the hippocampus, cerebellum and 
amygdala where abnormalities have been linked to autism. Expression was also found 
in the heart, digits, eyes and teeth, which match the multisystem phenotypes seen in 
Timothy syndrome (Splawski et al, 2004). More recently, mouse mutant models with 
the Timothy syndrome mutation, have been shown to have different social responses 
and demonstrate autistic traits (Bader et al, 2011). In this study, the homozygous 
mutation was fatal, so heterozygous G406R mouse mutants were studied for 
behavioural phenotypes and displayed altered social behaviour. These included 
increased contextual fear memory and altered ultrasonic vocalisation, these distinct 
behaviours differences mirror the key aspects of autism (Bader et al, 2011). While this 
model has allowed insight into the behavioural and neural consequences of Timothy 
syndrome, the arrhythmogenic components of Timothy syndrome have not been 
identified in this mouse model. Timothy Syndrome has also been modelled in iPS cells, 
where human myocyte iPS cells from a Timothy patient were used to study arrhythmia 
and identify drugs. While a useful model for analysing the mutation effect in one cell 
type and having the advantage of a higher throughput compared to in vivo models, 
cellular models lack the complexity to model a multisystem disorder such as Timothy 
syndrome (Yazawa and Dolmetch, 2011). Zebrafish embryos, as a small, vertebrate in 
vivo model with high throughput capability, could be a useful tool for analysing Cav1.2 
channel abnormalities such as in Timothy syndrome.   
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4.1.5 Characterisation of a novel calcium channel mutant cacna1c 
(sa6050). 
A principle aim of this study was to establish the use of the zebrafish recording system 
for analysis of cardiac electrical perturbance observed in the ECG due to genetic 
mutation. Work so far has focussed on drug induced arrhythmia and it was important to 
confirm that the recording system was sensitive and robust enough to reliably record 
changes induced due to genetic variance. Study of mutations associated with human 
cardiovascular disease (in particular arrhythmia) in an in vivo zebrafish mutant model 
advances understanding of these conditions and allows screens to be developed for 
potential treatments.  
The zebrafish mutant cacna1c (allele sa6050) was generated as part of the Wellcome 
Trust Sanger Institute zebrafish mutation project using ENU protocol 
(http://www.sanger.ac.uk/sanger/Zebrafish_Zmpgene/ENSDARG00000008398#sa6050).  
As in human, the zebrafish cacna1c gene codes the Cav1.2 protein; the alpha 1C 
subunit of the L-type voltage dependant calcium channel which is essential for normal 
cardiac function (Alday et al, 2014). This gene is a homologue to the human cacna1c 
gene, and as already described, mutations of this gene have been implicated in human 
cardiac diseases, including arrhythmia and hypertrophy. Human diseases associated 
with genetic changes in the cacna1c gene fall into gain of function or loss of function 
mutations with different implications. In human disease the most notable examples of 
these groups are Timothy (gain of function) and Brugada (loss of function) syndromes, 
(Betzenhauser et al, 2015). Timothy syndrome, as described in section 1.4 is a 
multisystem disorder with an associated cardiac phenotypes of a long QT with and 
resultant bradycardia (Fukuyama et al, 2014). The causal mutations of Timothy 
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syndrome are gain of function mutations in the cacna1c gene produce the characteristic 
long QT phenotype seen in these patients (Wemhömer et al, 2015). Brugada syndrome 
is characterised by a short QT phenotype and an ST segment elevation caused by a loss 
of function mutation (Antzelevitch et al, 2007). It has also been linked to sodium 
channel gene SCN5A, the same gene associated with LQT 3. The SCN5A mutations 
linked to Brugada cause frameshift and deletions leading to failed channel expression 
and reducing INa availability, also missense mutations linked to loss of voltage 
dependant activation/inactivation (Antzelevitch, 2001).  
The zebrafish mutant imported for this project has a point mutation at an essential 
splice site in the cacna1c gene, and is expected to have a pronounced arrhythmia 
phenotype observable on an ECG. Visual observation at 5 dpf of the mutant by the 
Sanger institute describes a severe bradycardiac and cardiac malformations, so a 
bradycardic, prolonged action potential is expected. Analysis of this mutant may show 
that it has parallels with human disease states associated with L-type calcium channel 
abnormalities such as Timothy or Brugada syndromes.  
 
4.1.6 Utilising the larval recording system for detecting ECG 
differences due to genetic mutation. 
A high resolution ECG recording system to analyse cardiac responses to drug treatment 
will be advantageous for cardiac drug safety testing. Previous work has shown that the 
larval zebrafish recording system is robust and sensitive for analysing ECG changes 
due to drug treatment, and this study has demonstrated the potential and feasibility of a 
high throughput larval zebrafish ECG recording system for this purpose. ECG analysis 
of cardiac function will be a useful tool for investigating cardiac mutant phenotypes. To 
expand further the potential applications of the larval recording system, this study 
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aimed to demonstrate the utility of this system for recording ECG changes as a result of 
genetic mutation. To test the sensitivity of the recording system, ECG recordings from 
an arrhythmic mutant were performed. 
A zebrafish mutant with a point mutation in the L-type calcium channel alpha 1C 
subunit (cacna1c gene) was selected. This channel is responsible for movement of 
calcium during the action potential in the heart and is essential for normal cardiac 
function. It is a T>G conversion at an essential splice site, and it was expected that this 
mutation would cause cardiac arrhythmia phenotypes in the ECG.  
 
4.1.7 Aims 
• Testing the sensitivity of the ECG recording system for detecting and analysing 
cardiac mutant phenotype via detecting ECG signal abnormalities 
• To use the larval zebrafish recording technique to detect potential presence of an 
arrhythmia in the cacna1c mutant (allele 6050, Sanger institute) compared to 
wild type embryos.  
• To use a profile of cardiac acting drugs to assess their effect on the cacna1c 
mutant and wild type embryos to analyse changes to phenotype in response to 
these drugs and potential rescue effects.  
• To draw comparisons to human calcium channelopathies such as Timothy 
syndrome and critically assess the potential use of the cacna1c mutant (sa6050) 
as a disease model.  
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4.2. Methods 
4.2.1 Zebrafish husbandry 
For all experiments, with the exception of the mutant experiments, wild-type Tubingen 
long fin zebrafish embryos were used as this is the background of the cacna1c mutant. 
All zebrafish were handled according to the UK animal (Scientific Procedures) Act of 
1986. Adult zebrafish were maintained using standard conditions in a flow-through 
system of aerated, charcoal filtered tap water with a 12 hour light/dark cycle 
(Techniplast; UK). 
Breeding pairs were set up in separate breeding tanks, filled with system water and left 
over night. Embryos were collected the following morning and transferred into petri 
dishes containing E3 medium (Sigma Aldrich) and incubated at 28 oC until 3 dpf.  The 
cacna1c embryos were taken out at 2dpf for visual screening into separate petri dishes 
containing E3 medium and then returned to the incubator.  
 
4.2.2 The cacna1c sa6050 mutant 
The zebrafish mutant line used for the mutant data was an L-type calcium channel 
mutant, cacna1c. This mutant was produced at the Wellcome Trust Sanger Institute as 
part of their zebrafish mutation project. Sanger produced this mutant using ENU 
mutagenesis followed by screening for embryos displaying atypical phenotypes. Sanger 
had previously confirmed a mutation in the F2 line with considerable cardiac and 
systemic effects observable at 5 days post fertilisation (dpf).  
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4.2.3 Visual screening for cacna1c homozygous mutants 
The cacna1c mutant embryos clutches were visually assessed for a cardiac phenotype 
at 2 dpf. This was to screen out homozygous mutants away from heterozygous and wild 
type siblings. At 2dpf (days post fertilisation), the embryos were removed from the 
incubator and 1ml of 4% MS-222 (ethyl-3-aminobenzoate methanesulfonate , Sigma-
Aldrich) was added to the plate. This anaesthetised the embryos for ease of 
manipulation for visual screening. As it was already established from Sanger that by 5 
dpf a pronounced cardiac oedema has developed, it was predicted that there would be 
some sign of this phenotype developing at 2 dpf. Larvae were orientated ventrally and 
on their side to assess for cardiac phenotype. Once it was discovered that a subgroup 
within the clutch had a cardiac oedema, this phenotype was used as the screening 
criterion for homozygous mutants at 2 dpf. Visual screening took place under a light 
microscope (Nikon SMZ600). Following visual assessment, embryos were split into 
those with and those without an oedema. Embryos were rejected if the cardiac oedema 
was coupled with yolk necrosis, tail bending or other deformations as the oedema can 
not in those instances be confidently attributed to the mutation. The screened embryos, 
those with and without oedema were then returned to the incubator in separate petri 
dishes in fresh E3 medium to recover from the anaesthetic. Embryos with severe 
oedema were rejected for ECG analysis. This is because distance from the electrode can 
affect the quality of the signal, particularly with arrhythmic fish. ECG recording of the 
embryos at 4 or 5 dpf when the severe oedema and very slow heart rate had developed 
was extremely difficult due to the massive fluid build up. Following initial screening 
and ECG analysis, a phenotype of bradycardia was identified and also included in the 
visual screening criteria.  
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4.2.4 Genotyping analysis performed by Sanger Institute. 
Fin clips and embryos were fixed in methanol and genotyped at the Sanger Institute. A 
selection of screened 2dpf cacna1c mutant line were selected and placed into a 96 well 
plate, the liquid removed, the plate sealed and then put on ice to prevent degradation. 
23 positive and 23 negative embryos were selected. Plates were sent to the Wellcome 
trust Sanger institute for Genotype analysis. The genotyping tool used was KASP 
(Kollective allele specific PCR). This is a fluroecence based PCR reaction performed 
using a 96 well plat format allowing multiple samples to be analysed simultaneously. 
Results are displayed using the 96 well format and assigns a colour to each well 
representing the genotype.  
KASP genetic analysis was performed on the selected groups in duplicate and the 
results were then sent back. This was done to access accuracy of the screening process 
at 2 dpf.  
 
4.2.5 Assessment of 2 dpf analysis as a screening tool 
To determine the specificity and sensitivity of 2dpf screening, embryos were reassessed 
at 5dpf when the phenotype had developed further. Screening immediately prior to 
ECG recording was not possible due to time constraints on recording days (3 dpf). 
Reassessment of screened homozygous mutants after ECG was necessary as 
genotyping showed visual screening at 2 dpf was not always accurate. Embryos were 
kept in 96 well plates after ECG recording and if the more pronounced oedema had not 
developed by 5 dpf, the result was excluded from the development. This ensured 
accuracy in the mutant characterisation but unfortunately introduced bias into the 
experiment.  
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4.2.6 ECG procedure 
For all experiments, unless otherwise stated (non-MS-222 experiments) the zebrafish 
embryos were immobilised in 0.3 mg/ml MS-222 (Sigma).  
 
4.2.6.1 Recording set up 
For all experiments, 3 dpf embryos were orientated on a custom recording plate 
previously described, (2.2.2a) with 9ml E3 medium with 0.3mg/ml MS-222. The 
recording plate was then placed onto the heating pad compatible with Cryocon 22C 
(cryogenic control systems) temperature control (4.2.6). Throughout the recording 
temperature is monitored as slight changes in temperature can affect heart rate. The 
ECG recording system used for these experiments was the powerlab system as previous 
(2.2.2b) with the exception that the NPI single end point amplifier was exchanged for a 
2 channel amplifier to facilitate dual electrode recording (EXT-02 B, NPI) This 
facilitated atrium and ventricle recording.  
 
4.2.7 Temperature control 
The temperature was controlled using the, Cryocon 22C (cryogenic control systems) 
temperature control system that maintained the temperature of the recording plate at 
28oC. A custom heating plate was created compatible with this system to heat the 
recording plate to 28oC. The heating plate used insulated conductive wire folded in half 
and twisted along the length. This was then glued onto a petri dish lid in a spiral from 
the centre of the lid. At the edge, a gap was cut out the lip of the lid to allow the wires 
to exit and the plate to sit flat. The wires were then cut and a connector compatible with 
the Cryocon system was soldered on. This heated the plate evenly and maintained 
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temperature throughout the recording. The twisting and spiral pattern cancelled out 
noise generating from the wires from the recording, this was always the difficulty in 
creating a temperature controlled recording environment as whatever heating element 
used would be inside the faraday cage and so had to be electrically quiet. The 
temperature was monitored throughout the recording by the Cryocon temperature 
probe.  
 
4.2.8 ECG analysis and Statistics 
The digitised ECG signal was displayed using Labchart software and filters were 
applied to increase clarity of the signal, a bandpass filter (0.1-30Hz).  
Analysis of the signal was carried out using Labchart, which calculated the R-R, QRS, 
QT and QTc ECG parameters and the heart rate as per section 2.2.8.  
 
4.2.9 Drug stocks 
All drug stocks were made up in E3 medium. Terfenadine (Sigma) and Verapamil 
(Sigma) was prepared in 10 mM stock in E3 and DMSO (10 % Sigma Aldrich), to aide 
solubility. Isoprenaline was made up to 500mM stock, penicillin, 10Mm stock, 
flecainide, 1mM stock and metoprolol 500µM stock. Stocks were diluted using E3 and 
the final concentration of DMSO on the recording plate at 1 %. Chlorzoxazone stock 
was made up with 12% DMSO with E3 to a 6mM solution. This created the whole 
dosing range.  
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4.2.10 Literature search to seek candidate drugs to rescue phenotype 
A literature search was carried out to identify candidate drugs which may have a rescue 
effect on the mutant phenotype. Chlorzoxazone was chosen as try as it was an already 
marketed drug as a muscle relaxant, that it has been shown to have a positive effect in 
calcium overload in the brain and because it acts on calcium activated potassium 
channel (Gao et al 2012 and Liu, Lo and Wu, 2003).  
 
4.2.11 Chlorzoxazone LC50 bioassay 
The concentrations for basing the LC50 assay were calculated using the mouse LD50 
numbers as work has shown that there is a close correlation for these calculations 
between the two species (Ali, Mil & Richardson, 2011). The lowest human/murine 
LD50 for chlorzoxazone is 50mg/kg and a concentration of 300µM for zebrafish 
calculated. Estimations of zebrafish weight were used based on Hu et al, 2000. From 
this concentrations were decided on for the LC50 assay. The concentrations selected 
were: 30µM, 100µM, 300µM, ,(n=18 mutant, n=20 wild type) 600 µM and 1000 µM 
(n=14mutant, n=16 wild type) plus 2% DMSO and E3 control groups ,(n=18 mutant, 
n=20 wild type).  
Wild type and cacna1c mutant embryos were placed singularly in a 96 well plate and 
incubated at 28oC. Each well contained 200µl of test solution. Acute responses were 
taken at 15 minutes post treatment. After 24hrs each concentration was assessed for 
mortality. Observations for acute and 24hours post treatment performed under a light 
microscope (Nikon SMZ600). Larvae health was checked at 30 minutes, 1 hour and 24 
hours post commencement of treatment. Larvae were primarily checked for indications 
of cardiotoxicity (bradycardia, oedema, arrhythmia) and secondly, overall toxicity 
(death, necrosis). Data collected was used to create a mortality plot from which the 
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LC50 estimate was taken. 
  
4.2.12 Screening for asystolic events 
From initial visual observations a subpopulation of cacna1c mutants were identified, 
that showed a phenotype where several heart beats were ‘missed’ before normal sinus 
rhythm resumed. These were termed asystolic pauses. On closer assessment of these 
embryos during ECG recording it was observed that there was a loss of ECG signal 
associated with the cardiac asystole where the heart totally stopped beating for several 
beats, longer than a traditional sinus pause. This phenotype was added to the visual 
screening criteria. 2dpf larvae were visually assessed for these pauses as well as 
oedema. To visually assess for pauses, cacna1c larvae were observed in turn for the 
duration of 1 minute.  Any larvae displaying the pauses phenotype were selected out as 
homozygous mutant and collected for ECG analysis. Larvae were removed one at a 
time from the incubator to time to reduce cool down period which affected heart rate 
assessment.  
 
4.2.13 Introducing environmental stress through high salinity and 
orbital shaking procedure.  
The asystolic pauses phenotype was easy to screen for and a more definitive cardiac 
mutant phenotype, however it occurred at such a low incidence with in the homozygous 
population. To try to increase the incidence of the pauses phenotype within those 
screened as having bradycardia and oedema (homozygous mutants), environmental 
stresses were applied to try and induce this phenotype in other homozygous mutants. 
Increasing the incidence of this phenotype within the mutant population would greatly 
aid visual screening and improve accuracy. Embryos were exposed to high salt 
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concentrations and 5 minutes on an orbital shaker at 100 rotations per minute to stress 
them to try and induce the pauses phenotype to aide successful visual screening of 
homozygous mutant. The larvae were visually screened as normal and then split into 7 
groups for salinity exposure. E3 medium is a mix of salts and this was used at 
increasing concentrations 1 x (normal running concentration - control), 12.5x, 25x, 
35.5x, 50x, 75x, and 100x. 30 minutes after exposure the embryos were re-screened and 
number of embryos screened for the pauses phenotype before and after each 
concentration compared. In total n=50 across 3 biological repeats.  
Embryos were also exposed to 30 revolutions on a shaker (Orbital shaker, Stuart SSL1) 
as an alternative stressor to induce arrhythmia. This method is an adaptation of the 
method taken from Eto et al, 2014. This was to ‘shake’ up the embryos causing stress. 
A total of n=50 x3 embryos were assessed. These were also visually screened and 
counted before and after stress exposure for comparison. Mortality rate were also 
recorded.  
 
4.2.14 Statistics.  
All data groups were tested for normal distribution using Shapiro-Wilk and the 
Anderson-Darling tests for normality to guide further statistical analysis. The 
Anderson-Darling test was used as a validation to the results from the Shapiro-Wilk test 
as though normality tests generally have a low power for small sample sizes, the 
Shapiro-Wilk test has been shown to be the most powerful test when assessing 
normality.  
Statistical significance of heart rates between wild type, those screened as homozygous 
mutant and siblings controls was determined using a 3 way Anova test.  
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Statistical significance of dual electrode recorded drug treatments was performed using 
a 2 tailed T test. This compared the interval difference recorded in each electrode to 
compare if the same result was achieved for the 3 ECG parameters in these 2 electrode 
positions. To compare PR, QRS and QTc intervals recorded from cacna1c mutant and 
sibling controls, the Kruskal-Wallis and Mann-Whitney tests were employed. 
For the drug treatments (5 cardiac acting drugs, control drug and chlorzoxazone rescue 
treatments), the non-parametric Wilcoxon paired-signed test was used to compare pre 
and post drug treatment to determine significance. To compare cacna1c results against 
wild type shaker and salinity results, again the Kruskal-Wallis and Mann-Whitney tests 
were employed. 
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4.3. Results 
4.3.1 Phenotype screening of cacna1c mutants 
This study has displayed the use of the recording system to record ECG changes due to 
cardiac drug treatment. The next objective was to test the utility of the recording system 
to detect changes in cardiac electrical activity observed in ECG signal from a typical 
signal to a diseased state due to a genetic mutation. The ability to record, analyse and 
identify cardiac effects due to genetic mutation expands on the use of the recording 
system.  
This was a key aim for the study; to establish the use of the recording system for 
analysing successfully genetic cardiac conditions observable on an ECG.  
In order to test for the sensitivity of the larval recording system to detect ECG 
differences due to genetic mutation, rather than drug treatment, an appropriate mutant 
with an abnormal cardiac phenotype and therefore possible arrhythmia was chosen.  
 
4.3.1.1The cacna1c sa6050 mutant 
The zebrafish line chosen was an L-type calcium channel mutant with a point mutation 
at an essential splice site (allele name sa6050), developed at the Wellcome Trust Sanger 
Institute. This mutant develops a severe cardiac oedema in the pericardial sac as a result 
of the calcium channel abnormality by 5 dpf which is very easily observable, Figure 
4.2A, B. This study was focused on analysing the ECG differences directly as a result 
of the mutation before the secondary severe oedema and the more systemic effects 
observed at 5 dpf developed. ECG recording from embryos before the massive oedema 
at 5 dpf was also more straightforward as the increased fluid around the heart increased 
the distance between the heart and the electrode making locating the signal more 
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difficult. This was compounded with the fact that the heart was beating much more 
weakly and under stress and the pericardiac sac filled with fluid..  
 
4.3.1.2 Visual phenotype screening of the cacna1c mutant at 2 dpf. 
Genetic screening was not possible to perform per embryo so visual screening for 
phenotypes relevant to the mutant was performed. Clutches from individual pair-wise 
crosses were collected and grown up to 2 dpf and visually screened at this stage. 
Embryos were screened for any perturbance to the normal healthy embryo, in particular 
cardiac phenotypes. There was an observable cardiac deformation at 2dpf which by 5 
dpf had become an established observable cardiac oedema. Positively screened mutants 
from pair-wise clutches were compared against negatively screened siblings and wild 
type controls, example embryos for these groups shown in figure 4.2C, D, E. 
Genotypes for these embryos were confirmed by analysis performed by Sanger 
institute.  
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Figure 4.2. Assessment of visual phenotype of the cacna1c mutant. 
A) wild type 5dpf zebrafish  
B) Ref photo Sanger institute demonstrating the extent of the cardiac oedema which 
develops by 5 dpf. 
http://www.sanger.ac.uk/sanger/Zebrafish_Zmpgene/ENSDARG00000008398#sa6050
C) wild type control 3dpf 
D) positively screened mutant 3dpf 
E) negative sibling control 3dpf 
 
 
A 
B 
C 
D 
E 
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Once clutches were screened, they were counted to check for Mendelian distribution. 
This was to establish whether visual screening was sufficient and reliable enough to 
detect homozygous cacna1c mutants at 2 dpf, example clutches shown in Table 3.1. In 
addition to the structural cardiac deformations observable in figure 3.1, D, there were 
some embryos amongst the positively screened mutants which had an abnormal heart 
beat. There were periods, observed under the microscope, where the heart had asystolic 
events, usually for between 10 and 20 beats before resuming normal sinus rhythm. 
These periods were termed pauses and the proportion of mutants displaying this 
phenotype are also displayed in table 4.2.  
  
    Total 
     wild 
type 
 Heart 
defects 
% pauses % 
  66 43 23 34.85 6 26.09  
  150 103 47 31.33 8 17.02 
  75 46 29 38.67 3 10.34 
  95 66 29 30.53 4 13.79 
  60 50 10 16.67 5 50.00 
  82 58 24 29.27 2 8.33 
  123 75 48 39.02 2 4.17 
  164 113 51 31.10 9 17.65 
  207 143 64 30.92 5 7.81 
  190 160 30 15.79 10 33.33 
  423 343 80 18.91 3 3.75 
TOTAL 
AVERAGE 
143.66 109.09 39.55 28.82 5.18 16.69 
 
Table 4.2 Percentage heart defect and asystolic pauses distribution in cacna1c clutches 
from pair-wise crosses.  
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4.3.1.4 Genetic analysis of the cacna1c mutant performed at Sanger Institute. 
To check whether the phenotype was strong enough at 2 dpf to accurately identify 
positive mutants against negative siblings, a selection of positive and negatively 
screened embryos were genotyped. A pair-wise clutch was screened and separated out 
into positively screened mutants and negative siblings. These were placed into a 96 
well plate, the liquid removed, the plate sealed and then put on ice to prevent 
degradation. 23 positive and 23 negative embryos were selected. Plates were sent to the 
Wellcome trust Sanger institute for analysis. KASP genetic analysis was performed on 
the selected embryos. KASP (Kompetitive allele specific PCR) is a fluorescence based  
genotyping tool which utilises PCR. It accurately identifies wild type, heterozygous and 
homozygous mutant alleles. Samples are analysed on a 96 well plate so multiple 
samples are analysed simultaneously. Results are displayed using the 96 well format 
and assigns a colour to each well representing the genotype.  
The results showed that all the negatively selected siblings were either wild type or 
heterozygous, which was expected. Unfortunately, the positively selected mutants 
showed heterozygous and wild type embryos as well as homozygous mutants. This 
genotyping result showed that visually screening the embryos at 2dpf was not robust 
enough to accurately identify homozygous mutants, figure 4.3.  
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Figure 4.3. Genotyping performed by Sanger Wellcome Trust institute. KASP genetic 
analysis of embryos screened for presence or absence of cardiac phenotype. Result 
shows that only wild type and heterozygous embryos were selected as negative siblings 
but that these were also selected along with homozygous mutants in the positively 
screened group. This means the screening process at 2dpf is adequate for accurate 
selection of negative siblings, but not accurate enough to screen out positive 
homozygous mutants. Red: identified homozygous mutant, blue: identified heterozygous 
embryo, green, identified wild type embryo, pink: failed well with no result.  
 
This result indicated that additional screening was required after 2dpf to ensure 
accuracy in screening for homozygous mutants in heterozygous adult clutches. 
Therefore, homozygous mutants were confirmed after ECG analysis on 5 dpf when the 
severe oedema had developed, and so the phenotype more pronounced. Once the ECG 
Rows A,B selected for 
presence of a cardiac 
phenotype 
Repeated rows  E and F 
 
Rows C,D selected for 
absence of a  cardiac 
phenotype 
Repeated rows G and H 
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had been performed, the traces were labelled with a corresponding 96 well plate 
reference. This allowed ECG analysis to take place on 3dpf before the secondary 
systemic effects of the mutation had developed but ensured that true mutants were 
successfully identified and used for subsequent analysis. 
 
4.3.1.3 The heart rate of the cacna1c mutant is significantly slower than wild 
type embryos.  
At 3dpf, the heart rate of each of the screened groups, wild type, siblings and mutants 
were also recorded and the screened cacna1c mutants were found to have a 
significantly lower heart rate than the control groups, figure 4.4.   
 
 
 
 
 
 
Figure 4.4 Average heart rate for wild type, negative screened cacna1c siblings and 
screened cacna1c mutants P-value 0.00037. n=20. 
 
This Bradycardia was then used to confirm all positive screens as this phenotype is 
more closely associated with the calcium channel mutation. The bradycardia was first 
observed following ECG recording analysis of positively selected mutants. This 
coupled with the ECG differences helped to confirm the mutant phenotype. To increase 
the accuracy of the screening process, this bradycardia was included as a criterion to 
visually screen for in heterozygous pair-wise clutches by counting beats for 15 seconds 
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then multiplying by 4. The data displayed in figure 3.2 is from ECG measured heart 
rate averaged across a 2 minute section of recording, rather than the measurement from 
the 15 second visual assessment used for initial screening. This was due to those 
measurements being available from the recordings analysed through Labchart and 
ensured embryo heart rate and ECG interval analysis was from the same embryos.  
 
4.3.2. ECG analysis of the cacna1c mutant 
Following successful screening at 2 dpf for positive cacna1c homozygous mutants, the 
next step was to record the ECG of the screened groups and then analyse these 
compared to wild type recordings. For this reason, the ECG signals from the embryos 
were taken at 3 dpf as all previous in depth analysis of the normal larval zebrafish ECG 
is recorded from this stage. This allows close careful comparison of this data to the 
ECG recordings from the cacna1c mutants.  
 
4.3.2.1 Optimisation of dual electrode recording system for cacna1c mutant 
ECG analysis. 
Having developed positions for atrium and ventricle recording previously, see chapter 
2, this was utilised for a two electrode system to record from the atrium and ventricle 
simultaneously to allow direct comparison between the two chambers. The dual 
positions were as described in chapter 2, grid format figure 4.5A. 
To confirm that this dual recording was the most appropriate recording method for this 
experiment, dual atrium and ventricle signals were recorded pre and post 5µm 
Terfenadine treatment (3 dpf embryos n=20) and then the ECG intervals PR, QRS and 
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QTc were plotted for both electrode positions, atrium positioned electrode and the 
ventricle positioned electrode, figure 4.5B, C, D.  
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Figure 4.5 electrode position and parameter recording in dual electrode system.  
A) Electrode positions for atrium and ventricle electrodes are labelled.  
B,C,D) ECG intervals pre and post 5 µM Terfenadine treatment recorded from both 
electrodes from 3 dpf embryos. 
B) PR Intervals: Atrium electrode records PR interval increase more accurately than 
ventricle electrode and this increase is significant.  
C) QRS intervals: consistent in both electrodes.  
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D) QTc intervals: consistent across both electrodes. 
For detecting changes in PR interval, an atrial specific electrode is required. N=20 
embryos for these dual drug treatment recordings.  
  
To perform direct comparison between the atrium and ventricle electrode recordings, 
statistical analysis using a tailed t test was performed. This compared the interval 
difference recorded in each electrode to compare if the same result was achieved for the 
3 ECG parameters in these 2 electrode positions. Only the PR interval result showed a 
difference between the two electrodes, demonstrating that a more pronounced PR 
interval drug response was recorded from the atrium positioned electrode, highlighting 
the need for an atrium positioned electrode to analyse drug and mutant effects on this 
ECG parameter. The ventricle positioned electrode did not pick up the changes post 
drug treatment in the PR interval that the atrium positioned electrode picked up, figure 
3.3B. The QRS measurements were consistent in both electrodes with both showing the 
same increase in QRS interval, therefore comparison between the two recording 
showed no significant difference. Corroborating the result shown in Dhillon et al 2013, 
the QTc measurement was consistent across both recording positions and therefore 
comparison analysis was not significant. For analysing PR, QRS and QTc intervals in 
the cacna1c mutant, based on these results, the atrium component of the ECG signal, 
the PR interval, was measured from the atrium electrode and the ventricle ECG 
components (QRS and QTc) were measured from the ventricle positioned electrode. 
This was to maximise the accuracy of these measurements and allow analysis into finer 
differences such as the PR interval, which is more difficult to record due to the smaller 
size of the p wave.  
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4.3.2.2 ECG interval analysis of cacna1c mutant and sibling controls 
performed at 28oC. 
Dual atrium and ventricle recordings of cacna1c mutants (those visually screened as 
homozygous mutant) and sibling controls (those visually screened as having no cardiac 
phenotype) were taken at 3 dpf to analyse chamber specific differences between these 
two groups. These two groups were from embryo clutches visually screened at 3 dpf 
and recorded the same day. Due to time constraints and the n number needed this was 
not possible for the rest of the data groups as the whole day at 3 dpf was required for 
recording. Recording plates compatible with Cryocon 22C (cryogenic control systems) 
temperature control were developed to allow the ECG signal to be recorded at 28oC 
with consistent temperature monitoring. This is the optimal temperature for zebrafish 
embryo development so recording the heart activity via ECG at this temperature gives 
the most accurate picture of heart function in wild type and cacna1c mutant embryos. 
Previous attempts to record with controlled temperature failed as methods were either 
too electrically noisy for electrophysiological measurements or did not keep the 
temperature consistent and allow live monitoring of the temperature throughout the 
experiment. The cacna1c mutant and sibling control repeat recordings (n= 8 x3) were 
analysed using Labchart pro7 software (ADInstruments). This software produces an 
average cardiac cycle for highlighted sections of recording and gives the ECG 
parameter intervals for the averaged waveform allowing for outliers to be excluded, 
example cardiac cycles for mutant and control signals shown in figure 4.6A.  
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Figure 4.6 Analysis of the ECG phenotype in the cacna1c mutant. 
A) Example atrium and ventricle ECG signals from cacna1c mutant larvae and non-
phenotypic siblings at 3dpf 
B) ECG intervals for wild type and cacna1c.n=20 3dpf embryos.  
 
The P-R, QRS and QTc intervals, taken from the relevant chamber recording, PR from 
the atrium electrode and QRS and QTc from the ventricle electrode, of the control and 
A 
B 
Atrium 
Ventricle 
Sibling control cacna1c 
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cacna1c mutant were plotted and analysed for statistical significance. The ECG 
intervals in the cacna1c mutant embryos were consistently longer than those recorded 
in the control and the PR and QTc intervals were found to be significantly larger than 
the control figure 3.4B. This result shows a clear significant difference between 
screened homozygous mutants and sibling controls.  
 
4.3.2.3 Selection of diverse cardiac drugs for assessment effect on cacna1c 
mutant ECG.  
A set of cardiac acting drugs were chosen, each with a different mode of action on the 
heart, and their effects on the cacna1c mutant ECG assessed. Drugs were selected to 
target the different ion channels of the heart and affect the heart rate. Human cardiac 
acting drugs previously reported as showing cardiac activity in zebrafish were selected 
from the literature used for this project, these included some previously tested and some 
newly selected. Concentrations for these drugs were also taken from the literature 
(Dhillon et al, 2013, D’amico et al, 2012, Milan et al, 2003, Mittelstadt, et al, 2008, 
Berghmanset al, 2008 and Alzualde et al, 2016). The cacna1c mutation effects the 
voltage gated L-type calcium channel, so drugs affecting the function of this channel 
and the other cardiac ion channels were selected. This was to determine how blocking 
different channels, and therefore different phases of the zebrafish action potential, 
effect the cacna1c mutant ECG. The drugs selected were terfenadine (potassium 
channel blocker), verapamil (calcium channel blocker), and flecainide (sodium channel 
blocker). As well as these channel blockers, two further drugs were chosen to increase 
and decrease the heart rate: isoprenaline (non-selective beta receptor agonist) to 
increase cardiac output and metoprolol (selective β 1 Beta-blocker) to reduce heart rate. 
Penicillin was used as a non-cardiac acting control drug. The effect of these drugs on 
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the mutant phenotype were compared to wild type (tubingen long fin) responses. The 
sa6050 mutant was created in the long fin strain so this was used for wild type controls.  
 
4.3.3 Potassium channel blocker produces additive effect to the 
cacna1c mutant.  
The potassium channel blocker selected was terfenadine. This was because this drug 
has previously been used as a drug treatment analysis on wild type embryos. 
Terfenadine released onto the market as an antihistamine and was subsequently found 
to block the Kv11.1 potassium channel causing QT prolongation arrhythmia and was 
therefore removed from public use.   
ECG recordings were analysed by taking average measurements of the PQRST waves 
of the cardiac cycle across 2 minute sections (2 minute sections taken pre and 20 
minutes post treatment) . Examples of wild type and cacna1c mutant cardiac cycles pre 
and post 5 µM terfenadine treatment are shown in figure 4.7A,B. PR, QRS and QTc 
interval measurements taken from average cardiac cycles pre and 20 minutes post 
treatment of potassium channel blocker terfenadine. Terfenadine was found to 
exacerbate the mutant phenotype. There was a significant increase in the QRS and QTc 
intervals at 0.5µM and PR, QRS and QTc intervals at 5µM, in the cacna1c mutant; 
however this was also seen to a lesser extent, but still significant, in the wild type 
embryos figure 4.7C showing a bigger difference post treatment in the mutant 
compared to the wild type embryos. 
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Figure 4.7. The effect of a potassium channel blocker terfenadine in the cacna1c 
mutant at 0.5 µM and 5µM.  
A) ventricle signal from 3dpf wild type and cacna1c larvae.  
B). Ventricle signal from 3dpf wild type and cacna1c larvae 1min post 5uM 
Terfenadine treatment.  
C) ECG intervals for before and after Terfenadine treatment in wild type and cacna1c 
mutant 3dpf embryos. * indicate statistical significance between pre and post treatment 
measurements. *=<0.5 **=<0.05 ***=<0.005 p value.  
 
The final ECG interval measurements after 20 minutes treatment was not significantly 
different to the effect on wild type embryos, however this effect was reached in the 
mutant much quicker than in the wild type. When looking at the effect on the QTc 
interval overtime, post treatment, the QT prolongation effect seen in both the wild type 
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and cacna1c mutant post 5µM terfenadine treatment happens within the first 2 minutes 
in the mutant and only after 10 minutes in the wild type and at 0.5µM takes the 20 
minutes to reach the same final QT interval, figure 4.8. 
 
Figure 4.8. Plot of QTc interval across time from 2 mins before drug treatment and up 
to 20mins post drug treatment. 5 µM Terfenadine added at time=0.5 wild type and 
cacna1c mutant ECG responses to Terfenadine treatment at two concentrations. 
 
The difference between wild type and mutant at only 2 minute post drug treatment is 
significant for both concentrations. This demonstrates a more acute response to the drug 
treatment in the cacna1c mutant compared to the wild type. The QTc interval in the 
mutant measured at 2 minutes post Terfenadine treatment is significantly larger 
compared to the interval measured at 2 mins post treatment. This indicates the mutant is 
more sensitive to the drug effect than wild type embryos.  
 
* 
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4.3.4 Wild type zebrafish more profoundly affected by calcium channel 
blocker than the cacna1c mutant. 
The calcium channel blocker chosen was verapamil. This was because verapamil had 
previously been used for drug treatment analysis on wild type embryos. Verapamil is 
marketed as a treatment for hypertension, angina and some arrhythmia disorders and it 
works by relaxing the muscles of the heart and blood vessels.  
Average cardiac cycles from before and after both concentrations (0.5µM and 5µM) of 
Verapamil were used for analysis, example cardiac cycles from the ventricular 
electrode shown in figure 4.9A,B. For both the wild type and cacna1c mutant embryos 
the QTc was significantly affected with much bigger QT prolongation seen in the wild 
type compared to the mutant, for both verapamil concentrations figure 4.9C.  
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Figure 4.9. Analysis of calcium channel blocker verapamil on the cacna1c mutant at 
0.5µM and 5µM. 
A) ventricle signal from 3dpf wild type and cacna1c larvae.  
B) Ventricle signal from 3dpf wild type and cacna1c larvae 1min post 5uM Verapamil 
treatment. 
C) ECG intervals for before and after Verapamil treatment in wild type and cacna1c 
mutant 3dpf. . * indicate statistical significance between pre and post treatment 
measurements. *=<0.5 **=<0.05 p value.  
 
Verapamil treatment at 0.5µM and 5µM and produced a significantly prolonged QTc 
interval compared to pre-treatment measurements and at the 5µM dose there was a 
significantly increased QRS interval in the wild type embryos.  
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Figure 4.10: Plot of QTc interval across time. Drug added at time=0.5 wild type and 
cacna1c mutant ECG responses to Verapamil treatment at two concentrations. 
 
When looking at the QTc interval over time post Verapamil treatment, the wild type has 
a more marked, but not statistically significant, response in the first two minutes 
compared to the cacna1c mutant, figure 4.10. Therefore, treatment of a calcium 
channel blocker on the cacna1c mutant does not have an effect on the ECG phenotype 
compared to wild type controls. 
 
4.3.5 Non-selective Beta-agonist partially compensates the mutant 
phenotype 
Isoprenaline was selected to assess the effect of increasing cardiac output and heart rate 
on the cacna1c mutant. It is a non-selective beta-adrenergic agonist and is used for the 
treatment of Bradycardia and heart block. Isoprenaline was predicted to increase heart 
rate which may improve cardiac output and decrease the ECG intervals.  
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Isoprenaline consistently decreased ECG parameter inte-rvals across wild type and 
cacna1c. However, the more profound effect was seen in the cacna1c mutant with 
significant decreases in interval time for PR, QRS and QT, therefore tending towards 
normal range, figure 4.11A. The wild type interval difference was only significant in 
the QRS. There was also a significant increase in the heart rate in both the wild type 
and the mutant figure 4.11B.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: Analysis of non-selective beta agonist on the cacnalc mutant. 
A) ECG intervals of 3dpf wild type and cacna1c mutant larvae post Isoprenaline 
treatment. ECG parameters tend towards normal in the mutant post treatment.  
B). Heart rate increase in wild type and cacna1c mutant post 10uM Isoprenaline 
treatment.  
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As previously described, some positively screened mutants displayed the heart beat 
pauses phenotype where the heart ceased cardiac output for between 10-20 seconds 
before resuming normal rhythm. When these embryos were treated with isoprenaline, 
the pauses phenotype was resolved and normal rhythm maintained, figure 4.12.   
 
 
 
 
 
 
 
Figure 4.12 Pauses seen in 15% on mutants is corrected with 10uM Isoprenaline.  
A) 1 min section before treatment  
B) 1 min section post treatment  
C) 20 second section before Isoprenaline treatment  
D) 20s section post treatment.  
 
While this is an interesting result, it is not a true rescue of the mutant phenotype as 
increasing cardiac output does not address the underlying calcium charge imbalance 
due to channel dysfunction. Also interesting to note that when QT is corrected for heart 
rate (QTc) the difference between treated and untreated was not significant, suggesting 
that the changes are only due to pacing the heart to increase heart rate and not changing 
cardiac ion channel function. However clinically, TdP is treated by pacing the heart so 
this result may be clinically significant.  
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4.3.6 Non-cardiac acting control drug has no effect on the cacna1c  
mutant. 
The non-cardiac drug selected was Penicillin. This has been used as a control drug 
previously and therefore was known not to affect cardiac function (Dhillon et al, 2013). 
Penicillin is used as a beta-lactam antibiotic has not been reported to cause any 
cardiotoxicity in humans or zebrafish. Control drug penicillin induced no effect on the 
ECG intervals PR, QRS and QTc in either the wild type or cacna1c mutant embryos, 
figure 4.13. 
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Figure 4.13 Analysis of control drug Penicillin on the cacna1c mutant at 0.5mM and  
1mM. 
A) wild type ECG signal before (Top) and after (bottom) 1mM penicillin treatment  
B) cacna1c mutant ECG signal before (Top) and after (bottom) 1mM Penicillin 
treatment.  
C) Intervals recorded with 0.5mM and 1mM Penicillin N=8 x3 for wild type and 
mutant. No drug effect observed for control drug penicillin.  
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The waveforms and ECG intervals for both wild type and cacna1c mutant showed no 
difference between pre and post treatment with penicillin as expected.  
 
 
 
 
 
 
 
 
 
Figure 4.14 0.5mM and 1mM Penicillin treatment from 2 minutes pre treatment and up 
to 10minutes post treatment.  
 
There was also no significant change in QTc across the 10 minute drug treatment for 
both wild type and cacna1c mutant as expected as Penicillin is not reported to cause 
cardiac problems in humans or zebrafish, figure 4.14.  
 
4.3.7 Sodium channel blocker has additive effect on the cacna1c 
mutant phenotype. 
Flecainide was selected to assess the effect of a sodium channel blocker on the cacna1c 
mutant phenotype. It is used as an anti-arrhythmic drug to treat a fast or irregular heart 
rhythm. It does this by regulating movement of sodium, prolonging the cardiac action 
potential. It is also occasionally used for Brugada patients (short QT) to exaggerate the 
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characteristic ECG phenotype of the disease to aide diagnosis (Yan and Antzelevitch, 
1999). It is also used in LQT 3 which is caused by a mutation in the SCN5A gene 
encoding the sodium channel NaV1.5 causing prolonged sodium current causing 
delayed repolarisation, and hence a long QT (Moss and Kass, 2005). Sodium channel 
blocker cardiotoxicity has been extensively described. Tricyclic anti depressants act as 
sodium channel blockers and patients present with arrhythmic ECGs displaying wide 
QRS complexes (Amiri et al, 2016). Re-entrant rhythms are also seen from class 1c 
antiarrhythmics, such as flecainide, causing arrhythmias such as AV block.  Flecainide 
also inhibits opening of potassium channels, in particular the Ikr channel (hERG) 
thereby prolonging the action potential (Andrikopoulos, Pastromas and Tzeis, 2015).  
It was predicted that a sodium blocker such as flecainide will have an additive effect on 
the mutant phenotype, further reduce cardiac output and prolong the action potential. 
This was proven correct, flecainide had an additive effect on the mutant phenotype, 
with large increases in, PR, QRS and QTc intervals for both concentrations, figure 
4.15A. The wild type was also affected, but only at the higher concentration.  
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Figure 4.15 Effect of sodium channel flecainide blocker on wild type and cacna1c 
mutant 3dpf embryos at 50µM and 100µM.  
A) There was a global increase in ECG intervals in both wild type (100µM) and mutant 
(both concentrations) with the more profound effect seen in the mutant. Sodium channel 
blocker caused QRS widening as well as prolongation of PR and QTc intervals.  
B) Graph showing drug response of cacna1c mutant and wild type against time. -1 = 
baseline recording before drug was added. 0 = time at which drug was added. 1-20 
minutes post drug treatment. The cacna1c mutant had a rapid response to the sodium 
blocker at both concentrations. Wild type did not respond at 50µM.  
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The effect over time was also assessed and the mutant had a more acute response to 
sodium channel blockade than the wild type, with a significantly bigger response 2 
minutes post treatment than the wild type figure 4.15B.   
 
4.3.8 Selective beta 1 beta-blocker increases prolongation of cardiac 
cycle. 
The Beta-blocker selected was metoprolol which is a selective beta1 receptor blocker 
used to treat angina and hypertension. Conflicting literature information made it 
difficuly to predict whether metoprolol will increase or decrease the QTc and other 
parameters. Its use for treatment for tachycardia suggests it will lengthen the cardiac 
cycle and therefore ECG intervals, but it is also used for some long QT patients 
suggesting it would shorten the QT. However, Sun et al, 2014 investigated the toxicity 
of two beta blockers including metoprolol on zebrafish embryos and reported that 
metoprolol decreased the heart rate (Sun et al, 2014). It is therefore likely that if 
metoprolol lowers the heart rate, the cardiac cycle will be slower, therefore longer 
action potential phases and therefore longer ECG intervals recorded. 
The results show that for both wild type and mutant, there was a global increase in ECG 
intervals. This was particularly observable for the 50µM dose, figure, 4.16A   
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Figure 4.16. Effect of selective beta 1 beta-blocker metoprolol on wild type and 
cacna1c mutant 3dpf embryos at 10µM and 50µM.  
A) There was a global increase in ECG intervals in both wild type and mutant with the 
more profound effect seen in the mutant.  
B) Graph showing drug response of cacna1c mutant and wild type against time. -1 = 
baseline recording before drug was added. 0 = time at which drug was added. 1-20 
minutes post drug treatment. The cacna1c mutant had a more acute response to the 
beta blocker than the wild type.  
 
The response over time was also assessed and the mutant, once again had the more 
acute response to beta blocker treatment compared to wild type, with a significantly 
bigger response 2 minutes post treatment than wild type Figure 4.16B.  
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4.3. 9 Screening for asystolic events phenotype in cacna1c mutant. 
A small subsection of positively screened cacna1c mutant embryos were observed to 
have periods where cardiac output halted completely for a short amount of time upon 
ECG recording. This was where the heart stopped beating for a short period of up to 20 
seconds before resuming normal rhythm. This was observable under the microscope 
and on the ECG where the trace flat lined for short periods of time, usually for between 
5 and 15 beats (PQRST). When these were subsequently observed under a light 
microscope, it was clear that during these periods the contractions in both atrium and 
ventricle stopped (asystolic event) and then restarted a few missed heart beats later. 
This phenotype, where electrical activity and cardiac output was paused for a period of 
several beats, was termed pauses.  
 
4.3.9.1 Visual screening and population proportions 
To investigate this phenotype further the clutch screening protocol embryo heartbeats 
were observed for this phenotype for 2-3 minutes from the screened group to determine 
the proportion of mutants displaying this phenotype. These numbers are reported in 
table 4.3 
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Total screened  2275 
Total negative  1759 
Total positive  516 
Total A.S 62  
A.S % positive 12.0155  
A.S % total 2.72527 
 
Table 4.3.  Table shows proportion of screened cacna1c clutches screened as mutant, 
and out of those screened, which displayed the asystolic pauses phenotype. Whole 
clutches were screened into those positively identified as displaying a mutant cardiac 
phenotype, including those with the pauses phenotype and those that were negative for 
a cardiac phenotype (total positive and total negative) Of those screened as positive, 
those which had asystolic pauses (A.S) phenotype were also identified via observational 
screening (Total A.S). This is expressed as a % of total positively screened embryos 
(A.S % positive) and then as a % of total embryos screened (A.S % total). 
 
This result shows that the proportion of embryos in the clutch with the pauses 
phenotype was very low and are present as a subpopulation of the screened 
homozygous mutants.  
 
4.3.9.2 Inducing the asystolic events phenotype in the cacna1c mutant. 
It was thought that this phenotype was the early signs of the more severe phenotype 
(large oedema) observable by 5 dpf developing. If this pauses phenotype could be 
induced in all homozygous mutants in the clutch then it may be useful as a screening 
tool at 2dpf to increase the accuracy of the visual screening. Environmental stresses 
were applied to the embryos to try and exacerbate the phenotype and induce pauses in 
the mutant, the clutches were exposed to high salinity and 30 rotations on an orbital 
shaker. These were selected as they were readily available. The embryos are normally 
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raised in an embryo medium E3. Following the initial screening, positively screened 
cacna1c mutants were exposed to increasing E3 concentrations at 12.5, 25, 35.5, 50, 75 
and 100 times the usual 1x concentration (see 2.2.11 for standard protocol) for 30 
minutes after an initial screening. This meant that numbers of embryos with the pauses 
phenotype before and after salinity or shaker stress could be compared. Embryos were 
exposed to 5 minutes on an orbital shaker at 100 rotations per minute. At high salinity 
(75 and 100x) an increase in embryos with asystolic pauses were observed, figure 4.17 
A. Shaking induced pauses in both cacna1c mutants and wild type embryos at 3dpf, 
figure 4.17 B. This means that orbital shaking can not be used to induce pauses in the 
homozygous mutant as wild type embryos were also affected. In order to use stress to 
induce a more severe phenotype in the mutant to aide clutch screening, the negative 
siblings within the clutch need to not be affected.  
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Figure 4.17 The effect of high salinity and orbital shaking on inducing the asystolic 
pauses phenotype in the cacna1c mutant and wild type controls.  
A) % increase in number of embryos with asystolic pauses phenotype after exposure to 
different salt concentrations. N=20 per concentration of screened homozygous mutants. 
B) Number of embryos with pauses phenotype before and after orbital shaking in 
cacna1c mutant and wild type.  
C) Number of embryos with asystolic pauses phenotype before and after 75x and 100x 
E3 medium concentration in cacna1c and wild type. At 100x concentration increase in 
embryos with asystolic pauses is significant in both.  
D) high % mortality in embryos (wild type and cacna1c) after high salt (75 and 100x 
E3 medium) and after orbital shaking. This high mortality % plus the induction of 
pauses in wild type is demonstrative of the unsuitability of asystolic pause induction to 
aide screening of cacna1c mutants.  
 
Following the initial experiment using 6 increasing concentrations of E3 medium (n= 
100 positively screened mutants per concentration) the top two salt concentrations, 75x 
and 100x were selected for further study as these showed the greatest increase in 
embryos with the pauses phenotype. The other concentrations did not have a significant 
difference and therefore were not useful for pause induction. Further cacna1c clutches 
and wild type control clutches were exposed for 30 minutes to 75 and 100x E3 
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concentration. Pre and post counts of number of embryos with asystolic pauses were 
collected. Results between wild type and cacna1c mutant compared, figure 4.17 C. 
Both cacna1c mutant and wild type showed an increase in embryos with the pauses 
phenotype after exposure to both concentrations. The results for wild type and cacna1c 
mutant were statistically significant for 100x concentration. This means that high 
salinity and orbital shaking both induce an increase in asystolic pauses in the mutant 
but also cause this phenotype in the wild type. As an effect was also seen in the wild 
type, this can not be used to help identify homozygous mutants as this approach would 
affect all genotypes. High mortality rates were observed for all these groups, figure 
4.17 D. This suggests that significant injury occurs during this stress. Shorter exposure 
times (10 mins) were trialled for the salt exposures, but did not produce a change in the 
number of embryos with pauses phenotype and therefore not usable to induce the 
phenotype. A successful way of inducing the pauses phenotype in 3 dpf embryos 
without also inducing the same response in the wildtype controls. Therefore, salt or 
orbital shaking exposure could not be used to help screen the cacna1c clutches.   
 
4.3.9.3 Video analysis of the asystolic events phenotype 
Those embryos found to have asystolic pauses were separated out for further analysis 
by video recording. Video analysis allows a higher throughput of analysis compared to 
ECG and is therefore preferable, and was also used to find a different way to quantify 
the asystolic events. The cacna1c mutants screened positively for pauses were used for 
video analysis. SOHA (Semi-automated Optical Heartbeat Analysis) video analysis 
software (commercially available) was used to establish whether it was possible to 
detect the asystolic periods and if so, to characterise when these occur and how often. 
SOHA allowed input of raw video data, figure 4.18A which was then cropped down to 
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the heart and converted to a black and white .AVI file format. SOHA video analysing 
software allowed the user to mark the maximum diastole (relaxed heart) and systole 
(contracting heart) of the heart on the video, figure 4.18B and then plotted each 
diastole and systole (heart beat) in the video as a trace showing peaks (systole) and 
troughs (diastole), figure 4.18 C. As the embryo orientation used for video analysis (on 
its side) displayed both the atrium and ventricle, the ventricle was selected for analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18 Video analysis of asystolic pauses phenotype using SOHA video analysing 
software.  
A) image of a 3dpf zebrafish larvae with ventricle (V) and atrium (A) labelled. Heart 
fluorescence is an overlay from images taken from Tg(VMHC:red) and 
Tg(AMHC:mcherry) which have ventricle and atrium fluorescence respectively.  
B) Embryo positioned on its side, with diastole position (red) and systole lines (green) 
overlaid.  
C) Diastole and systole for each heart beat plotted. Period of  asystole where diastole 
is maintained with no heart contraction (systole) for a period of 6 heart beats approx, 
indicated by the red dashed line.  
V 
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From these traces, it was easily observable where the periods of heart inactivity (MB 
events) had occurred during that recording section. This indicated that the SOHA 
software was sensitive enough to detect these asystolic evernts. When all the diastole 
points from a recording were plotted together, it gave a clear picture of how many 
asystolic events there were and also how long their duration was. This further analysis 
was carried out in the SOHA software, the diastole points picked up in the recording to 
be plotted on a graph, with seconds representing the length of the video on the x axis 
and seconds representing the length of each diastole on the y axis figure 4.19 A. This 
easily visualised the number of pauses in the recording and also their duration. When 
this data for n=20 embryos with pauses phenotype was aggregated the average number 
of pauses observed in a 60 second segment and the average duration of the pauses were 
calculated figure 4.19 B.  
 
 
 
 
 
 
 
Figure 4.19 Output data (diastole plots) of video analysis and aggregated data from 
mutants pre-screened for asystolic pauses. 3dpf embryos n=20. 
A) Example graph of plotted diastoles from a single recording. Peaks indicate asystolic 
pauses; y axis denotes length of the asystolic pause.  
B) Aggregate data from the video analysis of the pauses phenotype. Average number of 
pauses in a 60 second section 2.57. Average duration of pauses section 9.33. error bars 
show standard deviation.  
Results showed that on average in a 60 second section there were 2.57 asystolic pauses 
which lasted an average of 9.33 seconds. This showed that there was quite a variability 
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in the length of the asystolic pauses and that they occurred roughly every 10-30s in the 
embryos.  This analysis allowed zebrafish embryos displaying the pauses phenotype to 
be analysed to gain information on how often and how long these asystolic pauses took 
place. This gives additional information about the phenotype of the cacna1c mutant. 
Given the low incidence in the population, it is likely that the variance in mutant 
phenotype is a result of the penetrance of the mutation.  
 
4.3.10 Effect of chlorzoxazone treatment on the cacna1c mutant.  
 
When the cacna1c mutant was treated with Isoprenaline, to assess the effect of a non-
selective beta agonist on the heart, it was noted that the asystolic pauses were resolved, 
and that the heart rate, and ECG parameter measurements were all tending towards 
normal range. However, this was not a true rescue of the mutant phenotype as this did 
not address the underlying channelopathy and imbalance of charge. Isoprenaline works 
to increase cardiac output, but doesn’t directly affect the cardiac action potential, it just 
stimulates the heart to beat faster. This prompted a search to find a potential rescue 
drug, which would truly rescue the phenotype.  
 
4.3.10.1 Identification of chlorzoxazone as a candidate rescue drug. 
A literature search was carried out to identify possible candidates that would truly 
reverse the phenotype to wild type, by reducing the QTc, increasing the heart rate and 
reducing both the frequency and duration of asystolic pauses by directly affecting the 
cardiac action potential and imbalance of charge in the myocytes caused by the calcium 
channelopathy. The literature search focused on novel therapeutic agents that had 
previously not been applied to the zebrafish model. chlorzoxazone was identified as it 
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had previously been shown to be effective in addressing calcium imbalance in neurons, 
it was hypothesised that it may produce a similar effect on the calcium imbalance in the 
cacnac1c mutant, and, consequently, Timothy syndrome patients (Liu, Lo and Wu, 
2003, Seebohm, 2004 and Gao et al, 2012). This drug was also chosen as it is an 
existing drug on the market, and so there was the potential to repurpose it.  
This drug is on the market as a smooth muscle relaxant, and its mode of action is to 
activate potassium channels to remove excess charge out of the cell as K+ ions allowing 
the cell to return to a resting state ready for the next contraction.  
It was suspected that it would work in a similar way in a cardiac setting, aiding 
repolarisation such that the heart returns to a resting state quicker, meaning that the 
QTc interval would reduce and the heart rate increase.  
 
4.3.10.2 Chlorzoxazone LC50 assay and dosing range  
An LD50 is the lethal dose (material) required for 50% mortality in a population. An 
LC50 is the concentration required for 50% mortality in a population and as such these 
two toxicological measurements are related. Several studies have reported on the strong 
correlation between murine LD50 drug assays and zebrafish LC50, therefore this was 
used as a starting point in calculating an initial dosing range (Ali, Mill and Richardson, 
2011 & Ducharme et al, 2014). The lowest human/murine LD50 for chlorzoxazone is 
50mg/kg and a concentration of 300µM for zebrafish calculated. Estimations of 
zebrafish weights for this were taken from Hu et al, 2000. A dosing range of 30µM, 
100µM and 300µM was decided and n=18 cacna1c and n=20 wild type embryos were 
dosed per concentration plus 2% DMSO and E3 control groups. N=14 cacna1c and 
n=16 wild type were also assessed at 600 and 1000µM. Embryos were dosed for a 24 
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hour period and then counted for % mortality. Acute response was assessed 15 minutes 
after treatment. Control groups showed 0% mortality.  Percentage mortality plotted 
against the log of the dose for wild type and cacna1c were used to calculate the dose 
which causes 50% mortality (LC50). LC50 was calculated as 197.9 µM for the wild 
type larvae and 180.2 µM for the mutant larvae, by using the equation of the trend line, 
inputting y=50 and solving for x, figure 4.20.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20 Log-Dose mortality charts for wild type and cacna1c mutant  
A) wild type Log-Dose mortality chart when treated with chlorzoxazone. 
B) cacna1c mutant Log-Dose mortality chart when treated with chlorzoxazone. 
Percentage mortality against log-dose of chlorzoxazone plots. n=18 cacna1c 20 wild 
type x3. The trend used to calculate the concentration of 50% mortality- the LC50.  
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The assessment of the acute response after 15 minutes treatment identified several 
phenotypes. These were noted and the number of larvae displaying these phenotypes at 
the different concentrations were tabulated, table 4.4 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.4 Visual phenotypes observed 15 minutes post chlorzoxazone treatment for wild 
type and cacna1c mutant. 
A) wild type acute response phenotypes. 
B) cacna1c mutant acute response phenotypes. 
Phenotypes observed after 15 minutes observation were paralysis and cardiac 
arrhythmias and show a dose-dependent increase. Asystolic pauses were only observed 
in mutant larvae. E3, DMSO, 30-300 µM n=18 cacna1c, n=20 wild type. 600-1000 µM 
dose n=14 cacna1c, n=16 wild type 
 
Acute phenotypes observed appear to follow a dose-dependent increase, as expected. 
These phenotypes were paralysis and cardiac arrhythmias, this is consistent with the 
location of chlorzoxazones mode of action, the heart, muscles and neurons. Paralysis 
was noted in lack of fin movement and inability to self-right. Cardiac arrhythmias were 
observed by heart rate count and qualitative visualisation. These were bradycardia, 
A 
B 
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asystolic pauses (mutants only) and irregular heart beat. In the mutant, irregular heart 
rate and bradycardia occurred preceding periods of asystole. The phenotypes also 
correlate with the murine/human LD50 of 300µM.  
These results of the LC50 and the therapeutic dose range used in adults of 250-750 mg 
(roughly 10 mg/kg or 60 µM dose) helped to decide a dose range of 10-100 µM for the 
chlorzoxazone rescue experiments.   
 
4.3.10.3 Effect of chlorzoxazone as a rescue drug for the cacna1c mutant 
As previously stated, the cacna1c mutant has a significantly slower heart rate and a 
significantly longer PR interval and QTc interval compared to wild type and sibling 
controls.  
To investigate and analyse the chlorzoxazone response in the cacna1c mutant, 
heterozygous adults were crossed and raised in E3 medium and the resultant clutches 
were screened as described in 3.1.2. At 3dpf, ECG recordings were taken with 
chlorzoxazone (CHZ) drug treatment to assess the effect on heartrate, QTc and the 
pauses phenotype. ECGs were taken 5 minutes prior to drug treatment and up to 30mins 
post treatment using the single electrode recording system. This was because the 
primary phenotypes identified in the mutant were low heart rate, heart beat pauses and a 
long QT. These can easily be analysed using a single electrode system which is less 
time consuming to collect data. An initial experiment with 50µM CHZ treatment (n=5) 
showed on average, a significant reduction in asystolic pauses, and QTc interval and an 
increase heart rate after 10mins treatment, figure 4.21A.   
The cacna1c mutants treated with CHZ, those with the asystolic pauses phenotype, 
displayed a complete absence of pauses post treatment figure 4.21B.  
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A Average number of pauses/ 
minute 
Heart 
rate 
QTc % 
reduction 
Pre 3 85 0.703 
12.8% 
Post 0.4 104 0.613 
Figure 4.21 Preliminary experiment of the effect of candidate rescue drug 
chlorzoxazone on the cacna1c mutant phenotype by single electrode ECG recording 
system. N=5 3 dpf cacna1c homozygous mutants. 
A) Table showing average number of asystolic pauses, heart rate and QTc interval pre 
and 10mins post 50µM CHZ treatment.  
B) 1minute ECG trace sections, example of pauses phenotype pre and post CHZ 
(chlorzoxazone). treatment from one embryo. B.1) pre CHZ treatment and B.2) post 
treatment. No asystolic pauses after CHZ treatment and increased rhythmicity.  
 
 
Following this initial experiment, which showed a positive effect on the mutant 
phenotype, a more in depth experiment was carried out to explore chlorzoxazone as a 
potential rescue drug for the cacna1c mutant. For this experiment, n=8 for wild type 
and cacna1c mutant for 10, 50 and 100µM CHZ concentrations and 2% DMSO 
controls were carried out. For both groups, DMSO showed no effect on heart rate or 
QTc.  
For 10µM there was no significant difference on heart rate or QTc in the wild type 
group, however, there was significant reduction in QTc in the mutant. At 50µM, there 
B.1 
B.2 
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was a significant increase in heart rate and reduction in QTc for both the mutant and 
wild type. At 100µM there was no significant difference seen in the wild type but 
statistically significant difference in heart rate and QTc interval for the cacna1c mutant, 
these results are summarised in figure 4.22. 
 
 
 
 
 
Figure 4.22. Analysis of rescue drug chlorzoxazone on the mutant phenotype across 3 
concentrations. QTc and heart rate differences pre and 30 mins post treatment. All QTc 
changes were a reduction and all heart rate changes were an increase. The statistical 
significance of these were calculated using non-parametric Wilcoxon paired-signed 
test. DMSO control group does not have any effect on wild type or cacna1c. No 
response in the wild type at 10µM but a response seen in the mutant, with a significant 
reduction in QTc. There were significant changes in heart rate and QTc for both wild 
type and cacna1c at 50µM while at 100µM only significant changes were seen in the 
cacna1c mutant. Cacna1c mutant showed a positive dose-response correlation.  
These results suggest that the use of CHZ at higher concentrations corrects both heart 
rate and QTc. The 100µM concentration is preferable as this produced a significant 
therapeutic effect in the cacna1c mutant without effecting the wild type. Dose response 
across total treatment time is shown in figure 4.23.  
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Wild type cacna1c 
 
HR QTc HR QTc 
P value  0.2626 0.4838  0.0117 0.0117  
significant No No Yes Yes 
     
Figure 4.23 Comparison of DMSO control and 100µM chlorzoxazone treatment on the 
cacna1c mutant phenotype.   
A)  DMSO control treatment: QTc and heart rate against treatment time for wild type 
and cacna1c mutant. DMSO given at 0 minutes.  
B) 100 µM CHZ treatment: QTc and heart rate recorded against treatment time for 
wild type and cacna1c mutant. Chlorzoxazone treatment given at 0 minutes. No 
significant change in QTc or heart rate in the wild type group, there is significant 
decrease in QTc and increase in heart rate in the cacna1c group. 
A 
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The aim of this chapter was to demonstrate the utility of the ECG recording system to 
analyse a cardiac mutant. As well as amply demonstrating that clear, reliable 
differences between wild type and mutant lines can be detected, recorded and analysed 
using ECG recording and analysis techniques, a rescue of mutant phenotype has also 
been demonstrated. Use of chlorzoxazone for treatment of severe arrhythmias has not 
been reported previously and opens up a potential alternate use for CHZ in the 
treatment of calcium channel arrhythmias.  
 
4.3.11 Comparison of Timothy syndrome and sa6050 zebrafish 
mutant.  
The most well known human condition associated with calcium channel dysfunction 
with a long QT phenotype is Timothy syndrome. The ‘classic’ Timothy syndrome 
mutation is G406R located on exon 8 or alternate splice exon 8a. Analysis of the 
G406R mutation (exon 8/8a) associated with Timothy syndrome and the sa6050 
cacna1c mutant were compared and the protein sequences were aligned to determine if 
it is possible to conclude that the zebrafish sa6050 line, coupled with phenotype data, is 
comparable to Timothy syndrome in humans. In Timothy syndrome, the mutation is a 
missense mutation within exon 8/8a producing a change in amino acid from glycine to 
arginine, causing a gain of function by the loss of voltage dependant activation 
(Splawski et al, 2004). In the zebrafish sa6050 mutation, the mutation is at an essential 
splice site, at the end of exon 6, chromosome 4. This causes the proceeding intron to 
not be cut out, and instead included in transcription, leading to an early stop codon and 
a greatly truncated protein, causing a loss of function, figure 4.24.  
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Figure 4.24. Summary of the mutation type and location of the Timothy syndrome 
mutation and the cacna1c sa6050 zebrafish mutation.  
A) The sa6050 mutation is at an essential splice site resulting in the proceeding intron 
to be included, leading to an early stop codon and a truncated protein with a loss of 
function. Timothy syndrome has a point missense mutation leading to a gain of function 
mutation.  
B) Alignment of nucleotide bases with amino acids for Bi) zebrafish sa6050 splice site 
mutation and Bii) Timothy G406R missense mutation.  
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Amino acid sequence alignment of human and zebrafish protein sequences was 
performed to look at the differences in location. The zebrafish sa6050 mutation is 
located at amino acid position 317, upstream of the human Timothy mutation at 
position 406. The other reported Timothy mutation is at position 402. Both the human 
and zebrafish proteins are over 2000 amino acids (zf 2196, hm 2221) so in the overall 
protein size are relatively close in sequence, figure 4.25. 
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Figure 4.25 Sequence alignment of human cacna1c protein sequence against zebrafish 
cacna1c protein sequence. Double arrows show location of the sa6050 mutation is not 
a conserved residue in human. Arrows and labels also show the location of the 2 
described Timothy syndrome (TS) mutations G402S and G406R. these are in highly 
conserved amino acid sequences, although the sa6050 and TS mutations are within 100 
aa of each other.  
 
Although there are differences in mutation type, location and contrasting gain and loss 
of function seen in these mutations, both produce a long QT phenotype.  
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4.4. Discussion 
It has previously been established that ECG changes due to cardiac drug treatment can 
be measured and analysed by larval zebrafish ECG recording. Analysis of cardiac 
dysfunction by ECG measurement is advantageous as it is a robust, high resolution and 
comprehensive method allowing analysis of electrical activity as well as contractility. 
To further establish this method for cardiac analysis, it was important to establish its 
utility for detecting cardiac ECG differences as a result of genetic mutation. A mutant 
was chosen from the Sanger Institutes zebrafish mutation project cacna1c sa6050. This 
is an L-type calcium channel mutant with a suspected loss of function mutation from a 
point mutation at an essential splice site. This was a new cacna1c mutant and had not 
been characterised prior to this study. 
 
4.4.1 Visual phenotype and genetic analysis of the cacna1c mutant. 
Heterozygous cacna1c embryos were imported from the Sanger Institute and grown up 
to adulthood. These were then crossed and the resultant clutches screened for 
phenotypes associated with the cacna1c mutation. This was firstly to confirm the 
phenotype has manifested sufficiently to positively identify mutants within a mixed 
clutch, and secondly to check for Mendelian distribution to confirm positive 
identification of homozygous mutants. Thirdly, numerical distribution of phenotypes 
would confirm whether the heterozygous embryos had any phenotype.  
Visual screening of cacna1c clutches from heterozygous adult crosses at 2 dpf revealed 
a proportion of embryos with a cardiac pheonotype. This was an observable cardiac 
oedema causing abnormal pericardial sac shape which were identifiable against 
negative siblings within the clutch and wild type controls. Counts from clutches showed 
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this proportion of heterozygous crosses to be an average of 28.82% presenting with this 
cardiac phenotype. Mendelian distribution supports this to be the homozygous mutants. 
There was no visual difference between negatively screened siblings and wild type 
controls, suggesting there is no visual cardiac phenotype in the heterozygous embryos 
as expected. The heart rate of wild type, negative siblings and screened mutants were 
also recorded. Negatively screened siblings had no significant difference in heart rate 
compared to wild type controls; however, the embryos screened for cardiac 
deformations had a significantly lower heart rate than both negative siblings and wild 
type controls. This confirms the visual screening as robust enough to identify 
homozygous mutants. The lower heart rate also is one of the first indications of the 
cacna1c phenotype, and suggests that the ECG will show further cardiac dysfunction.  
Visually screened groups were genotyped, by the Sanger Institute, to check if the 
phenotype was strong enough at 2 dpf to accurately screen out the homozygous mutant. 
All those selected for having no cardiac phenotype were heterozygous or wild type, as 
expected. However, the result of those selected as homozygous mutant revealed that as 
well as homozygous mutants being selected, there were also heterozygous and wild 
type embryos selected indicating that the phenotype was not strong enough at 2dpf to 
accurately screen those out. There may also have been an environmental factor creating 
phenotype other than the mutant. To compensate for this, the positive group was 
rescreened at 3dpf before ECG recording, and at 5dpf, when the established phenotype 
of large cardiac oedema accompanied by a low heart rate by 5 dpf. Those used for ECG 
analysis on day 3, were kept in 96 well plates, labelled and those which did not develop 
the large oedema by 5 dpf, the result was discounted from the data set. While this 
ensured accuracy in the mutant result it also unfortunately introduced bias. This is a 
significant limitation of the work and further work would be required to address this 
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issue. Towards the end of the experiments when this was being addressed, the 
experiment that was planned was to cross the heterozygous adults, collect and grow up 
the clutch to 3 dpf and then blindly ECG as many as possible on that day. Those would 
then go into a 96 well plate and their ECGs labelled correspondingly and analysed. The 
embryos would then be genotyped and then compare the ECG and genotype results. 
This, if they all matched up, would substantially corroborate the mutant ECG result and 
link it to the genotype. Once this was established then screening and excluding results 
based on ECG result would be possible without bias. Unfortunately, this experiment 
could not be performed due to poor fecundity in the line, new generations grown up 
also failed to produce and time ran out. Going forward, the priority would be to 
stabilise the line so these vital experiments can be performed to strengthen the results 
detailed here.  
Screening at 2 dpf and then rescreening at 5 dpf, while it introduced bias, it ensured that 
ECG analysis could be performed at 3 dpf, before the secondary systemic effects of the 
mutation developed, while ensuring the accuracy and robustness of the ECG result.  
 
4.4.2. ECG analysis of the mutant phenotype 
The purpose of this study was to analyse the direct consequence of the mutation before 
secondary and systemic effects of the compromised cardiac system start. The cardiac 
abnormalities observed at 2 dpf develop into the significant cardiac oedema and 
progressively slower heart rate observed at 5 dpf. The extent of the oedema was such 
that the heart was stretched out and clearly strained from the effect of the fluid. 
Although screening of mutants would be quicker at 5 dpf due to their more obvious and 
defined phenotype against their negative siblings, ECG analysis is extremely difficult 
with a profound oedema, this is due to the large increase in distance from the surface of 
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the pericardial sac and the heart, such that a signal is not possible. The heart rate is also 
so slow by this stage that dosing in the regular concentration of MS-222 (0.3 mg/ml) is 
enough to cause the heart to stop completely. At 5 dpf, the phenotype has developed 
sufficiently that the embryo has secondary and systemic effects beyond the arrhythmic 
phenotype which is a direct effect of the mutation. For this reason, heterozygous 
clutches were screened at 2 dpf and ECG signals recorded at 3 dpf. Previous work in 
Dhillon et al, 2013 had already confirmed 3 dpf as the earliest developmental stage 
from which to record detailed, reproducible ECG signal from zebrafish larvae. Having 
already used this stage as the standard for all wild type analysis it was sensible to 
record the mutant at this stage to allow for close comparison to this wild type data. 
Screening at 2 dpf facilitated this by allowing a full day of ECG recording to occur at 3 
dpf. This was the optimal stage to analyse the cacna1c mutant ECG phenotype as it 
allows comparison to wild type data, while also early enough for analysis of the 
phenotype before secondary effects from the mutation.  
ECG recordings of cacna1c mutant and wild type embryos were recorded and analysed 
using Labchart software to produce heart rate (RR interval), PR, QRS and QTc 
intervals. These were then tested for statistical significance and the results plotted. 
Results showed that all three of the ECG signal intervals were consistently prolonged 
than those recorded in sibling controls, with the PR and QTc intervals significantly 
prolonged in the homozygous mutant. This suggests that the mutation is affecting 
atrium and ventricle function, which is consistent with movement of calcium being 
affected. Movement of calcium from L-type calcium channels affects phases 0, 2, and 3 
of the cardiac cycle. At phase 0 there is a rapid increase in voltage due to sodium 
channels opening and releasing sodium into the cell causing depolarisation. In the 
sinoatrial node cells in the atrium this membrane voltage increase is due to L-type 
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calcium channels which open in response to the pacemaker potential (phase 4). In phase 
2 the membrane potential remains balanced due to movement of different ions in and 
out of the cell. L-type calcium channels are activated by movement of sodium in phase 
0 open releasing calcium into the cell. This released calcium binds to and activates 
more calcium channels (Ryanodine receptors) releasing a large influx of calcium into 
the cell from intercellular calcium stores on the sarcoplasmic reticulum. This massive 
increase in calcium is what causes the myocyte to contract. This calcium mediated 
excitation-contraction coupling is how both the atrium and ventricle contract. In phase 
3 of the action potential, the L-type calcium channels close, triggering the beginning of 
repolarisation. Potassium channels open and the sodium/calcium exchanger pumps 
calcium out of the cell giving a net loss of positive current, repolarising the cell back to 
resting potential. Loss of calcium in the cell causes the cell to relax, ending the 
contraction, (Golan et al, 2011, Verkerk and Remme, 2012 and Alday, et al, 2014). In a 
diseased state, where atrial depolarisation (PR) and ventricular repolarisation (QTc) are 
significantly lengthened this would suggest that movement of calcium into and out of 
the cardiac myocytes is inhibited. This would also explain the low heart rate, as 
contraction/relaxation would be slower giving a low heart rate.  
All of this evidence together suggests that the ECG changes seen in the cacna1c mutant 
are result of decreased function in the L-type calcium channel as a result of the point 
mutation.  
The ECG results shown here against sibling controls show clear, significant differences. 
Howver, through some of the proceeding drug treatment results, some variation in the 
baseline measurements was observed. This could possibly indicate a heterozygous 
response. However there was no bradycardia or ECG result specifically reported in the 
initial comparison when comparing those groups. Clearly further work on genetic 
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characterisation and further phenotypic analysis of this mutant is required to fully 
understand this mutant.  
 
4.4.3 Potassium channel blocker has an additive effect on the mutant 
phenotype. 
A potassium channel blocker was selected to assess its effect in the mutant ECG. 
Blocking potassium channels, in particular the hERG (IKr ) channel, is well known to 
have an arrhythmic effect in both human and zebrafish. Blockage of potassium 
channels responsible for repolarisation leads to delayed repolarisation and as a result, a 
QT prolongation observed on the ECG (Langheinrich et al, 2003). The potassium 
blocker selected for this study was terfenadine. This is a well known hERG and zERG 
channel blocker with a well established QT prolongation effect, and is still frequently 
used to demonstrate a models utility to pattern arrhythmia (Pratt et al, 1996, Alzualde et 
al, 2016). It was predicted that the use of a potassium blocker on the cacna1c mutant 
would have an additive effect, and this was confirmed by ECG analysis. This was 
expected as aberrant calcium and potassium channel activity should have a drastic 
effect on the cardiac action potential.  
 
4.4.4 Calcium channel blocker produces little effect in the mutant 
compared to wild type. 
A calcium channel blocker was chosen to assess its effect on the mutant, as mutant 
response to a calcium channel blocker would be informative of the type of mutation this 
is. The calcium channel blocker selected was verapamil. This drug is used to treat 
hypertension and ventricular tachycardias, by reducing cardiac output by blocking 
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calcium channels (Salhanick and Shannon, 2003). With this mode of action, blocking 
calcium channels in a calcium channel mutant would have one of two effects. Firstly, if 
the mutation is causing a gain of function phenotype, blocking channels would partly 
correct the phenotype by reducing channel function. Secondly if this was a loss of 
function mutation then blocking the channels wouldn’t have a big effect as function is 
already knocked down. The degree of this would depend on how much function is lost 
via the mutation. In this case, the wild type larvae had a much more pronounced 
response to verapamil than the mutant. Lack of response in the mutant to a calcium 
channel blocker would suggest a loss of function mutation as if function was already 
knocked down, and further knock down by drug treatment would be minimal compared 
to a wild type response. Further analysis of the splice site mutation location and effect 
on the transcription of the protein (see section 3.11) suggests a null mutation where a 
grossly truncated protein results in loss of function.  This indicates that drug responses 
can be used to give information on the type of mutation without genetic analysis.  
 
4.4.5 Non-selective beta-agonist increases the heart rate and reduces 
QTc  
A non selective beta agonist was selected to assess the effect of increased cardiac 
output on the mutant phenotype. The non-selective beta agonist chosen was 
isoprenaline. Treatment of the beta agonist has a stimulating effect on the cacna1c 
mutant, and speeds up the heart rate such that it tends towards the wild type heart rate 
range, temporarily alleviating mutant phenotypes. Isoprenaline treatment was observed 
to increase heart rate, decrease PQRST intervals and decrease frequency of the pauses 
phenotype.  However, this is only due to stimulating the heart to beat faster and does 
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not address the underlying charge imbalance from impaired calcium channel function. 
Because of this, the QTc remains unchanged after treatment. This means that treatment 
of isoprenaline is not a complete rescue of the mutant phenotype and this triggered the 
search for a drug which would completely reverse the phenotype to normal heart rate 
and QTc ranges (QTc 0.35-0.45ms and heart rate 110-130bpm at 28 degrees).  
 
4.4.6 Non cardiac-acting control drug has no effect on either wild type 
or cacna1c embryos 
A control drug, known to not have any cardiac phenotype in human and zebrafish was 
selected as a control. The control drug selected was penicillin. This drug was selected 
as it had been used in a previous zebrafish ECG study and was shown to not have a 
cardiac phenotype (Dhillon et al, 2013). As expected, penicillin did not have any effect 
on heart rate or QTc interval in either the wild type or cacna1c mutant embryos. This 
confirms that responses seen by other drugs are due to the drug treatment exclusively 
and not due to the experimental set up, anaesthesia, electrode position, embryo 
manipulation or experiment duration. The drawback of this drug is that it has poor 
uptake into zebrafish as it is a large molecule and perhaps a control drug such as 
metformin, which was also trialled for use would have been preferable.  
 
4.4.7 Sodium channel blocker has an additive effect on cacna1c 
mutant.  
Flecainide is a class 1c antiarrhythmic and is used to treat and prevent tachycardia and 
atrial fibrillation. As such, by blocking sodium channels, it causes the ventricular action 
potential duration to lengthen, thereby reducing the heart rate. In slowing the heart, and 
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lengthening the action potential, the ECG parameter intervals will also lengthen. In 
addition it has also been described that flecainide is a potassium channel blocker, 
including the hERG channel. It is well known and documented that hERG blockers 
cause a long QT phenotype (Andrikopoulos, Pastromas, and Tzeis, 2015). It was 
expected that this drug would exacerbate the mutant phenotype and cause an increase in 
QT as it reduced the heartrate. As predicted, flecainide treatment had an additive effect 
on the cacna1c mutant phenotype. In addition to inhibiting sodium channel function, 
and potassium channel function, it has also been reported that flecainide blocks the 
ryanodine receptor from opening, which reduces spontaneous release of calcium ions 
from the sarcoplasmic reticulum; hence its use as a therapeutic agent against ventricular 
tachycardia (Andrikopoulos, Pastromas, and Tzeis, 2015). This may be why there was 
such a pronounced effect on the mutant, with a global increase in all ECG parameters.  
 
4.4.8 Selective beta 1 Beta-Blocker has an additive effect on the 
cacna1c mutant 
A beta blocker was selected to assess the effect of decreasing cardiac output in the 
mutant. The beta blocker selected was metoprolol which is a selective beta 1 beta 
blocker used to treat hypertension and has been reported to cause bradycardia and 
arrhythmia in zebrafish (D’Amico et al, 2012). Beta blockers are used to control 
tachycardia, and as such were expected to exacerbate the phenotype by reducing heart 
rate, and in turn lengthen the ECG intervals. Metoprolol treatment reduced cardiac 
output as expected which caused a drop in heart rate and an increase in PR, QRS and 
QTc intervals at 50µM.  The PR and QRS intervals lengthen in correlation with the 
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drop in heart rate, however, the QT interval is corrected for heart rate to produce the 
QTc, which had also lengthened, independent of the heart rate.  
 
4.4.9 The use of a set of diversely acting cardiac acting drugs is 
informative on mutation target. 
These 6 drugs were carefully selected as having diverse cardiac effects, known to effect 
human and zebrafish hearts. These were selected to firstly, block each main cardiac ion 
channel systematically and then secondly to increase and decrease the cardiac output. 
The collated data would then give an overall picture of the mutant phenotype, with 
respect to wild type larvae. Using a cross section of cardiac acting drugs can be used to 
help identify the phenotype instead of genetics. For example, treating the mutant with 
terfenadine had an additive effect to the mutant exacerbating the phenotype, whereas 
when a verapamil, a calcium channel blocker, was added there was almost no effect on 
the mutant QTc interval despite a significant response in the wild type. This further 
indicates a calcium channel abnormality in the mutant, which is confirmed via the 
genetic analysis. In addition, using drugs such as isoprenaline and metoprolol to 
increase and decrease cardiac output is also informative, stimulating the heart using 
isoprenaline in a disease state where there is already a tachycardic arrhythmia would 
greatly exacerbate and increase arrhythmicity, possibly to the point of cardiac arrest. 
However, in cases such as the sa6050, where there is a bradycardia, isoprenaline 
treatment can temporarily improve heart rate, decreasing arrhythmia. Similarly use of a 
beta blocker such as metoprolol to decrease output would improve rhythmicity in a 
tachycardic heart and be proarrhythmic with a bradycardia. A loss of function mutation 
in cardiac ion channels, such as in the case of the sa6050 mutation is aggravated upon 
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treatment with metoprolol, whereas it responded positively to isoprenaline treatment. 
Conversely, with gain of function mutations this may be reversed. Beta agonist and 
antagonist response can therefore also give information about the nature of the cardiac 
phenotype.  
 
4.4.10 Screening for asystolic pauses phenotype and video analysis 
A sub-phenotype observed throughout recordings can be described as sections of loss 
of rhythmicity, termed here as asystolic pauses. These are periods where the heart stops 
beating for a variable length of time before resuming rhythmicity.  Embryos screened 
positively as a cacna1c mutant due to presence of cardiac deformations and low heart 
rate were observed for 2-3minutes to assess for the presence of the pauses phenotype. 
Those which were positively screened were analysed by video analysis using SOHA 
software (Semi-automated optical heartbeat anaylsis). This data was collated with ECG 
recording to give an overall picture of these periods of complete loss of cardiac output. 
Not all embryos screened for cardiac deformations (oedema) and low heart rate 
displayed this phenotype. It was initially thought that the pauses phenotype was part of 
the progression of the overall mutation effect as it developed towards the profound 
phenotype observed at 5dpf. It is clear from the original description of the mutant by 
Sanger and this study’s observation that the embryos develop severe oedema along with 
other systemic effects by 5 dpf. However, there was no increase in the number of 
embryos displaying asystolic pauses at 5 dpf compared to 3 dpf so perhaps the low 
incidence is due to mutation penetrance. 
Video analysis software detected each systole and diastole for each heart beat and 
produced an output clearly detecting asystolic pauses. Using systole/diastole outputs 
from the software can plot the diastoles, which clearly display 1) number of pauses 
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(number of peaks) and 2) quantifies the length of these asystolic pauses (y axis values). 
This helped to quantify and further characterise this phenotype.  
 
4.4.11 Chlorzoxazone treatment on the cacna1c mutant reduces 
frequency of asystolic events, reduces QTc interval and increases heart 
rate. 
Following the Isoprenaline result displaying an incomplete improvement in the mutant 
phenotype by stimulating the heart to increase heart rate, it became important to 
identify a drug which would truly rescue the mutant phenotype by addressing the 
calcium overload in the mutant cardiac myocytes. A literature search revealed 
candidates and chlorzoxazone was selected to be tested on the sa6050 mutant.  
It is marketed as a centrally acting smooth muscle relaxant (Liu, Lo and Wu, 2003). Its 
mode of action as a muscle relaxant is to activate Ca2+ activated potassium channels 
(Ik(Ca)), which removes K+ from the cell, helping to remove excess charge build up in 
the cell caused by slow acting calcium channels, by increasing potassium movement 
out of the cell. This action partially corrects for the calcium overload allowing the cell 
to return to a resting state ready for the next contraction (Alvina and Khodakhah, 2010). 
Calcium channels are also highly expressed in the brain and this chlorzoxazone agonist 
activity has shown to have efficacy in reducing charge imbalance from calcium 
overload in the neurons of cacna1aS218L mice, with equivalent affect predicted in human 
patients (Gao et al, 2012). This charge imbalance is similar to what is seen in Timothy 
patients (Dixon et al, 2011). It was suspected that chlorzoxazone treatment would have 
a similar effect on the calcium overload in the cardiac myocytes of the zebrafish sa6050 
mutant, aiding the repolarisation phase, allowing the cell to return to a resting state 
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ready for the next heart beat. Also, as an already marketed drug, it appealed as it was 
readily available and had already undergone drug development, safety testing and 
clinical trials for suitability in patients (Waldon et al, 1994).   
Mutants treated with 100uM chlorzoxazone were observed to have an increased heart 
rate, smaller QTc interval and improved rhythmicity and no effect was observed in the 
wild type controls.  
As described earlier, a subsection of mutants display a loss of rhythmicity resulting in 
periods where heart beats are missed. Treatment of chlorzoxazone was shown to 
improve both the length and frequency of  pauses in mutants displaying this phenotype. 
A drawback of this treatment is that while it removes excess charge from inside the 
cell, it does not address the calcium overload. Previous studies have shown that 
treatment with calcium activated potassium channel (SK channel) agonists may have a 
positive therapeutic effect in patients and mutant mice with calcium  overload in 
neurons, removal of charge by activation of potassium channels (Gao et al, 2012 and 
Alvina and Khodakhah, 2010). 
 
4.4.12 Comparison of sa6050 mutant to published Island beat mutant 
Sequence analysis of the sa6050 mutant indicated loss of function due to a greatly 
truncated protein. Rottbauer, et al, 2001 published a total loss of function mutation in 
the cacna1c gene called the island beat mutant, with 2 splice variants. The two splice 
variants reported of the mutant island beat (isl) have a much more severe phenotype 
than the sa6050 mutant, despite the 2 splice variants described being truncated much 
further downstream, with more of the protein left intact compared to sa6050 mutant. 
The Island beat mutant fails to grow the ventricle properly and has a silent ventricle 
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with sporadically uncoordinated atrial contraction from individual myocytes. This, in 
humans would be a foetal fatal condition and as such is not a model of Timothy 
syndrome, but perhaps of the role of the L-type calcium channel in development, 
particularly cardiac development. It is interesting that the sa6050 mutant has more 
functionality and less severe phenotype than isl: the chambers are formed correctly, and 
both contract, albeit with a progressive arrhythmia and severe cardiac phenotype. It is 
suspected that the vastly truncated protein in sa6050 is compensated from the failed 
expression from the mutated gene on chromosome 4 by expression of gene copies 
located on chromosomes 8 and 11. There are also 2 splice variants of this gene which 
are not affected by the mutation. The island beat mutant is described as a total loss of 
function, and as the phenotype is so severe, it is likely that there is no compensation by 
alternate genes or splice variants, however, this would need to be confirmed by further 
analysis, for example RNAseq data. 
The less severe phenotype seen in the sa6050 mutant compared to island beat suggests 
that the sa6050 mutant represents the human patient calcium channel arrhythmias more 
closely than island beat as in humans, calcium channel abnormalities are arrhythmic, 
characterised by QTc interval differences, and do not exhibit silent ventricle phenotype 
as this would be foetal fatal in humans.  
 
4.4.13 Relevance of cacna1c mutant to human disease: Timothy 
syndrome. 
In human disease, a gain of function mutation in the L-type calcium channel is 
characterised by a long QT phenotype. This is known as Timothy syndrome, a rare 
autosomal dominant disorder. The loss of function mutation in this calcium channel, in 
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human disease, is characterised by a short QT. This is known as Brugada syndrome. In 
the zebrafish cacna1c sa6050 mutant, a loss of function is assumed, due to the location 
of the mutation at an essential splice site and resultant truncated protein, but with a long 
QT.  
Sequence analysis of the sa6050 mutant indicates a long QT phenotype with a loss of 
function mutation. This is interesting as in human a loss of function mutation in 
cacna1c leads to a short QT phenotype (Antzelevitch et al, 2007) and a gain of function 
mutation leads to a long QT, as described in Timothy syndrome (Wemhöner et al, 
2015). Verapamil has also been reported to have efficacy in treating tachycardias 
associated with Timothy syndrome (Jacobs et al, 2016). But treatment with verapamil 
(Ca2+ blocker) on sa6050 had no effect, consistent with a loss of function mutation. 
Which would suggest that this sa6050 mutant can not be used specifically for Timothy 
syndrome, but may be useful for other calcium channel dysfunction induced 
arrhythmias.  
Comparison of the location and nature of the mutations in Timothy syndrome with the 
sa6050 mutant showed that there are fundamental differences. Timothy syndrome arises 
from a missense, gain of function mutation, whereas the sa6050 mutant is assumed to 
be loss of function from severe truncation, and the point mutation is located at an 
essential splice site. Despite this, similar phenotypes are seen. Both have a 
characteristic long QT phenotype. Therefore, it may be possible to use this mutant to 
analyse long QT phenotype arising from a cacna1c mutation.  
Incidence of the same phenotype from contrasting mutation fates in the same gene is 
interesting. Mechanistically, in Timothy syndrome, a long QT from a gain of function 
mutation arises due to a loss of voltage sensitivity, and therefore voltage gating, this 
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means that the channel is constitutively open. Therefore, constant calcium current flow, 
loss of pulse of on/off causing myocyte contraction/relaxation. If calcium always 
present, then the cell can not relax, removal of charge from the cell to return to resting 
potential for next heart beat takes longer and therefore QT interval, the repolarisation 
section on ECG, is prolonged (Wemhoner et al, 2015, Liao and Soong 2010 and 
Splawski et al, 2004).  
In the sa6050 mutant, it is hypothesized that the highly truncated protein has very 
little/no function. This truncation includes most of the major pore forming regions of 
the protein, making it most likely that there would be almost total loss of function. This, 
therefore would explain the bradycardia seen in these mutants as movement of calcium 
in and out of the cell to facilitate cardiac contraction/relaxation would take much longer 
and would rely on the other calcium channels, which under normal circumstances have 
a more minor role compared to the L-type calcium channel cav1.2. This would also 
result in the prolonged ECG intervals also described in this chapter, including a long 
QT phenotype.  
Overall, the sa6050 mutant is an L-type calcium channel mutant with a long QT 
phenotype which may be used to study and investigate calcium channelopathies 
resulting in LQT, and testing in this mutant could be used to highlight novel 
therapeutics. Chlorzoxazone, a smooth muscle relaxant, has been shown to reverse the 
mutant phenotype, increasing heart rate and reducing QTc interval towards normal 
range. It has already been indicated as a therapeutic in neuronal calcium overload, and 
here, it has been demonstrated that it may have a cardiac application also.  
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5. Overall conclusions  
 
This study aimed to further validate the zebrafish as a model of human cardiac 
arrhythmia in terms of cardiotoxicity and in human cardiac disease. Zebrafish as a 
model of cardiac arrhythmia and toxicity has been widely demonstrated, but barriers 
still exist which prevent translation from small-scale research studies to use as a screen 
for pharmaceutical drug development. Use of zebrafish larvae in drug screening is 
advantageous as they have conserved drug responses to human and represent an in vivo 
vertebrate model with high-throughput potential.  
The requirements and possibilities of introducing an in vivo zebrafish screen was 
discussed as part of the introduction to this project. Further validation of the zebrafish 
model to demonstrate how translatable zebrafish results are to human responses is 
required to convince many pharma companies to use zebrafish assays (Redfern et al 
2008). Also, one of the biggest concerns surrounding the use of zebrafish as a screen is 
dosing and ADME (absorption, distribution, metabolism and excretion). Zebrafish are 
exposed to a drug concentration in their surrounding medium and then, with larval 
forms, drug uptake is dependent on transdermal absorption. The efficiency of drug 
uptake depends on the individual compounds pharmacology and even if taken up 
successfully, there is still a question mark over metabolism while the larva is still 
developing (Redfern et al, 2008). There are also standardisation requirements 
surrounding husbandry and strains across labs to limit the impact of these on results 
(Planchart, et al, 2016). Even though some zebrafish assays with toxicological end 
points have been established in some CROs (contact research organisations), for large-
scale implementation of a zebrafish screen to happen, a big collaborative effort is 
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required between laboratories, pharmaceutical companies and regulatory authorities to 
overcome these hurdles (Redfern et al, 2008). 
This project proposes that an in vivo larval zebrafish ECG screen would be an effective 
tool for cardiac safety testing and (through the use of arrhythmic mutants) drug 
discovery. Despite demonstrating the potential for a high throughput system, there are 
still other considerations to answer before such a system is implemented as part of the 
drug development pathway. The current gold standard for detecting hERG interaction is 
a high throughput in vitro whole-cell voltage clamp assay capable of producing 
accurate data on hundreds of compounds a week. While the zebrafish would function 
better as a multi-end point assay, manual handling and orientation of embryos needs to 
be removed to compete with this. (Redfern, et al, 2008).  
 A principal aim of this project was to make steps towards a high throughput larval 
zebrafish recording system, and this was achieved through the development of reliable, 
reusable, resilient metal microfabricated electrodes. Utilising a microfabricated 
approach to ECG recording replaces the fragile glass capillaries with a recording device 
more suitable to a high throughput setting. Development of microfabricated electrode 
arrays successfully recording from zebrafish larvae, represents a significant 
advancement to the development of a high throughput ECG system. Further work is 
required to automate the recording process, however, a recent publication by Fuad, 
Kaslin and Wlodkowic, 2018, demonstrated an automated process for cardiac analysis, 
using a millifluidic system for automated embryo handling and positioning for imaging, 
producing high resolution images and heart rate analysis. This system was also 
compatible with drug treatments. Integrating the microfabricated electrode arrays 
developed as part of this study, with technologies such as the millifluidic lab-on-a-chip 
approach described in Fuad, Kaslin and Wlodkowic, 2018; would automate embryo 
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handling, positioning and recording, allowing high-throughput recording of ECGs. This 
would mark a significant step forward to using the zebrafish as a cardiotoxicity model 
for pharmaceutical development. Teaming this technology with automated ECG 
parameter measurement software also developed as part of this project, but not 
presented here, would complement and enable full automation of ECG recording 
procedure and analysis, (Barrett et al, 2015 – as yet unpublished).  
 Throughout this project various advancements and developments to the larval ECG 
recording procedure have been made. At the start of the project, the single electrode 
recording system as described in Dhillon et al, 2013 was in use. Demonstration of the 
use of metal electrodes, both twisted pair and microfabricated for larval zebrafish 
recording, are significant novel aspects of this work. Similarly, demonstration of a 
standardised dual electrode system recording distinct signals from two recording 
positions on the heart has not been shown previously. Various novel method 
developments of different recording platforms and embryo handling and orientation 
have been described during this work such as the stage allowing microfabricated 
recordings and the plate for on going temperature control and monitoring throughout 
experiments. In total, many different recording approaches have been demonstrated 
here showcasing the zebrafish as an arrhythmia model through ECG recording 
techniques.  This work to develop ECG recording techniques for zebrafish larvae was 
done as an alternative to other cardiotoxicity tools such as video and imaging analysis. 
This visual approach is possible in zebrafish embryos due to their optical transparency, 
however to utilise an ECG recording tool is closer to diagnostics performed in human. 
The data obtained from an ECG recording is also more detailed and gives a better 
overall picture of cardiac function. For example; visual screening for QT prolongation, 
is done by looking for induction of AV block, which is a separate phenotype itself and 
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as demonstrated by ECG recording, zebrafish can exhibit a long QT phenotype without 
having AV block. This makes ECG recording a more sensitive tool for analysing 
changes in cardiac function through drug treatment. In addition, multiple end points can 
be picked up by ECG analysis of the trace. For example, PR interval, QRS width, QT 
interval and heart rate (RR interval) can all be analysed from one recording. Each of 
these gives different information and gives an overall picture of cardiac function.  
Another principal aim of this study was to demonstrate the capability of the larval 
recording system for recording aberrant ECG signals due to genetic mutation and not 
from drug treatment. This was successfully performed using the cacna1c sa6050 
mutant which is part of a family of genes encoding the L-type calcium channel. This 
mutant, created as part of the Wellcome trust Sanger Institutes zebrafish mutation 
project, was chosen due to its significant cardiac phenotype observed at 5 dpf. It was 
also demonstrated that in-depth analysis of a mutant phenotype can be performed using 
ECG recording analysis and using a set of cardiac drugs can be informative of the 
nature of the mutation without genotyping. For example, looking at blocking different 
ion channels in turn and increasing and decreasing cardiac output revealed that 
blocking cardiac calcium channels had little effect on the mutant leading to a prediction 
of a loss of function mutation. If ion channel function is knocked down due to a 
mutation, knocking it down with a drug on top of that will not have much effect. In 
addition, increasing the heart rate had a positive effect on the mutant which lead to the 
search for a rescue drug that addressed the underlying charge build up caused by excess 
calcium. This platform also allowed identification of a novel use for a current drug, 
Chlorzoxazone, which rescued the mutant phenotype. Although the cacna1c mutant 
used in this study did not relate directly to a human disease mutation, the cacnac1c 
sa6050, may prove useful for further study of calcium channel abnormalities. With the 
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rise in CRISPR/cas9 technology for the creation of zebrafish mutant lines, a zebrafish 
mutant with the Timothy mutation, G496R could be created and assessed by ECG. 
Chlorzoxazone treatment could then be tested in this model to see if there is a positive 
effect on the mutant phenotype. However, a significant limitation to this mutant 
characterisation is that the genotype was not identified in those screened as 
homozygous mutant. There were problems visually screening the mutant at 2 dpf. 
Screening was performed at 2dpf to allow ECG recording at 3 dpf. However, 
identification of mutants was not accurate enough at this stage which lead to larvae 
being kept after ECG to check back at 5 dpf when the more pronounced cardiac 
phenotype had developed. The results were those screened as mutant developed the 
severe phenotype at 5 dpf were kept and the small proportion of those that didn’t were 
excluded. Sorting retrospectively in this way, while ensuring accuracy in the ECG 
results, introduced bias to the experiment. While the mutant ECG phenotype was 
confidently identified and reported here, it wasn’t without introducing bias into the 
experiment, which, going forward needs to be addressed for future experiments. For 
example, performing ECGs on the entire clutch and then genotyping and correlating the 
genotype to the ECG would go a long way to demonstrating the ECG phenotype 
observed here is directly linked to the genotype. Unfortunately, this experiment was not 
performed due to problems with embryo fecundity towards the end of the project.  
The aims of this study were to develop ECG recording techniques for zebrafish larvae, 
to develop recording technologies capable of high throughput and to demonstrate the 
utility of such a system to analyse cardiac mutants and this has been achieved. Further 
work to expand on what is presented here, can be done to implement the 
microfabricated electrodes as part of an automated high throughput system and create a 
proper genetic model of Timothy syndrome using CRISPR/cas9 techniques.  
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In conclusion, this study has taken steps to further validate the zebrafish larvae as a 
model of human cardiac arrhythmia. Use of electrographic techniques gives high 
resolution data for comparative analysis to human cardiac conditions and assessment of 
drug responses. 
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